

Federal Bureau of Investigation

Washington, D.C. 20535

November 16, 2020

Vladimir Kara-Murza c/o Covington & Burlington, LLP One City Center 850 Tenth Street, NW, Washington, DC 20001-4956

> Vladimir Kara-Murza v. Department of Justice Civil Action No.: 1:20-cv-00545-RC

FOIPA Request No.: 1410820-000 Subject: Kara-Murza, Vladimir (May 2015- July 2018)

Dear Mr. Kara-Murza:

The enclosed documents were reviewed under the Freedom of Information/Privacy Acts (FOIPA), Title 5, United States Code, Section 552/552a. Below you will find checked boxes under applicable statutes for the exemptions asserted to protect information exempt from disclosure. The appropriate exemptions are noted on the processed pages next to redacted information. In addition, a deleted page information sheet was inserted to indicate where pages were withheld entirely pursuant to applicable exemptions. An Explanation of Exemptions is enclosed to further explain justification for withheld information.

Section 552		Section 552a
(b)(1)	(b)(7)(A)	(d)(5)
(b)(2)	(b)(7)(B)	✓ (j)(2)
✓ (b)(3)	✓ (b)(7)(C)	(k)(1)
50 U.S.C., Section 3024 (i)(1)	(b)(7)(D)	(k)(2)
	✓ (b)(7)(E)	(k)(3)
	(b)(7)(F)	(k)(4)
(b)(4)	(b)(8)	(k)(5)
(b)(5)	(b)(9)	(k)(6)
✓ (b)(6)		(k)(7)

606 pages were reviewed and 346 pages are being released.

Please see the paragraphs below for relevant information specific to your request and the enclosed FBI FOIPA Addendum for standard responses applicable to all requests.

•	Document(s) were located which originated with, or contained information concerning, other Government Agency (ies) [OGA].
	This information has been referred to the OGA(s) for review and direct response to you. We are consulting with another agency. The FBI will correspond with you regarding this information when the consultation is completed.

Please refer to the enclosed FBI FOIPA Addendum for additional standard responses applicable to your request. "Part 1" of the Addendum includes standard responses that apply to all requests. "Part 2" includes additional standard responses that apply to all requests for records about yourself or any third party individuals. "Part 3" includes general information about FBI records that you may find useful. Also enclosed is our Explanation of Exemptions.

Although your request is in litigation, we are required by law to provide you the following information:

If you are not satisfied with the Federal Bureau of Investigation's determination in response to this request, you may administratively appeal by writing to the Director, Office of Information Policy (OIP), United States Department of Justice, 441 G Street, NW, 6th Floor, Washington, D.C. 20530, or you may submit an appeal through OIP's FOIA STAR portal by creating an account following the instructions on OIP's website: https://www.justice.gov/oip/submit-and-track-request-or-appeal. Your appeal must be postmarked or electronically transmitted within ninety (90) days of the date of my response to your request. If you submit your appeal by mail, both the letter and the envelope should be clearly marked "Freedom of Information Act Appeal." Please cite the FOIPA Request Number assigned to your request so it may be easily identified.

You may seek dispute resolution services by contacting the Office of Government Information Services (OGIS). The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769. Alternatively, you may contact the FBI's FOIA Public Liaison by emailing foipaquestions@fbi.gov. If you submit your dispute resolution correspondence by email, the subject heading should clearly state "Dispute Resolution Services." Please also cite the FOIPA Request Number assigned to your request so it may be easily identified.

Please direct any further inquiries about this case to the Attorney representing the Government in this matter. Please use the FOIPA Request Number and/or Civil Action Number in all correspondence or inquiries concerning your request.

See additional information which follows.

Sincerely,

Michael G. Seidel Section Chief Record/Information Dissemination Section

Information Management Division

Enclosure(s)

The enclosed documents represent the third interim release of information responsive to your Freedom of Information/Privacy Acts (FOIPA) request. These pages are properly Bates stamped FBI (20-cv-0545)-892 through FBI (20-cv-0545)-1497

The enclosed documents responsive to your request are exempt from disclosure in their entirety pursuant to the Privacy Act, Title 5, United States Code, Section 552(a), subsection (j)(2). However, these records have been processed pursuant to the Freedom of Information Act, Title 5, United States Code, Section 552, thereby affording you the greatest degree of access authorized by both laws.

Duplicate copies of the same document were not processed.

As previously indicated, documents were located which originated with, or contained information concerning another agencies. We are consulting with the other agencies and are awaiting their response. Our office has processed all other information currently in our possession. The FBI will correspond with you regarding those documents when the consultation is completed.

The FBI received an electronic payment submitted through pay.gov in the amount of \$25.00 for the first and second interim releases. Upon receipt of the enclosed CD please go to www.pay.gov to make an electronic payment* in the amount of \$15.00 for the third interim release, or make a check or money order payable to the Federal Bureau of Investigation and remit it to the Work Process Unit, Record Information/Dissemination Section, Information Management Division, Federal Bureau of Investigation, 170 Marcel Drive, Winchester, VA 22602. Please include the FOIPA Request Number/Civil Action Number with your payment. Failure to pay for this release within thirty (30) days from the date of this letter will close any pending FBI FOIPA requests from you. Nonpayment will also cause an automatic denial of any future FOIPA requests.

*Pay.gov is a secure web-based application that accepts credit card and ACH payments online, and is hosted by the United States Department of Treasury, Financial Management Service. For frequent FOIPA requesters, it is recommended to create a Pay.gov account to retain an online history of payments made through Pay.gov and to retain specific information for future payments. To make an electronic payment, complete the FBI Freedom of Information Act and Privacy Act Form located on Pay.gov. Please note: if a refund is necessary, there is less processing time to refund a credit card payment than an ACH payment.

FBI FOIPA Addendum

As referenced in our letter responding to your Freedom of Information/Privacy Acts (FOIPA) request, the FBI FOIPA Addendum provides information applicable to your request. Part 1 of the Addendum includes standard responses that apply to all requests. Part 2 includes standard responses that apply to requests for records about individuals to the extent your request seeks the listed information. Part 3 includes general information about FBI records, searches, and programs.

Part 1: The standard responses below apply to all requests:

- (i) **5 U.S.C. § 552(c).** Congress excluded three categories of law enforcement and national security records from the requirements of the FOIPA [5 U.S.C. § 552(c)]. FBI responses are limited to those records subject to the requirements of the FOIPA. Additional information about the FBI and the FOIPA can be found on the www.fbi.gov/foia website.
- (ii) Intelligence Records. To the extent your request seeks records of intelligence sources, methods, or activities, the FBI can neither confirm nor deny the existence of records pursuant to FOIA exemptions (b)(1), (b)(3), and as applicable to requests for records about individuals, PA exemption (j)(2) [5 U.S.C. §§ 552/552a (b)(1), (b)(3), and (j)(2)]. The mere acknowledgment of the existence or nonexistence of such records is itself a classified fact protected by FOIA exemption (b)(1) and/or would reveal intelligence sources, methods, or activities protected by exemption (b)(3) [50 USC § 3024(i)(1)]. This is a standard response and should not be read to indicate that any such records do or do not exist.

Part 2: The standard responses below apply to all requests for records on individuals:

- (i) Requests for Records about any Individual—Watch Lists. The FBI can neither confirm nor deny the existence of any individual's name on a watch list pursuant to FOIA exemption (b)(7)(E) and PA exemption (j)(2) [5 U.S.C. §§ 552/552a (b)(7)(E), (j)(2)]. This is a standard response and should not be read to indicate that watch list records do or do not exist.
- (ii) Requests for Records about any Individual—Witness Security Program Records. The FBI can neither confirm nor deny the existence of records which could identify any participant in the Witness Security Program pursuant to FOIA exemption (b)(3) and PA exemption (j)(2) [5 U.S.C. §§ 552/552a (b)(3), 18 U.S.C. 3521, and (j)(2)]. This is a standard response and should not be read to indicate that such records do or do not exist.
- (iii) Requests for Records for Incarcerated Individuals. The FBI can neither confirm nor deny the existence of records which could reasonably be expected to endanger the life or physical safety of any incarcerated individual pursuant to FOIA exemptions (b)(7)(E), (b)(7)(F), and PA exemption (j)(2) [5 U.S.C. §§ 552/552a (b)(7)(E), (b)(7)(F), and (j)(2)]. This is a standard response and should not be read to indicate that such records do or do not exist.

Part 3: General Information:

- (i) Record Searches. The Record/Information Dissemination Section (RIDS) searches for reasonably described records by searching systems or locations where responsive records would reasonably be found. A standard search normally consists of a search for main files in the Central Records System (CRS), an extensive system of records consisting of applicant, investigative, intelligence, personnel, administrative, and general files compiled by the FBI per its law enforcement, intelligence, and administrative functions. The CRS spans the entire FBI organization, comprising records of FBI Headquarters, FBI Field Offices, and FBI Legal Attaché Offices (Legats) worldwide; Electronic Surveillance (ELSUR) records are included in the CRS. Unless specifically requested, a standard search does not include references, administrative records of previous FOIPA requests, or civil litigation files. For additional information about our record searches, visit www.fbi.gov/services/information-management/foipa/requesting-fbi-records.
- (ii) **FBI Records.** Founded in 1908, the FBI carries out a dual law enforcement and national security mission. As part of this dual mission, the FBI creates and maintains records on various subjects; however, the FBI does not maintain records on every person, subject, or entity.
- (iii) Requests for Criminal History Records or Rap Sheets. The Criminal Justice Information Services (CJIS) Division provides Identity History Summary Checks often referred to as a criminal history record or rap sheet. These criminal history records are not the same as material in an investigative "FBI file." An Identity History Summary Check is a listing of information taken from fingerprint cards and documents submitted to the FBI in connection with arrests, federal employment, naturalization, or military service. For a fee, individuals can request a copy of their Identity History Summary Check. Forms and directions can be accessed at www.fbi.gov/about-us/cjis/identity-history-summary-checks. Additionally, requests can be submitted electronically at www.edo.cjis.gov. For additional information, please contact CJIS directly at (304) 625-5590.
- (iv) **National Name Check Program (NNCP).** The mission of NNCP is to analyze and report information in response to name check requests received from federal agencies, for the purpose of protecting the United States from foreign and domestic threats to national security. Please be advised that this is a service provided to other federal agencies. Private Citizens cannot request a name check.

EXPLANATION OF EXEMPTIONS

SUBSECTIONS OF TITLE 5, UNITED STATES CODE, SECTION 552

- (b)(1) (A) specifically authorized under criteria established by an Executive order to be kept secret in the interest of national defense or foreign policy and (B) are in fact properly classified to such Executive order;
- (b)(2) related solely to the internal personnel rules and practices of an agency;
- (b)(3) specifically exempted from disclosure by statute (other than section 552b of this title), provided that such statute (A) requires that the matters be withheld from the public in such a manner as to leave no discretion on issue, or (B) establishes particular criteria for withholding or refers to particular types of matters to be withheld;
- (b)(4) trade secrets and commercial or financial information obtained from a person and privileged or confidential;
- (b)(5) inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency;
- (b)(6) personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy;
- (b)(7) records or information compiled for law enforcement purposes, but only to the extent that the production of such law enforcement records or information (A) could reasonably be expected to interfere with enforcement proceedings, (B) would deprive a person of a right to a fair trial or an impartial adjudication, (C) could reasonably be expected to constitute an unwarranted invasion of personal privacy, (D) could reasonably be expected to disclose the identity of confidential source, including a State, local, or foreign agency or authority or any private institution which furnished information on a confidential basis, and, in the case of record or information compiled by a criminal law enforcement authority in the course of a criminal investigation, or by an agency conducting a lawful national security intelligence investigation, information furnished by a confidential source, (E) would disclose techniques and procedures for law enforcement investigations or prosecutions, or would disclose guidelines for law enforcement investigations or prosecutions if such disclosure could reasonably be expected to risk circumvention of the law, or (F) could reasonably be expected to endanger the life or physical safety of any individual;
- (b)(8) contained in or related to examination, operating, or condition reports prepared by, on behalf of, or for the use of an agency responsible for the regulation or supervision of financial institutions; or
- (b)(9) geological and geophysical information and data, including maps, concerning wells.

SUBSECTIONS OF TITLE 5, UNITED STATES CODE, SECTION 552a

- (d)(5) information compiled in reasonable anticipation of a civil action proceeding;
- (j)(2) material reporting investigative efforts pertaining to the enforcement of criminal law including efforts to prevent, control, or reduce crime or apprehend criminals;
- (k)(1) information which is currently and properly classified pursuant to an Executive order in the interest of the national defense or foreign policy, for example, information involving intelligence sources or methods;
- (k)(2) investigatory material compiled for law enforcement purposes, other than criminal, which did not result in loss of a right, benefit or privilege under Federal programs, or which would identify a source who furnished information pursuant to a promise that his/her identity would be held in confidence:
- (k)(3) material maintained in connection with providing protective services to the President of the United States or any other individual pursuant to the authority of Title 18, United States Code, Section 3056;
- (k)(4) required by statute to be maintained and used solely as statistical records;
- (k)(5) investigatory material compiled solely for the purpose of determining suitability, eligibility, or qualifications for Federal civilian employment or for access to classified information, the disclosure of which would reveal the identity of the person who furnished information pursuant to a promise that his/her identity would be held in confidence;
- (k)(6) testing or examination material used to determine individual qualifications for appointment or promotion in Federal Government service the release of which would compromise the testing or examination process;
- (k)(7) material used to determine potential for promotion in the armed services, the disclosure of which would reveal the identity of the person who furnished the material pursuant to a promise that his/her identity would be held in confidence.

FEDERAL BUREAU OF INVESTIGATION FOI/PA
DELETED PAGE INFORMATION SHEET
Civil Action# 20-cv-0545

Total Deleted Page(s) = 24Page 1 ~ Referral/Consult; Page 3 ~ Referral/Consult; Page 4 ~ Referral/Consult; Page 5 ~ Referral/Consult; Page 6 ~ Referral/Consult; Page 7 ~ Referral/Consult; Page 8 ~ Referral/Consult; Page 9 ~ Referral/Consult; Page 10 ~ Referral/Consult; Page 11 ~ Referral/Consult; Page 12 ~ Referral/Consult; Page 13 ~ Referral/Consult; Page 14 ~ Referral/Consult; Page 15 ~ Referral/Consult; Page 16 ~ Referral/Consult; Page 17 ~ Referral/Consult; Page 18 ~ Referral/Consult; Page 19 ~ Referral/Consult; Page 20 ~ Referral/Consult; Page 21 ~ Referral/Consult; Page 22 ~ Referral/Consult; Page 23 ~ Referral/Consult; Page 24 ~ Referral/Consult; Page 25 ~ Referral/Consult;

FEDERAL BUREAU OF INVESTIGATION FOI/PA
DELETED PAGE INFORMATION SHEET Civil Action# 20-cv-0545

Total Deleted Page(s) = 236
Page 1 ~ Referral/Consult;

Total Deleted Page(s) = 236Page 2 ~ Referral/Consult; Page 3 ~ Referral/Consult; Page 4 ~ Referral/Consult; Page 5 ~ Referral/Consult; Page 6 ~ Referral/Consult; Page 7 ~ Referral/Consult; Page 8 ~ Referral/Consult; Page 9 ~ Duplicate; Page 10 ~ Referral/Consult; Page 11 ~ Referral/Consult; Page 12 ~ Referral/Consult; Page 13 ~ Referral/Consult; Page 14 ~ Duplicate; Page 15 ~ Duplicate; Page 16 ~ Duplicate; Page 17 ~ Duplicate; Page 18 ~ Duplicate; Page 19 ~ Referral/Consult; Page 20 ~ Referral/Consult; Page 21 ~ Referral/Consult; Page 22 ~ Referral/Consult; Page 23 ~ Referral/Consult; Page 24 ~ Referral/Consult; Page 25 ~ Referral/Consult; Page 26 ~ Referral/Consult; Page 27 ~ Duplicate; Page 28 ~ Duplicate; Page 29 ~ Duplicate; Page 30 ~ Duplicate; Page 31 ~ Duplicate; Page 32 ~ Duplicate; Page 33 ~ Referral/Consult; Page 34 ~ Referral/Consult; Page 35 ~ Referral/Consult; Page 36 ~ Referral/Consult; Page 37 ~ Referral/Consult; Page 38 ~ Referral/Consult; Page 39 ~ Referral/Consult; Page 40 ~ Referral/Consult; Page 41 ~ Referral/Consult; Page 42 ~ Referral/Consult; Page 43 ~ Referral/Consult; Page 44 ~ Referral/Consult; Page 45 ~ Referral/Consult;

Page 46 ~ Referral/Consult;
Page 47 ~ Referral/Consult;
Page 48 ~ Referral/Consult;

```
Page 49 ~ Referral/Consult;
Page 50 ~ Referral/Consult;
Page 51 ~ Referral/Consult;
Page 52 ~ Referral/Consult;
Page 53 ~ Referral/Consult;
Page 54 ~ Referral/Consult;
Page 55 ~ Referral/Consult;
Page 56 ~ Referral/Consult;
Page 57 ~ Referral/Consult;
Page 58 ~ Referral/Consult;
Page 59 ~ Referral/Consult;
Page 60 ~ Referral/Consult;
Page 61 ~ Referral/Consult;
Page 62 ~ Referral/Consult;
Page 63 ~ Referral/Consult;
Page 64 ~ Referral/Consult;
Page 65 ~ Referral/Consult;
Page 66 ~ Referral/Consult;
Page 67 ~ Referral/Consult;
Page 68 ~ Referral/Consult;
Page 69 ~ Referral/Consult;
Page 70 ~ Referral/Consult;
Page 71 ~ Referral/Consult;
Page 72 ~ Referral/Consult;
Page 73 ~ Referral/Consult;
Page 74 ~ Referral/Consult;
Page 75 ~ Referral/Consult;
Page 76 ~ Referral/Consult;
Page 77 ~ Referral/Consult;
Page 78 ~ Referral/Consult;
Page 79 ~ Referral/Consult;
Page 80 ~ Referral/Consult;
Page 81 ~ Referral/Consult;
Page 82 ~ Referral/Consult;
Page 83 ~ Referral/Consult;
Page 84 ~ Referral/Consult;
Page 85 ~ Referral/Consult;
Page 86 ~ Duplicate;
Page 87 ~ Duplicate;
Page 88 ~ Duplicate;
Page 89 ~ Referral/Consult;
Page 90 ~ Referral/Consult;
Page 91 ~ Duplicate;
Page 92 ~ Duplicate;
Page 93 ~ Duplicate;
Page 94 ~ Referral/Consult;
Page 95 ~ Referral/Consult;
Page 96 ~ Referral/Consult;
Page 97 ~ Duplicate;
Page 98 ~ Duplicate;
Page 99 ~ Referral/Consult;
Page 100 ~ Duplicate;
Page 101 ~ Duplicate;
Page 102 ~ Duplicate;
```

```
Page 103 ~ Duplicate;
Page 104 ~ Duplicate;
Page 105 ~ Duplicate;
Page 106 ~ Duplicate;
Page 107 ~ Duplicate;
Page 108 ~ Duplicate;
Page 109 ~ Duplicate;
Page 110 ~ Duplicate;
Page 111 ~ Duplicate;
Page 112 ~ Duplicate;
Page 113 ~ Duplicate;
Page 114 ~ Duplicate;
Page 115 ~ Duplicate;
Page 116 ~ Duplicate;
Page 117 ~ Duplicate;
Page 118 ~ Duplicate;
Page 119 ~ Duplicate;
Page 120 ~ Duplicate;
Page 121 ~ Duplicate;
Page 122 ~ Duplicate;
Page 123 ~ Duplicate;
Page 124 ~ Duplicate;
Page 125 ~ Referral/Consult;
Page 126 ~ Referral/Consult;
Page 127 ~ Referral/Consult;
Page 128 ~ Referral/Consult;
Page 129 ~ Referral/Consult;
Page 130 ~ Referral/Consult;
Page 131 ~ Referral/Consult;
Page 132 ~ Referral/Consult;
Page 133 ~ Referral/Consult;
Page 134 ~ Duplicate;
Page 135 ~ Duplicate;
Page 136 ~ Duplicate;
Page 137 ~ Duplicate;
Page 138 ~ Duplicate;
Page 139 ~ Duplicate;
Page 140 ~ Referral/Consult;
Page 141 ~ Referral/Consult;
Page 142 ~ Referral/Consult;
Page 143 ~ Duplicate;
Page 144 ~ Duplicate;
Page 145 ~ Duplicate;
Page 146 ~ Duplicate;
Page 147 ~ Duplicate;
Page 148 ~ Duplicate;
Page 149 ~ Referral/Consult;
Page 150 ~ Referral/Consult;
Page 151 ~ Referral/Consult;
Page 152 ~ Referral/Consult;
Page 153 ~ Referral/Consult;
Page 154 ~ Duplicate;
Page 155 ~ Referral/Consult;
Page 156 ~ Referral/Consult;
```

```
Page 157 ~ Referral/Consult;
Page 158 ~ Referral/Consult;
Page 159 ~ Referral/Consult;
Page 160 ~ Referral/Consult;
Page 161 ~ Referral/Consult;
Page 162 ~ Referral/Consult;
Page 163 ~ Duplicate;
Page 164 ~ Referral/Consult;
Page 165 ~ Referral/Consult;
Page 166 ~ Referral/Consult;
Page 167 ~ Referral/Consult;
Page 168 ~ Referral/Consult;
Page 169 ~ Referral/Consult;
Page 170 ~ Referral/Consult;
Page 171 ~ Referral/Consult;
Page 172 ~ Referral/Consult;
Page 173 ~ Referral/Consult;
Page 174 ~ Referral/Consult;
Page 175 ~ Referral/Consult;
Page 176 ~ Referral/Consult;
Page 177 ~ Referral/Consult;
Page 178 ~ Referral/Consult;
Page 179 ~ Referral/Consult;
Page 180 ~ Referral/Consult;
Page 181 ~ Referral/Consult;
Page 182 ~ Referral/Consult;
Page 183 ~ Referral/Consult;
Page 184 ~ Referral/Consult;
Page 185 ~ Referral/Consult;
Page 186 ~ Referral/Consult;
Page 187 ~ Referral/Consult;
Page 188 ~ Duplicate;
Page 189 ~ Referral/Consult;
Page 190 ~ Referral/Consult;
Page 191 ~ Referral/Consult;
Page 192 ~ Referral/Consult;
Page 193 ~ Referral/Consult;
Page 194 ~ Duplicate;
Page 195 ~ Duplicate;
Page 196 ~ Referral/Consult;
Page 197 ~ Referral/Consult;
Page 198 ~ Duplicate;
Page 199 ~ Duplicate;
Page 200 ~ Duplicate;
Page 201 ~ Referral/Consult;
Page 202 ~ Referral/Consult;
Page 203 ~ Duplicate;
Page 204 ~ Duplicate;
Page 205 ~ Referral/Consult;
Page 206 ~ Referral/Consult;
Page 207 ~ Referral/Consult;
Page 208 ~ Duplicate;
Page 209 ~ Duplicate;
Page 210 ~ Referral/Consult;
```

```
Page 211 ~ Referral/Consult;
Page 212 ~ Referral/Consult;
Page 213 ~ Duplicate;
Page 214 ~ Duplicate;
Page 215 ~ Referral/Consult;
Page 216 ~ Duplicate;
Page 217 ~ Referral/Consult;
Page 218 ~ Duplicate;
Page 219 ~ Duplicate;
Page 220 ~ Referral/Consult;
Page 221 ~ Referral/Consult;
Page 222 ~ Referral/Consult;
Page 223 ~ Referral/Consult;
Page 224 ~ Referral/Consult;
Page 225 ~ Referral/Consult;
Page 226 ~ Referral/Consult;
Page 227 ~ Referral/Consult;
Page 228 ~ Referral/Consult;
Page 229 ~ Referral/Consult;
Page 230 ~ Referral/Consult;
Page 231 ~ Referral/Consult;
Page 232 ~ Referral/Consult;
Page 233 ~ Referral/Consult;
Page 234 ~ Referral/Consult;
Page 235 ~ Referral/Consult;
Page 236 ~ Referral/Consult;
```


- X Deleted Page(s) X
 X No Duplication Fee X
 X For this Page X

******* LABORATORY DIVISION SUPPORTING DOCUMENTATION ENVELOPE. Please Print Clearly The Environment Source of Ref. Car Co Co Market Eat Numbers Or WOO Number 2017-00404 2 AVAILUM DAKAT Cignori Cultura Contraction of Astrophy Representation Charles County SCS Search Sty FBI(20-cv-0545)-1152

b6 -1

b7C -1 b7E -1

Lab#	20	17	7-0	04	69
------	----	----	-----	----	----

WFO case

Fxaminer:

Case Summary b6 -1 b7c -1

Specimen ID Item 1

Specimen Type Blood

Inventory: 2/23/2017 Amount: 5mL

SOP Title	SOP	Rev	Instruments	Amount	Analyst	Started	Completed	Analytical Results	ė
Exclusionary Drug Screen by UPLC-ESI- FTMS	215	2	Exactive-1	0.3mL		9/28/2017	10/5/2017	not detected	b6 -1 b7C -1
Solid Phase Extraction (SPE) of Alkaline Drugs from Biological Fluids	203	7	MSD-5, ORBITRAP-3	1.0mL		10/2/2017	10/5/2017	ranitidine identified	

Specimen ID

Item 2

Specimen Type Urine

Inventory: 2/23/2017 Amount: 10mL

SOP Title	SOP	Rev	Instruments	Amount	Ana	lyst	Started	Completed	Analytical Results
Exclusionary Drug Screen by UPLC-ESI- FTMS	215	2	Exactive-1	0.3mt 0.2 ml			2/24/2017	2/27/2017	(data not used to generate supporting material for the scope of this report)
Arsenic in Urine and Hair by ICP/MS	320	0	ICPMS-1a	0.2mL			9/25/2017	10/5/2017	Barium elevated at approximately 93 ug/L. No other elevated elements of significance.
Direct Solvent Extraction of Acid- Neutral Drugs from Biological Fluids	201	5	MSD-4	0.5mL			9/25/2017	10/5/2017	not detected
Exclusionary Drug Screen by UPLC-ESI- FTMS	215	2	Exactive-1	0.3mL			9/28/2017	10/5/2017	not detected
Solid Phase Extraction (SPE) of Alkaline Drugs from Biological Fluids	203	7	MSD-5, ORBITRAP-3	1.0mL			10/2/2017	10/5/2017	phenethylamine identified (not reporting), ranitidine identified

Specimen ID

Item 3

Specimen Type Blood

Collected 4/24/217


Inventory: 4/26/2017 Amount: 4mL

1110 total 1/2 1/20/2017 Amount 1112						· · · · · · · · · · · · · · · · · · ·				
SOP Title	SOP	Rev	Instruments	Amount	F	Analyst	Started	Completed	Analytical Results	
Exclusionary Drug Screen by UPLC-ESI-FTMS	215	2	Exactive-1	0.3mL			9/28/2017	10/5/2017	not detected	b6 -1 b7C -
Solid Phase Extraction (SPE) of Alkaline Drugs from Biological Fluids	203	1	MSD-5, ORBITRAP-3	1.0mL			10/2/2017	10/5/2017	ranitidine identified	

Specimen ID

Item 4

Specimen Type Blood	Collected 4/24/217 Inventory: 4/26/2017 Amount: 4mL									
SOP Title	SOP	Rev	Instruments	Amount	Analy	rst	Started	Completed	Analytical Results	
Specimen Not Analyzed - See Comments	100b	0	Not Applicable				10/5/2017	10/5/2017	INA	b6 -1
Specimen ID Item 5	Specimen ID Item 5									
Specimen Type Urine	Specimen Type Urine Collected 4/24/217 Inventory: 4/26/2017 Amount: 30mL									
SOP Title	SOP	Rev	Instruments	Amount	Analy	st	Started	Completed	Analytical Results	
Arsenic in Urine and Hair by ICP/MS	320	0	ICPMS-1a	0.2mL			9/25/2017	10/5/2017	Ing significant elevations	b6 -1 b7C -1
Exclusionary Drug Screen by UPLC-ESI-FTMS	215	2	Exactive-1	0.3mL			9/28/2017	10/5/2017	not detected	
Solid Phase Extraction (SPE) of Alkaline Drugs from Biological Fluids	203	7	MSD-5, ORBITRAP-3	1.0mL			10/2/2017	10/5/2017	phenethylamine identified (not reporting), ranitidine identified	



ICP-MS Analysis 9/25/2017

Carried out to provide a screen and confirmation of any potentially toxic elements.

A calibration and control scheme was set up using separate lots of standard solutions containing 31 elements.

The backbone of the analysis was based off of TOX320-0 for Arsenic in urine and hair, with expansion of the scope to include other elements. Briefly, 100ut of specimen was diluted to 10mt in 2% nitric acid.

Internal standardization was added by 100ut, of a 10ug/L indium and gallium in 2% nitric acid.


(only indium was used for internal standardization purposes).

An eight point calibration curve from 1-100ug/L was used One calibrator level was dropped due to an apparent mispipet. Control levels evaluated were 4 and 40ug/L.

The ICP-MS was initially run in the scan (non-collision) mode to effect an overall view of the Items 2 and 5 urine samples, as well method performance.

For the heavy metals of interest, the calibration curves and controls are acceptable as a screen. For environmental/nutritional elements (such as Al, Fe, Zn, Mg, etc), the curves are flat and show evidence of contribution from background or inteferences. (These elements are not of toxicological interest at this time).

TOX320-0 used as backborg, expanded to include the elements




9/25/17 b6 -1 b7C -1

barium result 5 b6 -1
tech reviewd
10/19/17

Scan Analysis (No KED)

~~~~~	Item 2	Item 5	Notes	do KED?
Lithium	nd	elevated at 30ug/L	elevated, see KED follow up.	Y
Boron	Elevated at 700ug/L	Elevated at 700ug/L	Potential inteferent due to 12C spread, see KED reanalysis	Y
Cobalt	nd	nd	No elevation on either sample	
Copper	nd	elevated	Although elevated, not of tox significance.	
Arsenic	nd	150ug/L	>50ug/L potentially of sig., potentially an Ar intereference or dietary	Ty
Selenium	nd	100ug/L	within normal reference range	
Strontium	nd	250ug/L	elevated over normal reference range; potential sulfur oxide intefer.	
Molybdenum	nd	70ug/L	within normal reference range	
Barium	~80ug/£	nd	elevated over normal reference range; a few pot. Interferences	· · · · · · · · · · · · · · · · · · ·
Uranium	nd	nd	(does not confirm previous results by outside lab)	Y

KED (Kinetic Energy Discrimination) Reanalysis





Calibration and Control Scheme
CALIBRATION
Stock Solution
31 elements at 10ug/mL (10mg/L)
HIGH PARTY STANI
Stock Calibration Solution
52992
Cal # Level (ug/L) Final Vol (ng/L)

(10mg/L)	
RITY STANDARDS	10 mg/L
10+4	10 ug/mL

Cal #	Level (ug/L)	Final Vol (mL)	Spike Conc (ug/mL)	Spike Vol (mL)
1	1	50	10	0.005
2	2.5	50	10	0.0125
3	5	50	10	0.025
	10	50	10	0.05
5	25	50	10	0.125
6	50	50	10	0.25
7	80	50	10	0.4
8	100	50	10	0.5

CONTROL

Stock Solution

HIGH PYPHY STANDARDS

31 elements at 10ug/mL (10mg/L)

Stock Control Solution

10	mg/L
10	ug/mL

Control #	Level (ug/L)	Final Vol (mL)	Spike Conc (ug/mL)	Spike Vol (mL)
1	. 1	50	10	0.005
2	2.5	50	10	0.0125
Low	4	100	10	0.04
4	10	50	10	0.05
g	25	50	10	0.125
High	40	100	10	0.4
7	80	50	. 10	0.4
	100	50	10	0.5

Report

2017-00469

1827-2817

9/26/2017 8:28:30 AM



Instrument Name: Serial Number: iCAP Q SN02602R

Index	Label			Start Time	User name
1	blank	1 1	Runs 1	9/25/2017 3:21:21 PM	ICAP-Q\Thermo
2		1	1	9/25/2017 3:24:47 PM	ICAP-Q\Thermo
3	Cal 1	1	1	9/25/2017 3:28:14 PM	ICAP-Q\Thermo
4	Cal 2.5	1	1		ICAP-Q\Thermo
5	Cal 5	1	1	9/25/2017 3:35:08 PM	ICAP-Q\Thermo
6	Cal 10	1	1	9/25/2017 3:38:36 PM	ICAP-Q\Thermo
7	Cal 25	1	1	9/25/2017 3:42:04 PM	ICAP-Q\Thermo
8	Cal 50	1	1	9/25/2017 3:45:33 PM	ICAP-Q\Thermo
9	Cal 80	1	1	9/25/2017 3:49:02 PM	ICAP-Q\Thermo
10	Cal 100	1	1	9/25/2017 3:52:32 PM	ICAP-Q\Thermo
11	blank	1	1	9/25/2017 3:56:03 PM	ICAP-Q\Thermo
12	Control 4 A	1	1	9/25/2017 3:59:35 PM	ICAP-Q\Thermo
13	Control 40 A	1	1	9/25/2017 4:03:06 PM	ICAP-Q\Thermo
14	blank	1	1	9/25/2017 4:06:32 PM	ICAP-Q\Thermo
15	2017-00469 Item 2 A	1	1	9/25/2017 4:09:58 PM	ICAP-Q\Thermo
16	2017-00469 Item 2 B	1	1	9/25/2017 4:13:25 PM	ICAP-Q\Thermo
17	blank	1	1	9/25/2017 4:16:52 PM	ICAP-Q\Thermo
18	2017-00469 Item 5 A	1	1	9/25/2017 4:20:20 PM	ICAP-Q\Thermo
19	2017-00469 Item 5 B	1	1	9/25/2017 4:23:49 PM	ICAP-Q\Thermo
20	blank	1	1	9/25/2017 4:27:18 PM	ICAP-Q\Thermo
21	Control 4 B	1	1	9/25/2017 4:30:48 PM	ICAP-O\Thermo
22	Control 40 B	1	1	9/25/2017 4:34:18 PM	ICAP-Q\Thermo
23	blank	1	1	9/25/2017 4:37:49 PM	ICAP-Q\Thermo


initial sequence who KED b6-1 b7c-1

	interested in the second secon	
A CONTRACTOR OF THE PARTY OF TH	not reporting	_
Janes .		

b6 -1 b7C -1

	ľ	Š	L	9	į	į		C	ì	ŧ	á	ŀ	ċ	À	j	V,	E	3	ě	2	l	į	ì	ž		Ì			ı	ı	į	ŝ	ğ	Ĭ	2	į	ğ	9	1	2	3	ź		Ľ	3	ľ	2	į	3	3	e	3	Ī	2	l	Ł	ŝ		ľ	Ě	į		ŧ		I	ľ	Ĭ	ij	L	3	Š	ľ	i	É	3	á		ľ	ĺ	I	ì	1	ž	ġ	ì	ı	ã	ŧ.	I	ı	ì	l	2	ì	l
																					4	L)													Ī														1	C	ì	٠	•	3	۷	1																																	3		ı	4
•	•	•	~	•	~	•	~	۰	~	۰	~	۰	~	•	~	~	•	•	~	~	~	~	~	•	~	•	•	•	۰	•	~	•	~	~	~	~	•	~	~	~	~	•	~	•	~	•	~	•	۰	•	~	•	~	~	~	•	~	~	~	~	•	~	~	•	~	~	~	~	•	~	~	•	~	~	~	•	~	~	~	•	~	~	•	~	~	~	~	~	•	~	~	•	•	~	•


Calibration Curves:



f(x) = 1601.1791*x + 6245.8502 $R^2 = 0.9947$

BEC = 3.901 ppb

LoD = N/A




f(x) = 84635.7253*x + 33863824.4974


 $R^2 = 0.3853$

BEC = 400.113 ppb

LoD = N/A



f(x) = 353.4740*x + -548.3653




f(x) = 3859.7883*x + 239850.6502

 $R^2 = 0.9674$

BEC = 62.141 ppb

LoD = N/A




f(x) = 508.8149*x + 81491.3446

 $R^2 = 0.7544$

BEC = 160.159 ppb

LoD = N/A




f(x) = 5610.8574*x + 2074058.5992

 $R^2 = 0.6042$

BEC = 369.651 ppb

LoD = N/A




f(x) = 4412639.9547*x +

1335025402.3373

 $R^2 = 0.4645$

BEC = 302.546 ppb

LoD = N/A




f(x) = 4127.2332*x + 22390.9805

 $R^2 = 0.9981$

BEC = 5.425 ppb


LOD = N/A





f(x) = 3930.6896*x + 73348.5375 $R^2 = 0.9978$ BEC = 18.660 ppb

LOD = N/A




f(x) = 977.6450*x + 7077.3689 $R^2 = 0.9968$ BEC = 7.239 ppb

LoD = N/A


55Mn (STD) 730 5355

f(x) = 6248.1892*x + 118849.3664 $R^2 = 0.9982$ BEC = 19.021 ppbLoD = N/A




f(x) = 2159.4931*x + 26442.3756

 $R^2 \approx 0.9951$ BEC = 12,245 ppb LoD = N/A



 $R^2 = 0.8070$ BEC = 215.444 ppb




f(x) = 631.4763*x + 43830.5623 $R^2 = 0.9759$

BEC = 69.410 ppbLoD = N/A

f(x) = 1179.6872*x + 254156.0173


LOD = N/A



59Co (STD)

f(x) = 4298.0704*x + 3470.9265

 $R^2 = 0.9977$ BEC = 0.808 ppbLOD = N/A




f(x) = 482.4881*x + 1994.6778

 $R^2 = 0.9950$


BEC = 4.134 ppb

LoD = N/A





f(x) = 133.1352*x + 19499.2752 $R^2 = 0.8932$ BEC = 146.462 ppb LoD = N/A




f(x) = 2531.7442*x + -4587.3541 $R^2 = 0.9958$ BEC = -1.812 ppb LoD = N/A

2017-80


హా దూ కట

رب درب درب


-2017




f(x) = 70.5288*x + 10054.5503 R² = 0.9038 BEC = 142.560 ppb LoD = N/A




f(x) = 636.5706*x + 1219.0875 $R^2 = 0.9972$ BEC = 1.915 ppb LoD = N/A




f(x) = 6375.9030*x + 157770.5634 $R^2 = 0.9782$ BEC = 24.745 ppb LoD = N/A



f(x) = 1906.0129*x + -2756.2453 R² = 0.9973 BEC = -1.446 ppb LoD = N/A




f(x) = 1087.3773*x + 22117.3325 $R^2 = 0.9940$ BEC = 20.340 ppb LoD = N/A




f(x) = 860.1990*x + -173.0299 R² = 0.9975 BEC = -0.201 ppb LoD = N/A








f(x) = 7806.2472*x + -14843.9776 $R^2 = 0.9975$ BEC = -1.902 ppb LoD = N/A




f(x) = 4720.0682*x + -6962.2578 $R^2 = 0.9977$ BEC = -1.475 ppb LoD = N/A

2017-


(CD)




f(x) = 5186.7271*x + -7416.8225 $R^2 = 0.9972$ BEC = -1.430 ppb LoD = N/A




f(x) = 3677.0726*x + 3876.4665 $R^2 = 0.9974$ BEC = 1.054 ppb LoD = N/A




f(x) = 9202.7021*x + -11011.4618 $R^2 = 0.9960$ BEC = -1.197 ppb LoD = N/A



f(x) = 5524.7567*x + -6082.7588 R² = 0.9982 BEC = -1.101 ppb LoD = N/A



f(x) = 2139.5997*x + -3439.8621 $R^2 = 0.9980$ BEC = -1.608 ppb LoD = N/A




f(x) = 7757.0376*x + -28717.4471 R² = 0.9786 BEC = -3.702 ppb LoD = N/A



Report

9/26/2017 8:28:30 AM





f(x) = 7934.4068*x + -10653.8253 $R^2 = 0.9984$


BEC = -1.343 ppb

LoD = N/A

2817-88468

1627-1611

Report 9/26/2017 8:28:30 AM





		· · · · · · · · · · · · · · · · · · ·		nd.		14 14	NIM
Label	Vial	Rack	7.U (STD)	9Be (STD)	11B (STD)	23Na (STD)	24Mg (STD)
blank	1	1	-3.763 ppb	1.551 ppb	-159.294 ppb	-302.486 ppb	-399.913 ppb
cal 0	2	1	0.897 ppb	1.551 ppb	-40.117 ppb	-105.054 ppb	-151.161 ppb
Cal 1	3	1	2.572 ppb	2.570 ppb	~2.184 ppb	-20.502 ppb	-27.638 ppb
Cal 2.5	4	1	3.691 ppb	3.334 ppb	-15.669 ppb	-34.093 ppb	-49.067 ppb
Cal 5	5	1	7.706 ppb	5.908 ppb	45.357 ppb	77.633 ppb	94.075 ppb
Cal 10	6	1	8.281 ppb	8.625 ppb	-2.496 ppb	9.831 ppb	1.093 ppb
Cal 25	7	1	19.336 ppb	21.813 ppb	9.983 ppb	-3.994 ppb	13.833 ppb
Cal 50	8	1	3.272 ppb	1.580 ppb	26.799 ppb	64.085 ppb	85.364 ppb
Cal 80	9	1	82.534 ppb	81.988 ppb	105.186 ppb	129.314 ppb	132.005 ppb
Cal 100	10	1	99.380 ppb	99.262 ppb	83.324 ppb	65.313 ppb	59.201 ppb
blank	11	1	-3.720 ppb	1.551 ppb	-159,255 ppb	-302.427 ppb	-399.706 ppb
Control 4 A	12	1	7.036 ppb	3.786 ppb	61.630 ppb	158.694 ppb	197.032 ppb
Control 40 A	13	1	35.797 ppb	36,338 ppb	24.795 ppb	32.640 ppb	77.438 ppb
blank	14	1	-3.770 ppb	1.551 ppb	-158.744 ppb	-302.431 ppb	-399.710 ppb
2017-00469 Item 2 A	15	1	0.878 ppb	1.551 ppb	701.590 ppb	-213.337 ppb	-6.376 ppb
2017-00469 Item 2 B	16	1	2.253 ppb	1.551 ppb	790.839 ppb	-200.105 ppb	36.066 ppb
blank	17	1 , ,	-3.738 ppb	1.551 ppb	-158.842 ppb	-302.437 ppb	-399.720 ppb
2017-00469 Item 5 A	18	1 with	27.471 ppb	1.551 ppb	651.557 ppb	681.530 ppb	1,791.315 ppb
2017-00469 Item 5 B	19	1 "(*)("	ر المراج 32.163 ppb	1.551 ppb	792.649 ppb	681.530 ppb	2,270.319 ppb
blank	20	1	-3.589 ppb	1.580 ppb	-157.427 ppb	-300.036 ppb	-397.273 ppb
Control 4 B	21	1	4.848 ppb	3.164 ppb	23.264 ppb	74.109 ppb	53.574 ppb
Control 40 B	22	1	42.245 ppb	39.481 ppb	34.577 ppb	71.183 ppb	61.597 ppb
blank	17 .	1 .	-3.782 ppb	1.551 ppb	-159.216 ppb	-302.414 ppb	-399.699 ppb
	NA	ИÅ	p-d	n.d.	n.d.	NA	
Label	27AL(ST	D) 44Ca (STD)	51V (STD)	## 57/03/CSTTM	SSMn /STD\	######################################	

	00000000000000000000000000000000000000	######################################	***************************************				
D) 59Co (STD)	57Fe (STD)	55Mn (STD)	52Cr (STD)	51V (STD)	44Ca (STD)	27AF(SID)	Label
	-128.200 ppb	-11.596 ppb	-9.223 ppb	-3.154 ppb	-311.950 ppb	-37.376 ppb	blank
	-89.493 ppb	-7.847 ppb	-3.162 ppb	1.214 ppb	-137.285 ppb	-27.584 ppb	cal 0
	-30.366 ppb	-1.786 ppb	1.284 ppb	1.479 ppb	-25.293 ppb	-11.172 ppb	Cal 1
	-11.090 ppb	1.878 ppb	3.097 ppb	3.531 ppb	-23.283 ppb	-3.512 ppb	Cal 2.5
Analytica etelli (1900-1904) on transport of the contract of t	12.693 ppb	7.443 ppb	7.299 ppb	6.711 ppb	61.641 ppb	10.633 ppb	Cal 5
	29.262 ppb	11.517 ppb	8.895 ppb	9.686 ppb	7.987 ppb	18.785 ppb	Cal 10
	49.643 ppb	24.316 ppb	21.736 ppb	21.267 ppb	14.729 ppb	31.106 ppb	Cal 25
pb 2.990 ppb	55.342 ppb	11.450 ppb	6.293 ppb	5.034 ppb	70.517 ppb	15.232 ppb	Cal 50
dunanteriara anta araba ar	85.877 ppb	80.953 ppb	81.976 ppb	79.888 ppb	114.371 ppb	80.372 ppb	Cal 80
	87.480 ppb	99.178 ppb	99.213 ppb	100.938 ppb	73.348 ppb	97.288 ppb	Cal 100
	84.435 ppb	14.376 ppb	3.848 ppb	4.394 ppb	-221.735 ppb	26.689 ppb	blank
	62.768 ppb	14.689 ppb	9.567 ppb	8.534 ppb	141.397 ppb	27.749 ppb	Control 4 A
)	55.342 p 85.877 p 87.480 p 84.435 p	11.450 ppb 80.953 ppb 99.178 ppb 14.376 ppb	6.293 ppb 81.976 ppb 99.213 ppb 3.848 ppb	5.034 ppb 79.888 ppb 100.938 ppb 4.394 ppb	70.517 ppb 114.371 ppb 73.348 ppb -221.735 ppb	15.232 ppb 80.372 ppb 97.288 ppb 26.689 ppb	Cal 50 Cal 80 Cal 100 blank

1827-2817



abel	27Al (STD)	44Ca (SID)	51V (STD)	52Gr (STD)	SSMn (SID)	57/Fe (STD)	59Co (STD)
Control 40 A	51.392 ppb	73.732 ppb	40.543 ppb	40.787 ppb	44.868 ppb	69.371 ppb	37.659 ppb
blank	20.440 ppb	-220.352 ppb	3.898 ppb	2.957 ppb	13.787 ppb	45.390 ppb	3.227 ppb
2017-00469 Item 2 A	20.159 ppb	122.123 ppb	4.297 ppb	10.954 ppb	11.152 ppb	56.269 ppb	3.064 ppb
2017-00469 Item 2 B	25.595 ppb	167.627 ppb	5.360 ppb	11.231 ppb	12.653 ppb	70.237 ppb	3.768 ppb
olank	17.536 ppb	-224.704 ppb	4.460 ppb	2.462 ppb	13.299 ppb	43.963 ppb	3.202 ppb
2017-00469 Item 5 A	38.966 ppb	4,541.836 ppb	12.958 ppb	19.745 ppb	19.717 ppb	205.458 ppb	5.353 ppb
2017-00469 Item 5 B	46.786 ppb	5,549.572 ppb	16.995 ppb	22.910 ppb	26.237 ppb	244.475 ppb	5.861 ppb
blank	27.415 ppb	-211.669 ppb	4.414 ppb	1.991 ppb	13.659 ppb	51.923 ppb	3.330 ppb
Control 4 B	14.382 ppb	66.122 ppb	8.213 ppb	6.414 ppb	10.571 ppb	43.457 ppb	4.695 ppb
Control 40 B	36.675 ppb	64.657 ppb	42.615 ppb	41.383 ppb	42.365 ppb	27.134 ppb	41.031 ppb
blank	4.569 ppb	-243.267 ppb	2.722 ppb	0.547 ppb	6.151 ppb	4.734 ppb	2.480 ppb
000000000000000000000000000000000000000	n d.	not reporting	W/A-	ilems detected	ilem 5 detected	stem 5 detected	ise-5 delect
abel	60Ni (STD)	6300 (STD)	66Zn (STD)	75As (STD)	77Se (STD)	82Se (STD)	88Sr (STD)
blank	-3.393 ppb	-9.734 ppb	-51.095 ppb	-3.056 ppb	-94.845 ppb	-80.446 ppb	-24.508 ppb
cal O	-2.400 ppb	-3.305 ppb	-25.845 ppb	-0.652 ppb	-73.048 ppb	-45.976 ppb	-6.386 ppb
Cal 1	1.509 ppb	1.154 ppb	-3.565 ppb	1.234 ppb	-21.765 ppb	-19.730 ppb	1.987 ppb
Cal 2.5	2.953 ppb	1.460 ppb	-3.835 ppb	3.162 ppb	-6.798 ppb	-7.102 ppb	1.132 ppb
Cal 5	8.174 ppb	9.296 ppb	16.242 ppb	7.371 ppb	10.132 ppb	12.765 ppb	12.957 ppb
Cal 10	9.332 ppb	10.188 ppb	9.818 ppb	9.175 ppb	30.826 ppb	29.937 ppb	5.832 ppb
Cal 25	20.736 ppb	19.947 ppb	23.655 ppb	20.666 ppb	35.792 ppb	29.938 ppb	18.179 ppb
Cal 50	6.751 ppb	4.352 ppb	8.896 ppb	3.328 ppb	47.907 ppb	27.525 ppb	7.718 ppb
Cal 80	79.189 ppb	82.006 ppb	85.947 ppb	84.309 ppb	79.449 ppb	84.302 ppb	88.321 ppb
Cal 100	101.607 ppb	99.450 ppb	95.239 ppb	97.581 ppb	95.863 ppb	93.389 ppb	95.092 ppb
olank	5.727 ppb	-7.408 ppb	-22.511 ppb	1.006 ppb	40.906 ppb	27.241 ppb	-24.262 ppb
Control 4 A	6.577 ppb	8.506 ppb	17.403 ppb	7.185 ppb	48.434 ppb	42.286 ppb	16.318 ppb
Control 40 A	38.534 ppb	35.673 ppb	36.547 ppb	37.268 ppb	77.342 ppb	51.653 ppb	37.299 ppb
olank	6.024 ppb	-7.797 ppb	-25.686 ppb	1.193 ppb	32.027 ppb	20.854 ppb	-24.284 ppb
2017-00469 Item 2 A	5.594 ppb	-0.563 ppb	625.735 ppb	2.914 ppb	41.133 ppb	27.808 ppb	8.829 ppb
2017-00469 Item 2 B	5.789 ppb	0.040 ppb	676.249 ppb	3.722 ppb	59.574 ppb	38.028 ppb	10.500 ppb
olank	31.535 ppb	-8.136 ppb	-25.527 ppb	, 0.944 ppb	34,361 ppb	14.326 ppb	-24.306 ppb
2017-00469 Item 5 A	10.960 ppb	47.136 ppb	502.303 ppb	(148,589 ppb	120.792 ppb	85.439 ppb	256.577 ppb
2017-00469 Item 5 B	13.788 ppb	59.908 ppb	576.376 ppb	174.871 ppb	102.419 ppb	101.908 ppb	297.239 ppb
olank	9.434 ppb	11.314 ppb	-19.654 ppb	2.084 ppb	27.359 ppb	21.422 ppb	~23.880 ppb
Control 4 B	5.830 ppb	5.189 ppb	6.654 ppb	5.899 ppb	、27.816 ppb /	23.692 ppb	/ 7.952 ppb
Control 40 B	40.998 ppb	40.139 ppb	35.416 ppb	42.022 ppb	\42.714 ppb /	43.137 ppb	/ 45.424 ppb
olank	29.524 ppb	-8.242 ppb	-29.542 ppb	0.260 ppb	\ 9.229 ppb /	7.373 ppb	-24.309 ppb
	· · · · · · · · · · · · · · · · · · ·	elevetal to emperior to		not a symplement.	hwy ingr		b6
		port rest from from	8/11	United States	A		junits

Report 9/26/2017 8:28:30 AM

L may pomer toxiciss,




	Hem 5 detailed	n-d	n.d.	NA	n-l.	ilem 2 detected	1.8.
Label	95Mo (STD)	107Ag (STD)	111Cd (STD)	115In (STD)	121Sb (STD)	1378a (STD)	139La (STD)
blank	-17.461 ppb	2.025 ppb	-0.721 ppb	19.999 %	1.792 ppb	0.875 ppb	1.928 ppb
cal 0	-7.310 ppb	2.163 ppb	-0.564 ppb	74.329 %	1.829 ppb	1.108 ppb	1.941 ppb
Cal 1	-0.366 ppb	3.191 ppb	1.651 ppb	100.000 %	2.810 ppb	2.689 ppb	2.725 ppb
Cal 2.5	1.753 ppb	4.285 ppb	3.003 ppb	101.036 %	3.807 ppb	3.643 ppb	3.877 ppb
Cal 5	9.837 ppb	6.428 ppb	6.711 ppb	106.542 %	6.038 ppb	6.096 ppb	6.245 ppb
Cal 10	9.661 ppb	8.591 ppb	8.959 ppb	97.700 %	8.638 ppb	8.050 ppb	8.328 ppb
Cal 25	21.054 ppb	19.766 ppb	21.726 ppb	90.255 %	20.877 ppb	21.666 ppb	21.135 ppb
Cal 50	6.315 ppb	2.657 ppb	2.468 ppb	103.044 %	2.049 ppb	1.631 ppb	1.969 ppb
Cal 80	83.756 ppb	79.644 ppb	83.162 ppb	104.436 %	81.324 ppb	82.138 ppb	80.852 ppb
Cal 100	97.806 ppb	101.596 ppb	98.288 ppb	104.632 %	100.005 ppb	99.218 ppb	100.338 ppb
blank	-7.798 ppb	2.669 ppb	4.024 ppb	24.815 %	2.055 ppb	1.259 ppb	1.985 ppb
Control 4 A	11.837 ppb	4.819 ppb	6.303 ppb	140.109 %	4.154 ppb	4.050 ppb	4,221 ppb
Control 40 A	35.101 ppb	36.682 ppb	38.405 ppb	103.238 %	37.685 ppb	35.224 ppb	37.919 ppb
blank	-9.474 ppb	2.776 ppb	2.924 ppb	23.232 %	2.154 ppb	1.352 ppb	1.971 ppb
2017-00469 Item 2 A	-4.060 ppb	2.582 ppb	3.631 ppb	132.719 %	3.419 ppb	74.818 ppb	1.987 ppb
2017-00469 Item 2 B	-1.656 ppb	2.681 ppb	3.333 ppb	140.467 %	3.592 ppb	90.287 ppb	1.989 ppb
blank	-7.909 ppb	2.638 ppb	3.521 ppb	20.581 %	2.128 ppb	1.120 ppb	1.973 ppb
2017-00469 Item 5 A	67.397 ppb	2.717 ppb	5.061 ppb	129.285 %	2.275 ppb	5.654 ppb	1.994 ppb
2017-00469 Item 5 B	84.154 ppb	2.930 ppb	6.224 ppb	155.220 %	2.160 ppb	5.841 ppb	1.999 ppb
blank	-8.010 ppb	2.582 ppb	3.678 ppb	23.102 %	2.118 ppb	1.724 ppb	1.969 ppb
Control 4 B	7.117 ppb	4.372 ppb	4.700 ppb	110.622 %	3.954 ppb	3.689 ppb	3.852 ppb
Control 40 B	39.667 ppb	46.673 ppb	45.191 ppb	105.666 %	44.626 ppb	43.500 ppb	44.065 ppb
blank	-10.680 ppb	2.428 ppb	2.610 ppb	21.389 %	2.039 ppb	1.108 ppb	1.950 ppb
	n.d.	×.d.	n-d.	n.d.	n.d.	nd.	~d
Label 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		165Ho (STD)	172Yb (STD)	205TI (STD)	208Pb (STD)	209Bi (STD)	232Th (STD)
blank	1.524 ppb	1.210 ppb	1.608 ppb	1.484 ppb	0.820 ppb	1.731 ppb	3.705 ppb
cal 0	1.478 ppb	1.206 ppb	1.617 ppb	1.524 ppb	1.084 ppb	1.773 ppb	3.702 ppb
Cal 1	2.379 ppb	2.118 ppb	2.468 ppb	2.558 ppb	2.341 ppb	2.473 ppb	4.504 ppb
Cal 2.5	3.515 ppb	3.434 ppb	3.655 ppb	3.976 ppb	3.466 ppb	3.805 ppb	5.912 ppb
Cal 5	5.807 ppb	5.745 ppb	6.480 ppb	6.297 ppb	6.294 ppb	6.177 ppb	7.940 ppb
Cal 10	8.271 ppb	8.171 ppb	8.230 ppb	8.053 ppb	8.568 ppb	8.329 ppb	10.390 ppb
Cal 25	22.074 ppb	22.374 ppb	21.863 ppb	21.490 ppb	21.395 ppb	21.919 ppb	12.348 ppb
Cal 50	1.536 ppb	1.216 ppb	1.608 ppb	1.549 ppb	1.144 ppb	1.523 ppb	3.839 ppb
Cal 80	83.151 ppb	84.450 ppb	79.806 ppb	80.853 ppb	82.467 ppb	79.829 ppb	77.744 ppb
Cal 100	98.305 ppb	97.207 ppb	100.999 ppb	100.273 ppb	98.969 ppb	100.968 ppb	104.661 ppb
blank	1.550 ppb	1.215 ppb	1.626 ppb	1.481 ppb	2.143 ppb		

1027-2017



Label	153Eu (STD)	165Ho (STD)	172Yb (STD)	205TI (STD)	208Pb (STD)	209Bi (STD)	232Th (STD)
Control 4 A	3.625 ppb	3.558 ppb	3.912 ppb	3.917 ppb	3.327 ppb	1.583 ppb	6.036 ppb
Control 40 A	37.190 ppb	38.335 ppb	38.823 ppb	36.710 ppb	37.851 ppb	1.521 ppb	38.200 ppb
blank	1.517 ppb	1.224 ppb	1.608 ppb	1.477 ppb	1.724 ppb	1.445 ppb	3.908 ppb
2017-00469 Item 2 A	1.548 ppb	1.217 ppb	1.622 ppb	1.553 ppb	1.530 ppb	1.365 ppb	3.863 ppb
2017-00469 Item 2 B	1.540 ppb	1.212 ppb	1.626 ppb	1.570 ppb	1.819 ppb	1.383 ppb	3.798 ppb
blank	1.515 ppb	1.210 ppb	1.622 ppb	1.484 ppb	1.411 ppb	1.345 ppb	3.769 ppb
2017-00469 Item 5 A	1.571 ppb	1.220 ppb	1.626 ppb	1.712 ppb	2.785 ppb	1.409 ppb	3.779 ppb
2017-00469 Item 5 B	1.559 ppb	1.219 ppb	1.640 ppb	1.774 ppb	2.195 ppb	1.389 ppb	3.777 ppb
blank	1.519 ppb	1.208 ppb	1.617 ppb	1.488 ppb	1.353 ppb	1.268 ppb	3.746 ppb
Control 4 B	3.490 ppb	3.127 ppb	3.660 ppb	3.609 ppb	3.104 ppb	1.289 ppb	5.530 ppb
Control 40 B	41.621 ppb	46.545 ppb	42.992 ppb	47.992 ppb	44.206 ppb	1.286 ppb	43.650 ppb
blank	1.507 ppb	1.215 ppb	1.617 ppb	1.486 ppb	1.465 ppb	1.306 ppb	3.917 ppb

Label	PERMISID)
blank	1.359 ppb
cal 0	1.363 ppb
Cal 1	2.277 ppb
Cal 2.5	3.696 ppb
Cal 5	6.119 ppb
Cal 10	8.597 ppb
Cal 25	22.244 ppb
Cal 50	1.348 ppb
Cal 80	79.183 ppb
Cal 100	101.385 ppb
blank	1,359 ppb
Control 4 A	3.705 ppb
Control 40 A	36.011 ppb
blank	1.354 ppb
2017-00469 Item 2 A	1.377 ppb
2017-00469 Item 2 B	1.368 ppb
blank	1.345 ppb
2017-00469 Item 5 A	1.363 ppb
2017-00469 Item 5 B	1.362 ppb
blank	1.344 ppb
Control 4 B	3.316 ppb
Control 40 B	43.366 ppb
1316131K	5 , 344 7 (3111)



Report 9/26/2017 8:28:30 AM



Method Summary 9/26/2017 7:35:41 AM



Method Summary:

Isotope	Mode	Dwell time (s) # o	Channels Spac	cing	Resolution	Internal Standard
7Li (STD)	STD	0.01			Normal	
9Be (STD)	STD	0,01	1	0.1	Normal	
11B (STD)	STD	0.01	1	0.1	Normal	
23Na (STD)	STD	0.01	1	0.1	Normal	
24Mg (STD)	STD	0.01	1	0.1	Normal	
27AI (STD)	STD	0.01	1	0.1	Normal	
44Ca (STD)	STD	0.01	1	0.1	Normal	
51V (STD)	STD	0.01	1	0.1	Normal	
52Cr (STD)	STD	0.01	1	0.1	Normal	
55Mn (STD)	STD	0.01	1	0.1	Normal	
57Fe (STD)	STD	0:01	1	0.1	Normal	
59Co (STD)	STD	0.01	1	0.1	Normal	
60Ni (STD)	STD	0.01	1	0.1	Normal	
63Cu (STD)	STD	0.01	1	0.1	Normal	
66Zn (STD)	STD	0.01	1	0.1	Normal	
75As (STD)	STD	0.01	1	0.1	Normal	
77Se (STD)	STD	0.01	1	0.1	Normal	
82Se (STD)	STD	0.01	1	0.1	Normal	
88Sr (STD)	STD	0.01	1	0.1	Normal	
95Mo (STD)	STD	0.01	1	0.1	Normal	
107Ag (STD)	STD	0.01	1	0.1	Normal	
111Cd (STD)	STD	0.01	1	0.1	Normal	
115In (STD)	STD	0.01	1	0.1	Normal	
121Sb (STD)	STD	0.01	1	0.1	Normal	
1378a (STD)	STD	0.01	1	0.1	Normal	
139La (STD)	STD	0.01	1	0.1	Normal	
153Eu (STD)	STD	0.01	1	0.1	Normai	
165Ho (STD)	STD	0.01	1	0.1	Normal	
172Yb (STD)	STD	0.01	1	0.1	Normal	
205TI (STD)	STD	0.01	1	0.1	Normal	
208Pb (STD)	STD	0.01	1	0.1	Normal	
2098i (STD)	STD	0.01	1	0.1	Normal	
232Th (STD)	STD	0.01	1	0.1	Normal	
238U (STD)	STD	0.01	1	0.1	Normal	

No. of sweeps	Time per sweep	p[s] Time per main i	run[s] Order of modes
			3.4 STD

b 6	-1
b7C	-1

Report

2017-80466

1027-2817

9/26/2017 12:50:21 PM



Instrument Name: Serial Number: iCAP Q SN02602R


I	ndex	Label	Main Runs		Start Time	User name
	1	blank	3	1		ICAP-Q\Thermo
		cal 0	3	1		ICAP-Q\Thermo
		Cal 1	3	1	9/26/2017 10:43:18 AM	ICAP-Q\Thermo
	4	Cal 2.5	3		9/26/2017 10:47:04 AM	ICAP-Q\Thermo
	5	Cal 5	3		9/26/2017 10:50:50 AM	ICAP-Q\Thermo
	6	Cal 10	3	1	9/26/2017 10:54:37 AM	ICAP-Q\Thermo
	7	Cal 25	3	1	9/26/2017 10:58:24 AM	ICAP-Q\Thermo
	8	Cal 50	3	1	9/26/2017 11:02:12 AM	ICAP-Q\Thermo
	9	Cal 80	3	1	9/26/2017 11:06:00 AM	ICAP-Q\Thermo
	10	Cal 100	3	1	9/26/2017 11:09:49 AM	ICAP-Q\Thermo
	11	blank	3	1	9/26/2017 11:13:38 AM	ICAP-Q\Thermo
	12	Control 4 A	3	1	9/26/2017 11:17:28 AM	ICAP-Q\Thermo
	13	Control 40 A	3	1	9/26/2017 11:21:19 AM	ICAP-Q\Thermo
	14	blank	3	1	9/26/2017 11:25:03 AM	ICAP-Q\Thermo
	15	2017-00469 Item 2 A	3	1	9/26/2017 11:28:48 AM	ICAP-Q\Thermo
	16	2017-00469 Item 2 B	3	1	9/26/2017 11:32:34 AM	ICAP-Q\Thermo
	17	blank	3	1	9/26/2017 11:36:20 AM	ICAP-Q\Thermo
		2017-00469 Item 5 A	3	1	9/26/2017 11:40:07 AM	ICAP-Q\Thermo
	19	2017-00469 Item 5 B	3	1	9/26/2017 11:43:54 AM	ICAP-Q\Thermo
	20	blank	3	1	9/26/2017 11:47:42 AM	ICAP-Q\Thermo
	21	Control 4 B	3	1	9/26/2017 11:51:31 AM	ICAP-Q\Thermo
	22	Control 40 B	3	1	9/26/2017 11:55:20 AM	ICAP-Q\Thermo
	23	blank	3	1	9/26/2017 11:59:10 AM	ICAP-Q\Thermo

callision cell reardysis



No. of sweeps | Time per sweep[s] | Time per main run[s] 10 0.08

Calibration Curves:




f(x) = 6.7263*x + 79.0544 $R^2 = 0.9826$ BEC = 11.753 ppb

LOD = N/A


LOD = N/A

4000 8

ಞ ca




f(x) = 366.7477*x + -214.6697 $R^2 \approx 0.9983$ BEC = -0.585 ppb



f(x) = 2.4103*x + 1155.4931 $R^2 = 0.5462$

BEC = 479.403 ppb

LoD = N/A




f(x) = 2330.3060*x + -891.6872

 $R^2 = 0.9986$

8EC = -0.383 ppb

LoD = N/A




f(x) = 106.8231*x + 163.8325

 $R^2 = 0.9943$

BEC = 1.534 ppb

LoD = N/A




f(x) = 12293.1490*x + -15536.5444 $R^2 = 0.9990$

BEC = -1.264 ppb

LoD = N/A





f(x) = 620.4407*x + 21932.5277 $R^2 = 0.9967$

BEC = 35.350 ppb

LoD = N/A

2817-88464 1827-2817



Label	7Li (KED) [ppb] 1	1B (KED) [ppb]	75As (KED) [ppb] 8	88Sr(KED)[ppb]
blank	-11.257	-476.637	-1.534	-35.189
cal 0	-1.346	-13.319	0.651	-0.263
Cal 1	-1.346	-10.553	1.244	-1.645
Cal 2.5	5.096	-7.787	2.710	1.794
Cal 5	0.636	42.006	5.488	8.953
Cal 10	10.548	50.304	10.137	11.017
Cal 25	31.857	-45.130	22.090	23.740
Cal 50	-3.328	7.426	0.651	2.289
Cal 80	71.504	93.181	85.747	77.906
Cal 100	105.204	101.480	96.084	101.735
blank	-11.257	-476.637	-1.502	-35.130
Control 4 A	0.636	-14.702	3.490	4.808
Control 40 A	41.769	22.642	43.253	42.412
blank	-11.257	-476.637	-1.534	-35.124
2017-00469 Item 2 A	-4.319	1,310.4791	0.432	1.013
2017-00469 Item 2 B	-8.780	1,459.891 기	0.807	2.240
blank	-11.257	-475.254 W ₃	ر -1.534 .	-35.167
2017-00469 Item 5 A	1.1327 much	266.0751	60.205 Televil	91.655 ₇ mir
2017-00469 Item 5 B	8.070 \ (chulch	217.663 ^ل 217	سر کری [59.019]	F. W 81.419 (1)
blank	-11.257	-473.871	-1.534 10 km	141° C -35 157
Control 4 B	1.132	-11.937	إنس المستراد 3.241	^y " 6.241
Control 40 B	39.787	-13.319	37.447	41.226
blank	-11.753	-479.403	-1.534	-35.140

Label	115In (KED) [%]	137Ba (KED) [ppb]	138Ba (KED) [ppb]	238U (KED) [ppb]
blank	70.521	0.740	0.557	1,399
cal 0	117.642	1.503	1.201	1.284€
Cal 1	100.000	1.940	1.911	2.039
Cal 2.5	101.760	3.321	3.531	3.191
Cal 5	109.260	5.294	5.466	5,418
Cal 10	104.584	9.885	10.156	9,672
				b6 FRI(20-0/-0545)-2

3/5

Report

9/26/2017 12:50:21 PM



Label	115In (KED) [%]	137Ba (KED) [ppb]	138Ba (KED) [ppb]	238U (KED) [ppb]
Cal 25	102.369	21.888	21.821	22.291
Cal 50	112.692	1.240	1.188	1.270
Cal 80	111.478	82.141	79.476	81.135
Cal 100	103.067	99.032	101.141	99.754
blank	14.228	0.776	0.613	1.291
Control 4 A	101.670	3.158	3.140	3.235
Control 40 A	109.139	41.019	42.255	40.091
blank	12.226	0.803	0.597	, 1.269
2017-00469 Item 2 A	120.677	ليريم 81.258	الم 91.487 _{7)ه} ر.	ر 1.288
2017-00469 Item 2 B	111.811	84.611 Jewan	95.385	1.291
blank	11.619	0.703	1 0.577	
2017-00469 Item 5 A	99.119	2.3497 5418	الالمرر 2.331 من الم	1.268
2017-00469 Item 5 B	104.553	2.349 " " " 2.312 2. " " " " " " " " " " " " " " " " " "	/ 2.182 كالم	1.269
blank	10.739	0.913	/ 0.836 \	、 、 1.266
Control 4 B	112.661	2.976	/ 3.393	3.132
Control 40 B	110.597	34.833	/ 41.819	36.922
blank	11.649	0.713	/ 0.593	1.268
	Ø			

Will use 138 Ba

91+95) = 93/m/

b6 -1 b7C -1

x= 2.2 m/ml



b6 -1 b7C -1

5/5

Intensities

9/26/2017 12:34:34 PM



Instrument Name - Senai Number - ICAP Q SN02602R

Labbook: Labbook Path: multielement urine screen KED.lmexp

Analysis index: 14 Analysis started at: 9/26/2017 11:25:03 AM Analysis label: blank User name: ICAP-Q\Thermo

75As (KED) 11B (KED) 115In (KED) | 1378a (KED) | 1388a (KED) | 238U (KED) Category Intensity average 3 cps 7 сря 0 срѕ 140 cps 1,343 cps 80 cps 500 cps 60 cps Intensity per Run 1 0 cps 0 cps 0 cps 60 cps 1,350 cps 70 cps 450 cps 90 cps Intensity per Run 2 0 cps 0 cps 0 cps 120 cps 1,310 cps 110 cps 340 cps 30 cps Intensity per Run 3 240 cps 1,370 cps 710 cos 10 cps 20 cps 0 cps 60 cps 60 cps Intensity RSD 173.2 % 173.2 % 65.5 % 2.3 % 33.1 % 38.0 % 50.0 %

b6 -1 b7C -1

b7E -2

Intensities

9/26/2017 12:34:34 PM



b7E -2

Instrument Name | Serial Number ICAP Q SN02602R

Labbook: Labbook Path: multielement urine screen KED.Imexp

Analysis Index:

15

Analysis started at: 9/26/2017 11:28:48 AM

Analysis label:

2017-00469 Item 2 A User name: ICAP-Q\Thermo

Category 7Li (KED) 11B (KED) 75As (KED) 885r (KED) | 115in (KED) | 1378a (KED) | 1388a (KED) | 238U (KED) Intensity average 4,314 cps 4,141 cps 50 cps 210 cps 22,561 cps 13,261 cps 29,587 cps 212,300 cps 300 cps Intensity per Run 1 40 cps 22,952 cps 160 cps 13,077 cps 28,303 cps 208,123 cps 270 cps Intensity per Run 2 50 cps 4,431 cps 240 cps 22,060 cps 12,967 cps 31,682 cps 209,761 cps 180 cps Intensity per Run 3 60 cps 4,371 cps 230 cps 22,671 cps 13,738 cps 28,774 cps 219,016 cps 450 cps Intensity RSD 20.0 % 3.5 % 20.8 % 2.0 % 3.1 % 6.2 % 2.8 % 45.8 %

Intensities

9/26/2017 12:34:34 PM



Instrument Name: Serial Number: ICAP Q SN02602R

Labbook: Labbook Path: multielement urine screen KED imexp

Analysis index: 16 Analysis started at: 9/26/2017 11:32:34 AM

Analysis label: 2017-00469 Item 2 B User name:

ICAP-Q\Thermo

Category	7Li (KED)	11B (KED)	75As (KED)	885r (KED)	115In (KED)	1378a (KED)	1388a (KFD)	238U (KED)
Intensity average	20 cps	4,674 cps	250 cps	23,322 cps	12,286 cps	30,816 cps	221,385 cps	330 cps
Intensity per Run 1	20 cps	4,561 cps	230 cps	23,513 cps	12,737 cps	32,945 cps	219,722 cps	310 cps
Intensity per Run 2	40 cps	4,631 cps	220 cps	21,599 cps	11,566 cps	28,634 cps	217,062 cps	260 cps
Intensity per Run 3	0 cps	4,831 cps	300 cps	24,855 cps	12,557 cps	30,870 cps	227,373 cos	420 cps
Intensity RSD	100.0 %	3.0 %	17.4 %	7.0 %	5.1 %	7,0%	2.4 %	24.8 %

b6 -1 b7C -1

b7E -2

Intensities

9/26/2017 12:34:34 PM



Instrument Name: Serial Number: ICAP Q SN02602R

Labhaak Dath Labbook: multielement urine screen KED.imexp

Analysis Index: 17

Analysis started at: 9/26/2017 11:36:20 AM

Analysis label: blank User name: ICAP-Q\Thermo

Category	7Li (KED)	11B (KED)	75As (KED)	88Sr (KED)	115ln (KED)	137Ba (KED)	138Ba (KED)	238U (KED)
Intensity average	3 cps	10 cps	0 cps	113 cps	1,277 cps	43 cps	453 cps	50 cps
Intensity per Run 1	0 cps	0 cps	0 cps	90 cps	1,180 cps	80 cps	500 cps	50 cps
Intensity per Run 2	0 cps	20 cps	0 cps	150 cps	1,280 cps	20 cps	410 cps	40 cps
Intensity per Run 3	10 cps	10 cps	0 cps	100 cps	1,370 cps	30 cps	450 cps	60 cps
Intensity RSD	173,2 %	100.0 %		28.4 %	7.4 %	74.2 %	9,9 %	20.0 %

7-88 45

7-8845 - 28 3

Intensities

9/26/2017 12:34:34 PM



Instru	ment	Name:	Serial N	umber.
ICAP C)		SN0260	2R

Lahbook Path: multielement urine screen KED.imexp

Analysis index: 18

Analysis started at: 9/26/2017 11:40:07 AM

Analysis label: 2017-00469 Item 5 A User name: ICAP-Q\Thermo

Category	7L (KED)	11B (KED)	75As (KED)	88Sr (KED)	115In (KED)	137Ba (KED)	138Ba (KED)	238U (KED)
Intensity average	87 cps	1,797 cps	6,595 cps	78,799 cps	10,892 cps	647 cps	4,541 cps	53 cos
Intensity per Run 1	40 cps	1,700 cps	6,652 cps	75,440 cps	11,095 cps	670 cps	4,181 cps	60 cps
Intensity per Run 2	110 cps	1,870 cps	6,322 cps	77,144 cps	10,765 cps	610 cps	4,211 cps	40 cps
Intensity per Run 3	110 cps	1,820 cps	6,812 cps	83,813 cps	10,815 cps	660 cps	5,231 cps	60 cps
Intensity RSD	45.6 %	4,9 %	3.8 %	5.6 %	1.6 %	5.0 %	13.2 %	21.7 %

Intensities

9/26/2017 12:34:34 PM



į	į	Ì	ì	å	Ì	ì	ĺ	j	å	į	į	į	ĺ	i	į	ğ	ľ	ľ	į	1	i	Ü	Ì	Ċ	Ì	į	å	Ĭ	Ì	į	3	ľ	ì	į	į	١	Ì	ľ	Š	ľ	j	i	i	i	2	ľ	1	Ì	Š	i	i	
	3	ξ		A	Ì	>		Ċ	2																						S	1	Ų	ţ		2	ŧ		Ü		2	ſ	ì									

Labbook Paths multielement urine screen KED.imexp

Analysis index: 19

Analysis started at: 9/26/2017 11:43:54 AM User name: ICAP-Q\Thermo

Analysis label: 2017-00469 Item 5 8

Category	7L (KED)	11B (KED)	75As (KED)	88Sr (KED)	115In (KED)	137Ba (KED)	1388a (KED)	288U (KED)
Intensity average	133 cps	1,680 cps	6,468 cps	72,448 cps	11,489 cps	633 cps	4,194 cps	60 cps
Intensity per Run 1	140 cps	1,640 cps	6,472 cps	66,732 cps	11,886 cps	630 cps	4,301 cps	70 cps
Intensity per Run 2	120 cps	1,550 cps	6,322 cps	76,779 cps	10,475 cps	580 cps	3,811 cps	50 cps
Intensity per Run 3	140 cps	1,850 cps	6,612 cps	73,834 cps	12,106 cps	690 cps	4,471 cps	60 cps
Intensity RSD	8.7 %	9.2 %	2.2 %	7.1 %	7.7 %	8.7 %	8.2 %	16.7 %

2017-88469 1027-2817

Intensities

9/26/2017 12:34:34 PM



b7E -2

į	Ĭ	į	į	i	į	ì	ŀ	į	Ì	١	Ì	į	l	Ì	١	ì	١	ĺ	i	Ì	į	į	ì	į	į	١	l	į	į	ì	ì	į	j				ļ	ì	į		į	í	i	į	Ì	į		l	١	Ì	į	l	į	2	į	į	Ì	Š	į	į	ĺ	ě	ĺ	١	I	Ì
	j		Ċ		•	١	į			1																														Ì	į		C	١	1	į	ŝ		ĺ	}		į		ľ	Ì											

Labbook Path: multielement urine screen KED imexp

Analysis started at: 9/26/2017 11:47:42 AM

Analysis index: 20 Analysis label: blank blank User name:

ICAP-Q\Thermo

Category	7L (KED)	11B (KED)	75As (KED)	88Sr (KED)	115In (KED)	1378a (KED)	1888a (KED)	238U (KED)
Intensity average	3 cps	13 cps	0 cps	120 cps	1,180 cps	120 cps	1.057 cps	27 cps
Intensity per Run 1	0 cps	0 cps	0 cps	130 cps	970 cos	120 cos	1,080 cps	10 cps
Intensity per Run 2	10 cps	0 cps	0 cps	120 cps	1,370 cps	130 cps	1,150 cos	30 cps
Intensity per Run 3	0 cps	40 cps	0 cps	110 cps	1,200 cps	110 cps	940 cps	40 cps
Intensity RSD	173.2 %	173.2 %		8.3 %	17.0 %	8.3 %	10.1 %	57.3 %

2017-00469 1027-26:7

Intensities

9/26/2017 12:34:34 PM



Instrument Name: Serial Number ICAP Q SN02602R

Labbock: Labbook Path: multielement urine screen KED imexp

Analysis index: 21

Analysis started at: 9/26/2017 11:51:31 AM

Analysis label: Control 4 B

User name:

ICAP-Q\Thermo

20000000000								
Category	7LI (KED)	11B (KED)	75As (KED)	88Sr (KED)	115 n (KED)	137Ba (KED)		DESIGNATION OF THE PARTY OF THE
Intensity average	87 cps	1,127 cps	510 cps	25,804 cps	12,380 cps	877 cos	7.015 cps	22,965 cos
Intensity per Run 1	60 cps	1,150 cps	450 cps	26,439 cps	11,816 cps	930 cps	7,032 cps	21,730 cps
Intensity per Run 2	70 cps	1,160 cps	440 cps	24,425 cps	12,256 cps	940 cos	7,202 cps	22.621 cps
Intensity per Run 3	130 cps	1,070 cps	640 cps	26,549 cps	13.067 cps	760 cos	6.812 cps	24,545 cps
Intensity RSD	43.7 %	4.4 %	22.1 %	4.6 %	5.1 %	11.5 %	2.8 %	6.3 %

Intensities

9/26/2017 12:34:34 PM



Instrument Name Serial Number ICAP Q SN02602R

Labbook: Labhook Path: multielement urine screen KED.Imexp

Analysis index: 22

Analysis started at: 9/26/2017 11:55:20 AM

Analysis label: Control 40 B User name:

ICAP-Q\Therma

Category	7L (KED)	118 (KED)	75As (KED)	88Sr (KED)	1151n (KED)	1878a KEN	TERES WEST	238U (KED)
Intensity average	347 cps	1,123 cps	4,164 cps	47,511 cps	12,153 cps	12.560 cms	96.560 cos	438,353 cps
Intensity per Run 1	410 cps	1,130 cps	4,171 cps	48,016 cps	11,055 cps	12,567 cps	92,923 cps	458.905 cps
Intensity per Run 2	340 cps	970 cps	4,281 cps	47,997 cps	12,967 cps	12.347 cos	97,093 cps	425,900 cps
Intensity per Run 3	290 cps	1,270 cps	4,041 cps	46,520 cps	12,437 cps	12,767 cps	99.663 cps	430,254 cps
Intensity RSD	17.4 %	13.4 %	2.9 %	1.8 %	8.1%	1.7 %		4.1 %

Exclusionary Drug Screen by UPLC-ESI-FTMS

2017-00469

Item 1, blood

Item 2, urine

Item 3, blood

Item 5, urine

nt watel

b6 -1 b7C -:

The samples were aliquoted, extracted, and analyzed on 09/28/2017 and 09/29/2017.

ь7c -1

2017-00469 102 冲B1(20-cv-0545)-1183



EXCLUSIONARY DRUG SCREEN BY UPLC-ESI-FTMS CHEMISTRY UNIT TOXICOLOGY SOP 215-2

CHEMIST:			
DATE:	9/28	3/17	

PROC	CEDURE:	WWW.0000000000000000000000000000000000		TO DO DO DE LA COLUMN DE LA COL
·	or blood specimens:	,		
1	Add 0.3 mL each sample and control to a properly-labeled	LOT NEC		
521	13 x 100 mm test tube. Add 25 μL of Internal Standard Working Solution.		X25758	
<u></u>			LOT: TOXZIS_ISTO_KOTO	
10	Add 0.7 mL 0.5 M, pH 5 Ammonium Acetate Buffer.		LOT:	<u>'</u> be
Þ	Add 0.6 mL DI water and vortex.			b7
ļ,				b7
16	Add 80 µL of 4.5 M Ammonium Hydroxide and vortex.		LOT Ammonia: 나를 하면 나	
L	Prepare fresh by combining 1.4 mL deionized water and 0.6 n	nl. concentra	ited ammonium hydroxide in a test tube	
Fi	or urine specimens:			
J. J.	Add 0.3 mL each unknown and control to a properly-labeled	LOT NEC	GCTL: 72312	
	13 x 100 mm test tube.		E dien's E dien	
je.	Prepare hydrolysis control urine (0.005 mL morphine gluc	LOT Mor	rp Gluc Cil WS:	
	ctl ws to 0.3 mL negative control urine).		pposition, Added 15 july	
surfate part	Add 25 µL of Internal Standard Working Solution.		LOT: TOXZES ISTO_1(6570)	
A.	Enzymatic Hydrolysis:	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~) and white and a contract of the contract of	b
J. J. W.	Add 0.6 mL of 0.5 M, pH 5 Ammonium Acetate Buffer		T OT	b7
A. S.	Liga 616 Bits of 672 Mr. bit 3 Antinounnin Acetate Dittel.		LOT:	
AR S	Add 100 μL β-Glucuronidase (H. Rufescena)		LOT: /)cro/a	
a de la companya de l	Vortex, cap, and incubate 30 minutes at 68° C.		LOI: Acota	
, Marie	Cool to room temperature.		}	
The second	Add 0.6 ml. DI water and vortex.			
, jide of	Add 80 µL of 4.5 M Ammonium Hydroxide and vortex.		LOT Ammonia: 163894	
	Prepare fresh by combining 1.4 mL deionized water and 0.6 m	nl. concentra	nted ammonium bydrovide in a test tube	
			and an analysis of the control of th	
	r all specimens: epare SLE cartridge:		Low	
	<u> </u>		LOT: 16196627GF	
Lo	ad samples by gravity. Brief application of low vacuum will be nec	cessary at the	e start of loading. DO NOT ELUTE.	
All	low to stand for 5 minutes.			
	pply 3 mL of 95/5 dichloromethane / isopropanol and allow to absor-	rb.	LOT:	
	low to stand for 5 minutes. DO NOT APPLY VAC			b6
Eh	ate by gravity into 16 x 100 mm culture tubes with 2 x 4 mL 95/5 di	ichloromath	200 / Icongrapho)	bo
Bri	iefly apply full vacuum to complete elution.	emonomeme m	me : isopropanor	b7E
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
E.V.	aporate at 45° C. When eluent volume reaches 0.5-1 mL, vortex bri	iefly before e	evaporating to dryness.	
Re	consititute with 0.1 mL of 95/5 water / acetonitrile.		LOT:	
Fil	ter with 0.43 jum centrifuge tubes.			
	alyze 20 µL of extract by UPLC-ESI-FTMS.			
	onal Notes / Deviations			
	TARRELLA LA TARRELLA LA			
. Marin				b6



EXCLUSIONARY DRUG SCREEN BY UPLC-ESI-FTMS CHEMISTRY UNIT TOXICOLOGY SOP 215-2 INSTRUMENTAL METHOD PARAMETERS


CHEMIST:		
DATE:	9/28/17	

b6 -1 b7C -1

200hada4hadaa	**********	10000100000000000000000000000000000000				Buch #5	
LC/MS Instrumer	ıt N	ame: CU-EXACTIVE-1	M	lethod File Name: Exclusion	ice".		••••
Mobile Phase A:	2	5 mM ammonium formate with 0.1% formic acid	Lo		naoitticiùicab		•
Mobile Phase B:	Æ	acetonitrile with 0.1% formic acid	Lo	1#			
Mobile Phase Gradient:	Ø	Start at 95% A, hold 0.9 min	Į,	Ramp to 60% A at 2.67 min. Hold 2 min	Æ	Ramp to 0% A at 5.56 min, Hold 1.44 min	
	Ŕ	Ramp to 95% A at 7.25 min, Hold 2.75 min	(a)	Total Run Time = 10 min	Æ	Event table: at 6.25 min, cycle inject valve	b6 -1 b7C -1
LC Column:	Çi	Waters Cortecs C18-UPLC; 50x2.1	mm	x 1.6 μm, 5x2.1 mm precolumn C	olumi	18N: 017034308177332	b7E -9
2.00	æ	Flow Rate = 0.5 mL/min	E	Temperature = 30°C	T		
	9	Injection Volume = 20 μL	تتر	Temperature = 14°C			
Autosampler:	Æ	Seal & Weak Washes 10 / 90 acetonitrile;water Strong wash 437 407 107 3			Lot	#	
00000000000000000000000000000000000000	2	www.diamahamitasibabaasibaasibaasibaasibaasibaasibaa	000000000	NAMES AND ADDRESS OF THE STREET OF THE STREE	Lot	#	
Mass Spectrometer:	12	Source = ESL positive ion	22	Mode = full scan MS	æ	FTMS 70000 resolution	
stenos aperte ameter:	ij	Range 180-525 m/z	Þ	Max Ionization Time = 50 ms	12	AGC=1e6	

NOTES & DEVIATIONS:

	b6 -1
	b7 C −:



Path				
Inj Vol				
20 uL	VELLEV	abali?		
File Name	Sample Name	Position	Instrument Method	
20170929_01	sb	2:A,5		
20170929_02	sb	2:A,5		
20170929_03	ncu	2:A,6		
20170929_04	2017-00469, 2, urine	2:A,7		
20170929_05	hydrolysis check	2:8,6		
20170929_06	sb	2:A,8		
20170929_flush	sb-flush	2:B,2		
20170929_standby	sb-standby	2:8,4		

b6 -1 b7C -1

b6 -1 b7C -1 b7E -2

b7E -2

7-aminoflunitrazepam

alprazolam

bromazepam

clonazepam

diazepam

estazolam

flurazepam

flunitrazepam

etizolam

chlordiazepoxide

desalkylflurazepam

desmethylflunitrazepam

4

+

4

4

+

+

4

4

4

+

N/A

				Exclusion	ary Scree	ning by UP	LC/FTMS				
Batch:	20170928				•		-			2017.4	0469, 1, blood
Method:	ExclusionSOP_TargetingScreening	ıg					Sample	·		20117	70403, 1, DIOUU
Inst. Method:		~					Comment				
Acquired:	9/28/2017 23:27						Commen		······································	·····	
Sample Type:	Unknown		Lab Name:	FBI Laborator	v:		File				20170928 34
Vial Position	1:D.6		Ассау:	Exclusionary S	•	X 215		***************************************	***************************************		20710020
Detected	Target Name	+1-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes	
	d5-alprazolam	4	1.64E+07	3.07 (-0.03)314.1215	314.1221	0.54	100.00	6 of 7	······································	
	d5-hydroxalprazolam	+	2.86E+06	2.91 (-0.03)330.1165	330.1170	0.58	100.00	6 of 6	·····	
	d4-clonazepam	+	4.51E+05	3.08 (-0.03	320.0735	320.0739	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	100.00	4 of 5	·····	·····
	d4-7-aminoclonazepam	+	3.90E+06	2.06 (-0.01	290.0993	290.0997	0.43	100.00	5 of 6	***************************************	
	d5-diazepam	+	1.05E+07	3.7 (-0.05)		**********		100.00	5 of 7	***************************************	
•	d5-oxazepam	+	1.14E+06	2.99 (-0.01				100.00	4 of 5		
•	d6-zolpidem	+	8.17E+06	2.36 (-0.01				100.00	3 of 3	***************************************	
•	d3-benzoylecgonine	+	7.70E+07	1.96 (-0.01	·			100.00	5 of 5		
•	d3-diphenhydramine	+	5.43E+06	2.73 (0)	259.1884	259,1888		100.00	3 of 4		·····
•	d6-oxycodone	+	1.77E+07	1.71 (-0.01)		322.1925		100.00	4 of 4		
•	d3-morphine	+	1.35E+07	0.56 (0)	289.1626	289.1630		100.00	4 of 4		······································
•	d3-hydrocodone	*	1.33E+07	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	303.1783	303.1787	~~~	100.00	3 of 4		
	morphine	4.	N/A	N/A (N/A)	286.1438	N/A	N/A	***************************************	N/A		······
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A	**********	N/A		***************************************
	hydroxymidazolam	+	N/A	N/A (N/A)	342.0804	N/A	N/A		N/A	·	·····
***************************************	hydroxytriazolam	+	N/A		359.0461	N/A	N/A	~~~~~	N/A		······
	7-aminoclonazepam	+	N/A	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	286.0742	N/A	N/A		N/A		·····

N/A (N/A)

284.1194 N/A

309.0902 N/A

289.0539 N/A

300.0779 N/A

285.0789 N/A

295.0745 N/A

343.0779 N/A

314.0936 N/A

388.1586 N/A

N/A

N/A

N/A

316.0080

300.0898

316.0484

b7E -2

b6 -1 b7C -1



N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A N/A

brompheniramine

chlorpheniramine

N/A

N/A

N/A (N/A)

N/A (N/A)

Exclusionary Screening by UPLC/FTMS

				EXCIDING	ial A priced	mig by Or	rclutions.				
Batch:	20170928						Sample			2017-00	0469, 1, blood
Method:	ExclusionSOP_TargetingScreening	ng					Online's		***************************************		
Inst. Method:							Comment				
Acquired:	9/28/2017 23:27									***************************************	-
Sample Type:			Lab Name:	FBI Laborator	rý		File		·		20170928_34
Vial Position	1:D.6		Accepy:	Exclusionary	Screening TOX	(215					
L				****	·····						
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	MMU	lsotopic Pattern Score (%)	Num Isotopes Matched	Notes	
***************************************	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A	N/A		N/A	·	
***************************************	lormetazepam	4-	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A		
····	medazepam	+	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A	***************************************	
***************************************	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A	***************************************	***************************************
	nordiazepam	+	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A	***************************************	
	oxazepam	+	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A	·····	
	phenazepam	+	N/A	N/A (N/A)	348.9738	N/A	N/A	N/A	N/A	***************************************	
	prazepam	4	N/A	N/A (N/A)	325.1102	N/A	N/A	N/A	N/A	***************************************	
	temazepam	+	N/A	N/A (N/A)	301.0738	N/A	N/A	N/A	N/A		
	tetrazepam	+	N/A	N/A (N/A)	289.1102	N/A	N/A	N/A	N/A	······································	
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A		
	6-acetylmorphine	+	N/A	N/A (N/A)	328.1543	N/A	N/A	N/A	N/A	***************************************	
	codeine	+	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A	····	
	dihydrocodeine	+	N/A	N/A (N/A)	302.1751	N/A	N/A	N/A	N/A		
	dihydromorphone	+	N/A.	N/A (N/A)	288.1594	N/A	N/A	N/A	N/A	·	
	EDDP	4	N/A	N/A (N/A)	278.1903	N/A	N/A	N/A	N/A	~~~	
	hydrocodone	4	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A		
	hydromorphone	+	N/A	N/A (N/A)	286.1438	N/A	N/A I	V/A	N/A		•
	norcodeine	+	N/A	N/A (N/A)	286.1438	N/A	N/A I	V/A	N/A	7	
	normorphine	+	N/A	N/A (N/A)	272.1281	N/A	N/A I	V/A	N/A	~~	
	noroxycodone	+	N/A	N/A (N/A)	302.1387	N/A	N/A I	V/A	N/A	7	
	oxycodone	+	N/A	N/A (N/A)	316.1543	N/A	N/A I	V/A	N/A	7	
	oxymorphone	+	N/A	N/A (N/A)	302.1387	N/A	N/A I	V/A	N/A	7	
	ecgonine methyl ester	+	N/A	N/A (N/A)	200.1281	N/A	N/A I	V/A	N/A	~	
•	benzoylecgonine	+	1.16E+05	1.96 (0)	290.1387	290.1390	0.33 8	39.00	1 of 2	ĭL	
	cocaethylene	+	N/A	N/A (N/A)	318.1700	N/A	N/A I	V/A	N/A	hat ou	Usi Y
	cocaine	+	1.32E+05	2.31 (0.01)	304,1543	304 1556	1.25.8	35.00	1 of 2	1	0

319.0804 N/A

275.1310 N/A

b6 -1 b7C -1

b7E -2


N/A

N/A

N/A N/A

N/A N/A

				Exclusion	ary Screer	ning by UF	LC/FTMS					
Batch:	20170928						Sample	ı.		2017	-00469, 1, bloc	nd
Method:	ExclusionSOP_TargetingScreening						Danipie					
Inst. Method:							Comment	•				
Acquired:	9/28/2017 23:27						4777	·	······································	***************************************		-
Sample Type:	Unknown		Lab Name:	FBI Laborator	y		File				20170928	34
Vial Position	1:D.6		Accou;	Exclusionary	Screening TO	X 215		***************************************	***************************************	····		Anna '
					-							
Detected		+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		·····
***************************************		+	N/A	N/A (N/A)	272.2009	N/A	N/A	N/A	N/A			
	dextrorphan	4	N/A	N/A (N/A)	258.1852	N/A	N/A	N/A	N/A	***************************************	***************************************	
	diphenhydramine	+	N/A	N/A (N/A)	256.1696	N/A	N/A	N/A	N/A	~~~~~~		
	doxylamine	+	N/A	N/A (N/A)	271.1805	N/A	N/A	N/A	N/A		***************************************	
	hydroxyzine	+	N/A	N/A (N/A)	375.1834	N/A	N/A	N/A	N/A	***************************************		
	norchlorcyclizine	+	N/A	N/A (N/A)	287.1310	N/A	N/A	N/A	N/A			
	pheniramine	+	N/A	N/A (N/A)	241.1699	N/A	N/A	N/A	N/A	*****	***************************************	
	tetrahydrozoline	+	N/A	N/A (N/A)	201.1386	N/A	N/A	N/A	N/A			
	zaleplon	+	N/A	N/A (N/A)	306.1349	N/A	N/A	N/A	N/A			
	zolpidem	+	N/A	N/A (N/A)	308.1757	N/A	·····	N/A	N/A			····
	zopiclone	+	N/A	N/A (N/A)	389.1123	N/A	·····	N/A	N/A			~~~
	duloxetine	+	N/A	N/A (N/A)	298.1260			N/A	N/A	•		
		•••••		······································		•						



b7E -2

800

-

ထာ

863

~


27-2817

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


2017-00469 1 blood


Compound:	d5-alprazolam	Compound:	d5-hydroxalprazolam	Compound:	d4-clonazepam	Compound:	d4-7-aminoclonazepam
RT(exp)	3.1	RT(exp)	2.94	RT(exp)	3.11	RT(exp)	2.07
RT(delta)	3.07 (-0.03)	RT(delta)	2.91 (-0.03)	RT(delta)	3.08 (-0.03)	RT(delta)	2.06 (-0.01)
Area:	16430000	Area:	2859900	Area:	450930	Area:	3899200
m/z:	314.1221	m/z:	330.1170	m/z:	320.0739	m/z:	290.0997
delta	(mmu): 0.54	delta	(mmu): 0.58	delta	(mmu): 0.49	delta	(mmu): 0.43
12500000 - 12500000 - 12500000 - 12500000 - 12500000 - 12500000 - 12500000 - 12500000 - 12500000 - 12500000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 1250000000 - 12500000000 - 12500000000 - 125000000000000000000000000000000000000	RT. 3.37 AA 16623946.18	2400205 2206008 2000000 1800000 1800000 420000 420000 1000000 1000000 400000 200000	RT 1.91 AA 2828574.15	250005 250005 250005 190000 150000 250000	FRT 2-358 AAX 4525532-196	2500000 2500000 2500000 1500000 1500000	877.2.35 AX 30000782.97

Compound:	d5-diazepam	Compound:	d5-oxazepam	Compound:	d6-zolpidem	Compound:	d3-benzoylecgonine
RT(exp)	3.75	RT(exp)	3	RT(exp)	2.37	RT(exp)	1.97
RT(delta)	3.7 (-0.05)	RT(delta)	2.99 (-0.01)	RT(delta)	2.36 (-0.01)	RT(delta)	1.96 (-0.01)
Area:	10496000	Area:	1143800	Area:	8172500	Area:	76963000
m/z:	290.1108	m/z:	292.0900	m/z:	314.2137	m/z:	293,1578
delta	(mmu): 0.45	delta	(mmu): 0.46	delta	(mmu): 0.25	delta	(mmu): 0.27



	SEC 2.95		
	A4 5988772 07	•	
10000003-{	{		
- }			
¥00000-			
4	8		
smm{	8		
	- 3		
TUDOWS -	- 8		
SURRE	#		3
SALESSON -			- 1
500000-			- 3
			į
4000000			3
1			3
300000-	!		3
, i			- 3
10X002~	[iii]		- 1
1	}		- }
1000000			3
\$00000 \$00000 \$00000 \$00000 \$00000 \$00000 \$00000 \$00000			3
325	25 22	33 Imminonium	1
40.	2.5. 2.2	A. 24	- 3





TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_34 Acquired 9/28/2017 23:27

2017-80469

1827-2817

Compound:	d3-diphenhydramine	Compound:	d6-oxycodone	Compound:	d3-morphine	Compound:	d3-hydrocodone
RT(exp)	2.73	RT(exp)	1.72	RT(exp)	0.56	RT(exp)	1.83
RT(delta)	2.73 (0)	RT(delta)	1.71 (-0.01)	RT(delta)	0.56 (0)	RT(delta)	1.8 (-0.03)
Area:	5431600	Area:	17715000	Area:	13513000	Area:	13292000
m/z:	259.1888	m/z:	322.1925	m/z;	289.1630	m/z:	303,1787
delta	(mmu): 0.42	delta	(mmu): 0.5	delta	(mmu): 0.39	delta	(mmu): 0.4
8	RF 2.72 AA 562-675.5 (18000000 14000000 12000000 12000000 12000000 1000000 1000000 10000000 10000000	RT 1.71 AA 1771519E2E	7500203 - 750020000 - 750020000000000000000000000000000000000	FT 0.56 AA *251252:19	**************************************	RT : 80 AA : 200004:15


Compound:	morphine	Compound:	hydroxyalprazolam	Campound:	hydroxymidazolam	Compound:	hydroxytriazolam
RT(exp)	0.56	RT(exp)	2.9	RT(exp)	2.67	RT(exp)	2.9
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area	N/A	Area:	N/A
n/z:		m/z:		m/z:		m/z:	
ielta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
52 - 53 - 53 - 53 - 53 - 53 - 53 - 53 -	877.0.52 AN 8450 35 36 37	20 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	SE 230 AA 500 SE 230	25 25 25 27 27 27 27 27 27 27 27 27 27 27 27 27	90 257 A+ Dax	92	**************************************


ccc

File 20170928_34 Acquired 9/28/2017 23:27

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 6 of 12





Page 7 of 12 File 20170928_34 TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS 9/28/2017 23:27 Acquired 2017-00469, 1, blood diazepam estazolam etizolam Compound: flunitrazepam Compound: Compound: Compound: RT(exp) 3.7 RT(exp) RT(exp) 3.25 3.22 RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A Area: N/A Area: N/A N/A Area: Area: m/z: m/z: m/z: m/z: (mmu): N/A delta delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 2500 50003-327~ 4930 40003 23300 XXX. SX-43-2800,-202 30... :S93-23-1032 10-27.3.75 AA: 3330 **33**0. ١. 10. 87, 3,00 84, 6,00 87.3.28 44.200 AT 1.22 AA 0.00 3.4 flurazepam lorazepam lormetazepam medazepam Compound: Compound: Compound: b6 -1 b7C -1

RT(exp)	2.71	RT(exp)	3.04	RT(exp)	3.43	RT(exp)	2.71	b7C -1
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
m/z:		m/z:		m/z:		m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	
20 - 20 - 20 - 20 - 20 - 20 - 20 - 20 -	87° 2.7°; 64° 5.50°	2		22 23	90° 2.43 AA 300° 24 25 35	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	877.2 77 AA 3335 25 27 FBI(20-cev	r-0545)-119

b6 -1 b7C -1

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_34 Acquired 9/28/2017 23:27 Compound: |midazolam

2817-80469

1827-7817

2017 004C0 1 L

Compound: midazolam	Campound:	nordiazepam	Compound:	oxazepam	Compound:	2017-00469, 1, bloo phenazepam
RT(exp) 2.67	RT(exp)	3.19	RT(exp)	2.98	RT(exp)	3.45
RT(delta) N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area: N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z:	m/z:		m/z:		m/z:	
delta (mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
25 18 2) 25	25	87° 3 '49 40° 8:20 32: 22 23	22 - 22 - 22 - 22 - 22 - 22 - 22 - 22	23 25 34 44 032 84. 7.88	23 - 23 - 23 - 23 - 23 - 23 - 23 - 23 -	707 3.45 A4, 520 3.4 52 38

Compound:	prazepam	Compound:	temazepam	Compound:	tetrazepam		Compound:	triazolam	
RT(exp)	5.33	RT(exp)	3.27	RT(exp)	3.68	***************************************	RT(exp)	3.12	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	***************************************	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A		Area:	N/A	
m/z:		m/z:		m/z:		~~~~~~	m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A		delta	(mmu): N/A	
22 23 23 23 23 23 23 23 23 23 23 23 23 2	871 S 233 404 J 330 55 S 4 S 5	190000 - 1900000 - 1900000 - 190000 - 190000 - 190000 - 190000 - 190000 - 190000 - 1900000 - 1900000 - 190000 - 190000 - 190000 - 190000 - 190000 - 190000 - 1900000 - 190000 - 190000 - 190000 - 190000 - 190000 - 190000 - 1900000 - 190000 - 190000 - 190000 - 190000 - 190000 - 190000 - 1900000 - 190000 - 190000 - 190000 - 190000 - 190000 - 190000 - 1900000 - 190000 - 190000 - 190000 - 190000 - 190000 - 190000 - 1900	27 3.77 AA 2.25 23 24	55000 - 5	RT 3.68 AX 255 36	25	100 - 100 -	507 2 12 44 555 5	:BI(20:cv-054


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928 34 Acquired 9/28/2017 23:27

817-88

æ~ (C)

1827-2817




Compound	EDDP	Compound.	hydrocodone	Compound:	hydromorphone	Compound:	norcodeine	
RT(exp)	2.87	RT(exp)	1.8	RT(exp)	0.86	RT(exp)	1.46	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	b6 -1
Area:	N/A	Агеа:	N/A	Area:	N/A	Агеа:	Ň/Á	b7C −1
m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	
32692 1 92692 1 22695	57 28 20 57 28 20	1,5000 1,	87 1.82 An 2:00 An 2:00	2883 - 2485 - 2485 - 2583 - 25	AT 3.86 AA DOS	730 731 731 731 731 731 731 731 731 731 731	% 1.46 A4 5.00 14 15 FBI(20-cv-0	45)-119

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_34 Acquired 9/28/2017 23:27

em em

1827-2017




Compound:	ecgonine methyl ester	Compound:	benzoylecgonine	Compound:	cocaethylene	Compound:	cocaine	b6 −1
RT(exp)	0.26	RT(exp)	1.96	RT(exp)	2.5	RT(exp)	2.3	ъ7С −:
RT(delta)	N/A (N/A)	RT(delta)	1	RT(delta)	N/A (N/A)	RT(delta)	2.31 (0.01)	
Area:	N/A	Area:		Area:	N/A	Area:	131950	
m/z:		m/z:	290.1390	m/z:		m/z:	304.1556	
delta	(mmu): N/A	delta		delta	(mmu): N/A	delta	(mmu): 1.25	
2 2/ 2000 - 2000 -	22 03 34	120000 U 1112000 U 100000 U 100000 U 10000 U 10000 U 10000 U 10000 U 10000 U 10000 U 10000 U 10000 U	77.1.8 A. (1553).28	15255 - 15265 - 15265 - 15265 - 5256	97: 2:55 AA 5:00 234 25 25 27	90000 - 90000 - 70000 - 90000 - 90000 - 10000 - 10000 - 10000 -	25 FBI(20-cv-0	45)-119

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_34 Acquired 9/28/2017 23:27

ළක ක #~~ €377 683

1827-281)



Compound:	diphenhydramine	Compound:	doxylamine	Compound:	hydroxyzine	Compound:	norchlorcyclizine
RT(exp)	2.73	RT(exp)	} . :	RT(exp)	2.98	RT(exp)	2.98
RT(delta)	N/A (N/A)	RT(delta)		RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
\rea:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
n/z:		m/z:		m/z:		m/z	
lelta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
**************************************	RT 2.73 AA 2.55 2.7 28 28	152050 142050 120000 120000 42000 42000 75	FD 1.54 AN COD 15 25 21	150000 160000 190000 190000 190000 190000	977.2.285 AM-0.020	20 20 20 20 20 20 20 20 20 20 20 20 20 2	577.2% A 3.00 35 FBI(20-cv-05

File 20170928_34 Acquired 9/28/2017 23:27

TT EVEROSIONAVI SCHEEMING DI OLIC\LIMS

Compound:	pheniramine	Compound:	tetrahydrozoline	Compound:	zalepion	Compound:	2017-00469, 1, bloc zolpidem
RT(exp)	1.93	RT(exp)	1.87	RT(exp)	2.86	RT(exp)	2.35
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
rea:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
n/z: lelta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A
100 - 100 -	44/ 500 44/ 500 48/ 1/ 66	: #1.8	RT : 52 22	2 27	97: 2,5% A4: 0,00 28 28 28	50000 - 60000	\$12.55 AN 5.00 25

<u> L&</u>			<u> </u>		<u> </u>	 2.0 Ju
Compound:	zopiclone		Compound:	duloxetine	1	
RT(exp)	2.13		RT(exp)	3.02	1	
RT(delta)	N/A (N/A)		RT(delta)	N/A (N/A)		
Area:	N/A		Area:	N/A		
m/z:			m/z:		1	
delta	(mmu): N/A		delta	(mmu): N/A	1	
22 - 22 - 22 - 22 - 22 - 22 - 22 - 22	80 243 84 500 25 22	23	19000 - 19000	ST 122 AA 620 25 25 25 25		

b7E -2

b6 -1 b7C -1

Exclusionary Screening by UPLC/FTMS

Batch:	20170928						Sample						sb
Method:	ExclusionSOP_TargetingScreeni	ing					برمه	***************************************				***************************************	
Inst. Method:							Comment						
Acquired:	9/28/2017 23:05							***************************************				***************************************	-
Sample Type:			Lab Name:	FBI Laborator	ry		File					20170928	32
Vial Position	1:D,4		Assay:	Exclusionary	Screening TO)	(215							

Detected	Target Name	*/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	isotopic Pattern Score (%)	Num Isotopes Matched	Notes			
-	d5-alprazolam	+	N/A	N/A (N/A)	314.1215	N/A	N/A		N/A		***************************************		
	d5-hydroxalprazolam	+	N/A	N/A (N/A)	330.1165	N/A	N/A	N/A	N/A			***************************************	~~~~~
	d4-clonazepam	4-	N/A	N/A (N/A)	320.0735	N/A	N/A	N/A	N/A			····	-
-	d4-7-aminoclonazepam	+	N/A	N/A (N/A)	290.0993	N/A	N/A	N/A	N/A	······································		***************************************	*************
	d5-diazepam	-1-	N/A	N/A (N/A)	290.1103	N/A	N/A	N/A	N/A			***************************************	
	d5-oxazepam	+	N/A	N/A (N/A)	292.0896	N/A	N/A	N/A	N/A		***************************************	***************************************	
	d6-zolpidem	+	N/A	N/A (N/A)	314.2134	N/A	N/A	N/A	N/A	············			
	d3-benzoylecgonine	+	N/A	N/A (N/A)	293,1575	N/A	N/A	N/A	N/A		ł	***************************************	**********
	d3-diphenhydramine	4.	N/A	N/A (N/A)	259.1884	N/A	N/A	N/A	N/A			*****************	***************************************
	d6-oxycodone	+	N/A	N/A (N/A)	322.1920	N/A	N/A	N/A	N/A	***************************************		***************************************	
	d3-morphine	+	N/A	N/A (N/A)	289.1626	N/A	N/A	N/A	N/A	***************************************	***************************************	distribution de la resident de la r	
	d3-hydrocodone	+	N/A	N/A (N/A)	303.1783	N/A	N/A	N/A	N/A		***************************************		
	morphine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A		************		***************************************
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A	N/A	N/A		****	***************************************	**********
	hydroxymidazolam	+	N/A	N/A (N/A)	342.0804	N/A	N/A	N/A	N/A			***************************************	
	hydroxytriazolam	+	N/A	N/A (N/A)	359.0461	N/A	N/A	N/A	N/A		***************************************		
	7-aminoclonazepam	+	N/A	N/A (N/A)	286,0742	N/A	N/A	N/A	N/A	~~~~~		-	************
	7-aminoflunitrazepam	+.	N/A	N/A (N/A)	284.1194	N/A	N/A	N/A	N/A				
	alprazolam	+	N/A	N/A (N/A)	309,0902	N/A	N/A	N/A	N/A			****************	
	bromazepam	+	N/A	N/A (N/A)	316.0080	N/A	N/A	N/A	N/A			*****************	
	chlordiazepoxide	+	N/A	N/A (N/A)	300.0898	N/A	N/A	N/A	N/A		***************************************	***************************************	***********
	clonazepam	+	N/A	N/A (N/A)	316.0484	N/A	N/A	N/A	N/A			***************************************	
	desalkylflurazepam	+	N/A	N/A (N/A)	289.0539	N/A	N/A	N/A	N/A		······	***************************************	***********
	desmethylflunitrazepam	+	N/A	N/A (N/A)	300.0779	N/A	N/A		N/A	·····	•••••		~~~~
	diazepam	+	N/A	N/A (N/A)	285.0789	N/A	N/A		N/A				•••••
	estazolam	+	N/A	N/A (N/A)	295.0745	N/A	N/A.	****	N/A		***************************************		
	etizolam	+	N/A	N/A (N/A)	343.0779	N/A	N/A	N/A	N/A			***************************************	
	flunitrazepam	+	N/A	N/A (N/A)	314.0936	N/A	N/A	N/A	N/A			************************	
***************************************	flurazepam	+	N/A	N/A (N/A)	388.1586	N/A	N/A	N/A	N/A				***************************************

Exclusionary Screening by UPLC/FTMS

Batch:	20170928						Sample					sb
Method:	ExclusionSOP_TargetingScreening	1g					Campio	***************************************			******	
Inst. Method:							Comment					
Acquired:	9/28/2017 23:05						Statististic	***************************************		~~~~~~~		
Sample Type:	Unknown		Lab Name:	FBI Laborator	Ý		File				2017092	3 32
Vial Position			Assay:		Screening TO	(215		~~~~~~		**************		
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes	······································	·······
	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A	N/A		N/A	······		
	lormetazepam	+	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A			
	medazepam	+	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A			
	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A			
	nordiazepam	+	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A			······································
	oxazepam	+	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A		······	
	phenazepam	+	N/A	N/A (N/A)	348.9738	N/A	N/A	N/A	N/A			
	prazepam	+	N/A	N/A (N/A)	325,1102	N/A	N/A	N/A	N/A			
	temazepam	+	N/A	N/A (N/A)	301.0738	N/A	N/A	N/A	N/A			
	tetrazepam	+	N/A	N/A (N/A)	289.1102	N/A	N/A	N/A	N/A	***************************************		•••••
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A	······································	***************************************	
	6-acetylmorphine	+	N/A	N/A (N/A)	328.1543	N/A	N/A	N/A	N/A		······	
	codeine	+	N/A	N/A (N/A)	300.1594	N/A	N/A.	N/A	N/A			
	dihydrocodeine	+	N/A	N/A (N/A)	302.1751	N/A	N/A	N/A	N/A	•••••	······································	••••••
	dihydromorphone	+	N/A	N/A (N/A)	288.1594	N/A	N/A	N/A	N/A			
	EDDP	+	N/A	N/A (N/A)	278.1903	N/A	N/A	N/A	N/A			
	hydrocodone	+	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A	~	•••••••••••	······································
	hydromorphone	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	~	***************************************	***************************************
	norcodeine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	_		***************************************
	normorphine	+	N/A	N/A (N/A)	272.1281	N/A	N/A	N/A	N/A			
	noroxycodone	+	N/A	N/A (N/A)	302,1387	N/A	N/A	N/A	N/A	~		······································
	oxycodone	+	N/A	N/A (N/A)	316.1543	N/A	N/A	N/A	N/A	-		
	oxymorphone	+	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A		······································	
	ecgonine methyl ester	+	N/A	N/A (N/A)	200.1281	N/A	N/A	N/A	N/A	***************	·····	
	benzoylecgonine	+	N/A	N/A (N/A)	290.1387	N/A	N/A	N/A	N/A			***************************************
	cocaethylene	+	N/A	N/A (N/A)	318.1700	N/A	N/A	N/A	N/A			****
	cocaine	+	N/A	N/A (N/A)	304.1543	N/A	N/A	N/A	N/A		·····	
	brompheniramine	+	N/A	N/A (N/A)	319.0804	N/A	N/A	N/A	N/A	~~~~	······································	***************************************
	chlorpheniramine	+	N/A	N/A (N/A)	275.1310	N/A	N/A	N/A	N/A	•••••	***************************************	***************************************

b7E -

b7E -2

b6 -1 b7C -1


2017-00468 1027-2017


					ary ocieci	25 20 3 20 .	~ w ~	-			
latch:	20170928						Sam	nie			si
lethod:	ExclusionSOP_TargetingScreening						our,	····	***************************************		
nst. Method:							Comme	ent			
cquired:	9/28/2017 23:05							***************************************		***************************************	***************************************
Sample Type:	Unknown		Lab Name:	FBI Laborator	У		F	ile			20170928_3
lal Position	1:D,4		Accay:	Exclusionary	Screening TOX	(215					
************				·····			····				
Detected	Target Name	+1-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num isotopes Matched		
	dextromethorphan	+	N/A	N/A (N/A)	272.2009	N/A	N.	A N/A	N/A	·	······································
	dextrorphan	+	N/A	N/A (N/A)	258.1852	N/A	N.	A N/A	N/A	***************************************	·····
	diphenhydramine	+:	N/A	N/A (N/A)	256,1696	N/A	N/	A N/A	N/A	***************************************	
	doxylamine	+	N/A	N/A (N/A)	271.1805	N/A	N/	A N/A	N/A		
	hydroxyzine	+	N/A	N/A (N/A)	375.1834	N/A	N/	A N/A	N/A	***************************************	······································
	norchlorcyclizine	+	N/A	N/A (N/A)	287.1310	N/A	N/	A N/A	N/A	·····	
	pheniramine	+	N/A	N/A (N/A)	241.1699	N/A	N/	A N/A	N/A	***************************************	
	tetrahydrozoline	+	N/A	N/A (N/A)	201.1386	N/A	N/	A N/A	N/A	·····	
	zalepion	+	N/A	N/A (N/A)	306.1349	N/A	N/	A N/A	N/A		
	zolpidem	7	N/A	N/A (N/A)	308.1757	N/A	N/	A N/A	N/A	~~~	
	zopiclone	+	N/A	N/A (N/A)	389.1123	N/A	N/	A N/A	N/A	***************************************	
	duloxetine	+	N/A	N/A (N/A)	298.1260	N/A	N/	A N/A	N/A	***************************************	······

b6 -1 b7C -1

File 20170928 32 9/28/2017 23:05 Acquired

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS





TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_32 Acquired 9/28/2017 23:05

2817-88466

1827-2817


Acquired	9/28/2017 23:05						sb
Compound:	d3-diphenhydramine	Compound:	d6-oxycodone	Compound:	d3-morphine	Compound:	d3-hydrocodone
RT(exp)	2.73	RT(exp)	1.72	RT(exp)	0.56	RT(exp)	1.83
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z:		m/z:		m/z:		m/z:	
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
2005-V 1500- 1003- 500-	7.7.8 2.	33.3	97.172 A4 000			5000 - 7502 - 7505 - 55	2 2 3 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5

Do -	-т
1.70	-
b7C	-1

Compound:	pound: morphine		hydroxyalprazolam	Compound:	hydroxymidazolam	Compound:	hydroxytriazolam
RT(exp)	0.56	RT(exp)	2.9	RT(exp)	2.67	RT(exp)	2.9
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu); N/A
1450 1450 1250 1250 1250 1250 1250 1250 1250 12		100 - 100 -	977.2-50 AA 0-00 28 09 50	200 7 25 25 25	ST. 2 ST AA 6 GS 28 27 28	\$5	******** *****************************

File 20170928_32 Acquired 9/28/2017 23:0

9/28/2017 23:05 sb 7-aminoclonazepam 7-aminoflunitrazepam alprazolam bromazepam Compound: Compound: Compound: Compound: 2.07 RT(exp) 2.27 RT(exp) 3.1 2.66 RT(exp)



		<u></u>	1 5			<u></u>	L		
Compound:	chlordiazepoxide	Compound:	clonazepam	Compound:	desalkylflurazepa	m Compound	desmethylflunitrazepai		
RT(exp)	2.46	RT(exp)	3.07	RT(exp)	3.19	RT(exp)	2.95		
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta			
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/Ā		
m/z:		m/z:		m/z:		m/z:			
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A		
		50 - 50 - 50 - 50 - 50 - 50 - 50 - 50 -		200		22 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -			
12-4	FR 2.46	10-1	RT 3.07	192	RT 3.19	₩ 43-1	900°20'98		

b6 -1 b7C -1

FBI(20-cv-0545)-1205

File

20170928 32 Acquired 9/28/2017 23:05 diazepam estazolam etizolam Compound: flunitrazepam Compound: Compound: Compound: 3.7 RT(exp) RT(exp) 3.25 RT(exp) 3.22 RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A Area: N/A N/A Area: N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A (mmu): N/A delta delta (mmu): N/A delta (mmu): N/A 33~ 30. 400. ۲ij., 1300 £80. 30. 20. 13.4 202. 8013.00 AA: 0.00 w. 12. AT 3.00 AA 0.00 87.326 44.600 970.3.22 AA: 0.00 3.4 flurazepam lorazepam Iormetazepam Compound: medazepam Compound: Compound: Compound RT(exp) 2.71 RT(exp) 3.04 3.43 2.71 RT(exp) RT(exp) b6 -1 N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) b7C -1 RT(delta) N/A Area: N/A Area: N/A Area: N/A Area: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A ∞ . ٠C-ED.-終さ 42;-35~ 32... 235 575.2.7: AA 8.00 27 FBI(20-ev-0545)-1206 File 20170928_32 Acquired 9/28/2017 23:05

. .

Compound:	midazolam	Compound:	nordiazepam	Compound:	oxazepam	Compound:	phenazepam	
RT(exp)	2.67	RT(exp)	3.19	RT(exp)	2.98	RT(exp)	3.45	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
∖rea:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
n/z:		m/z:		m/z:		m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	
22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	877,227 AX 500 28 27 28	70 50 50 50 50 50 50 50 50 50 50 50 50 50	FIL 3.19 AV DIXX	**************************************	AT 3.88 AA 5.88	20 20 20 20 20 20 20 20 20 20 20 20 20 2	AT 1 AC AA 1 D OT	
2's Compound	prazepam	Compound:	temazepam	Compound:	tetrazepam	Compound:	zk zk zk zk triazolam	b6 -
RT(exp)	5.33	RT(exp)	3.27	RT(exp)	3.68	RT(exp)	3.12	b7C
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
rea:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
n/z:		m/z:		m/z:	***************************************	m/z:		
lelta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	
500 - 500 -		2462 7265 7265 7265 7465 7465 7265		52. 52. 53. 53.		25 27 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7		

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_32 Acquired 9/28/2017 23:05

2017-00468 1027-2017

sb

Compound:	6-acetylmorphine	Compound:	codeine	Compound:	dihydrocodeine	Compound:	dihydromorphone
RT(exp)	1.77	RT(exp)	1.54	RT(exp)	1.5	RT(exp)	0.49
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Агеа:	N/A	Area:	N/A
m/z:		m/z:		m/z:		m/z:	
delta	(mmu): N/A	delta	(mmu): N/A	7		delta	(mmu): N/A
2503 - 25	AA 202	2500	3.8 ************************************	1883 - 1482 - 1785 - 17	2	32 - 32 - 32 - 32 - 32 - 32 - 32 - 32 -	es 2.78 20.5 AA

	<u> </u>	1.5	<u> </u>	19 15 15		98 99 99	1
Compound: EDDP	Compound:	hydrocodone	Compound:	hydromorphone	Сотрои	norcodeine	b b
RT(exp) 2.87	RT(exp)	1.8	RT(exp)	0.86	RT(exp)	***************************************	1 -
RT(delta) N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RTidelta	·····	
Area: N/A	Area.	N/A	Area:	N/A	Area:	N/A	
n/z:	m/z:		m/z:		m/z:		
letta (mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	1
20000 20000 20000 20000 20000 20000 20000 20000	90000 - 46000 - 46000 - 25000 - 25000 - 25000 - 15000 - 15000 - 15000 -	\$ \$ 80.00 mm.	1902-1 1203-1 1035-1 1035-1 200-1 500-1 500-1 100-1	90° D.&6 Ark J.000	1925 1925 1925 1925 1925 1925 1926 1926 1926 1926	#X 1.46 AA 202	

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_32 Acquired 9/28/2017 23:05

2017-00488

1827-2817

. č.

cquired	9/28/2017 23:05			~~~~			de) ====
ompound:	normorphine	Compound:	noroxycodone	Compound:	oxycodone	Compound:	oxymorphone	4
T(exp)	0.44	RT(exp)	1.69	RT(exp)	1.72	RT(exp)	0.64	
T(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	1
ea:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	_]
/z:		m/z:		m/z:		m/z:		
lta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	1
1330 - 1380 - 13	7. C.	2000 20		1300 2300 1020 1020 900 900 900 900 900 900 900 900 900	87° 12 86° 536 8 17 12 15	2503		b6 b70
mpound:	ecgonine methyl ester	Compound:	benzoylecgonine	Compound:	cocaethylene	Compound:	cocaine	اً آ
(exp)	0.26	RT(exp)	1.96	RT(exp)	2.5	RT(exp)	2.3	
(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
e:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
Z:		m/z:		m/z:		m/z:		
ta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	1
25050 - 25050 - 25050 - 25050 - 25050 -	MM 202 MWW	\$1000 - \$1000 - \$2000 - \$2000 - \$2000 -		2003-1 1935- 1935- 1935- 1935- 1935-		25050 - 25050 - 25050 - 25050 -	W72.72 AA E30	

b6 -1

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_32 9/28/2017 23:05 Acquired

600 422. 76~ ಯ

1027-2017

sb brompheniramine chlorpheniramine dextromethorphan dextrorphan Compound: Compound: Compound: Compound: 2.5 2.43 RT(exp) RT(exp) 2.65 RT(exp) RT(exp) 2.11 N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A Area: N/A N/A Area: N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta RT 2.65 AN: 0.05 5000 1600. 2000 4530-:400-40000 2500 1232 3830 2032 1000 RXX. 303 2000 822. 1500. 400-:005~ 590 AT 2.50 AA 0.00 500 500 2.10 A4:0000 2.5 dinhenhydramine doxylamine

Compound:	dipitermydramme	Compound:	uoxyiamine	Compound:	nyaroxyzine	Compound:	norchlorcyclizine	b7C -1	
RT(exp)	2.73	RT(exp)	1.94	RT(exp)	2.98	RT(exp)	2.98	B/C -1	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)		
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A		
m/z:		m/z:		m/z:		m/z:			
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A		
9060 4502 4502 5003 5003 1503 1503 1503 1503 2003	25 25 29 29 29 29 29 29 29 29 29 29 29 29 29	19200 - 19200	57: 134 A4: 2.00	25 25 25 25 25 25 25 25 25 25 25 25 25 2	RY 2.86 A6 530 29 22 55	23 23 23 23 24 25 25 25 25 25 25 25 25 25 25 25 25 25	25 25 FBI(20-cv-0	45)-1210	

File 20170928_32 Acquired 9/28/2017 23:05

Compound:	pheniramine	Compound:	tetrahydrozoline	Compound:	zaleplon	Compound:	zolpidem
RT(exp)	1.93	RT(exp)	1.87	RT(exp)	2.86	RT(exp)	2.35
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z:		m/z:		m/z:		m/z:	
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
75 - 75 - 75 - 75 - 75 - 75 - 75 - 75 -	48 25 25 94 202 822 4 85	30 - 30 - 30 - 30 - 30 - 30 - 30 - 30 -	80 - 50 AN 1500 - 15 - 25		RT 28 AX 285 23 25 20	19266 - 1 2026	77 2.25 74 2.20 74 2.20 75 2.25

b6	-	1	
b7C		-	1

Compound:	zopiclone		Compound:	duloxetine	}	
RT(exp)	2.13		RT(exp)	3.02		
RT(delta)	N/A (N/A)		RT(delta)	N/A (N/A)		
Area:	N/A		Area:	N/A		
m/z:			m/z:			
delta	(mmu): N/A		delta	(mmu): N/A		
	NT 273 AA D35 2 22	25	1405- 1405- 1505- 1505- 430- 200-	RT 2 22 AA 5 30 28 30	The second secon	22



Exclusionary Screening by UPLC/FTMS

Batch:	20170928						Sample			2017-004	469, 3, bloo	d
Method:	ExclusionSOP_TargetingScreening	g					Campio	***************************************	************		, .,	
Inst. Method:							Comment					
Acquired:	9/28/2017 23:50							***************************************	**********			
Sample Type:			Lab Name:	FBI Laborator	y		File	***************************************		***************************************	20170928_3	6
Vial Position	1:D.8		^^ ay:	Exclusionary (Screening TOX	(215						,
	·			***************************************		····						
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		
	d5-alprazolam	+	1.69E+07	3.07 (-0.03	314.1215	314.1220	0.45	100.00	6 of 8			
•	d5-hydroxalprazolam	+	2.82E+06	2.9 (-0.04)	330.1165	330.1170	0.58	100.00	5 of 6			
	d4-clonazepam	+	5.26E+05	3.07 (-0.04)320.0735	320.0739	0.46	100.00	4 of 5			~~~~
	d4-7-aminoclonazepam	+	5.37E+06	2.06 (-0.01)290.0993	290.0997	0.43	100.00	6 of 6		***************************************	~~~
•	d5-diazepam	+	1.15E+07	3.7 (-0.05)	290.1103	290.1106	0.30	100.00	6 of 7	······································		
•	d5-oxazepam	+	9.38E+05	2.98 (-0.02)292.0896	292.0901	0.52	100.00	6 of 6	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	***************************************	*********
	d6-zolpidem	+	9.36E+06	2.35 (-0.02	314.2134	314.2136	0.16	100.00	3 of 3	Г		
	d3-benzoylecgonine	+	7.22E+07	1.96 (-0.01)293.1575	293.1577	0.17	100.00	5 of 5			***************************************
	d3-diphenhydramine	+	4.56E+06	2.73 (0)	259,1884		0.45	100.00	3 of 4	***************************************		
•	d6-oxycodone	+	1.34E+07	1.71 (-0.01	322.1920	322.1924	0.35	100.00	4 of 4	L		
	d3-morphine	+	1.31E+07	0.56 (0)	289,1626	289.1630	0.36	100.00	4 of 4			
•	d3-hydrocodone	+	1.19E+07	1.8 (-0.03)	303.1783	303.1786	0.34	100.00	3 of 4		***************************************	
	morphine	- { -	N/A	N/A (N/A)	286,1438	N/A	N/A	N/A	N/A	***************************************		
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A	N/A	N/A	······································		
	hydroxymidazolam	+	N/A	N/A (N/A)	342.0804	N/A	N/A	N/A	N/A			
	hydroxytriazolam	+	N/A	N/A (N/A)	359.0461	N/A	N/A	N/A	N/A			
	7-aminoclonazepam	+	N/A	N/A (N/A)	286.0742	N/A	N/A	N/A	N/A	····		
	7-aminoflunitrazepam	+	N/A	N/A (N/A)	284.1194	N/A	N/A	N/A	N/A			
	alprazolam	+	N/A	N/A (N/A)	309.0902	N/A	N/A	N/A	N/A	······		
	bromazepam	+	N/A	N/A (N/A)	316,0080	N/A	N/A	N/A	N/A		_	
	chlordiazepoxide	+	N/A	N/A (N/A)	300.0898	N/A	N/A	N/A	N/A	***************************************		
	clonazepam	+	N/A	N/A (N/A)	316.0484	N/A	N/A	N/A	N/A		·····	***************************************
	desalkylflurazepam	+	N/A	N/A (N/A)	289.0539	N/A	N/A	N/A	N/A	***************************************		
	desmethylflunitrazepam	+	N/A	N/A (N/A)	300.0779	N/A	N/A	N/A	N/A	***************************************		
	diazepam	+	N/A		285.0789	N/A	N/A	N/A	N/A		***************************************	
	estazolam	+	N/A	N/A (N/A)		N/A	N/A	*****	N/A			~~~~~
	etizolam	+	N/A	N/A (N/A)	343.0779	N/A	N/A	N/A	N/A	······	***************************************	
	flunitrazepam	+	N/A	N/A (N/A)	314.0936	N/A	N/A	N/A	N/A	***************************************	***************************************	
	flurazepam	+	N/A	N/A (N/A)	388.1586	N/A	N/A	N/A	N/A			
										~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		***********

b7E -2

ecgonine methyl ester

benzoylecgonine

brompheniramine

chlorpheniramine

cocaethylene

cocaine

N/A

N/A

N/A

N/A

N/A

+

+

1.09E+05

N/A (N/A)

N/A (N/A)

N/A (N/A)

N/A (N/A)

N/A (N/A)

1.96 (0)

200.1281 N/A

318.1700 N/A

304.1543 N/A

319.0804 N/A

275.1310 N/A

290.1387

290.1387

N/A N/A

0.02 70.00

N/A N/A

N/A N/A

N/A N/A

N/A N/A

N/A

N/A

N/A

N/A

N/A

1 of 2

				Exclusion	ary Screer	ning by UF	PLC/FTMS				
Batch:	20170928						Sample	ı.		2017	-00469, 3, blood
Method:	ExclusionSOP_TargetingScreening	9					Odnipie	***************************************			
Inst. Method:							Comment				
Acquired:	9/28/2017 23:50							***************************************		•••••	······································
Sample Type:			Lab Name:	FBI Laborator	У		File				20170928_36
Vial Position	1:D,8		Assay:	Exclusionary	Screening TO)	(215				*,***,**	
L	······										
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes	
	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A	N/A	N/A	N/A		***************************************
***************************************	lormetazepam	+	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A	······	······································
	medazepam	+	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A	•••••••••••••	······································
	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A	***************************************	***************************************
	nordiazepam	+	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A	*************************************	***************************************
	oxazepam	+	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A		······
	phenazepam	+	N/A	N/A (N/A)	348.9738	N/A	N/A	N/A	N/A		······
***************************************	prazepam	+	N/A	N/A (N/A)	325.1102	N/A	N/A	N/A	N/A		······
	temazepam	+	N/A	N/A (N/A)	301.0738	N/A	N/A	N/A	N/A	~~~~	·····
	tetrazepam	+	N/A	N/A (N/A)	289.1102	N/A	N/A	N/A	N/A	***************************************	
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A	······	
	6-acetylmorphine	+	N/A	N/A (N/A)	328.1543	N/A	N/A	N/A	N/A	~~~~~	·····
	codeine	+	N/A	N/A (N/A)	300,1594	N/A	N/A	N/A	N/A		
	dihydrocodeine	+	N/A	N/A (N/A)	302,1751	N/A	N/A	N/A	N/A	~	
	dihydromorphone	+	N/A	N/A (N/A)	288.1594	N/A	N/A	N/A	N/A		
	EDDP	+	N/A	N/A (N/A)	278.1903	N/A	N/A	N/A	N/A	~~	
	hydrocodone	+	N/A	N/A (N/A)	300.1594	N/A	N/A		N/A		·····
	hydromorphone	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	~	
	norcodeine	+	N/A	N/A (N/A)	286,1438	N/A	N/A	N/A	N/A		***************************************
	normorphine	+	N/A	N/A (N/A)	272.1281	N/A	N/A		N/A		
	noroxycodone	+	N/A	N/A (N/A)	302.1387	N/A	N/A		N/A	······	······
	oxycodone	+	N/A	N/A (N/A)	316.1543	N/A	N/A		N/A		
	oxymorphone	+	N/A	N/A (N/A)	302.1387	N/A	N/A		N/A	·····	***************************************

b6 -1 b7C -1

b7E -2

720-

pursuin)

Batch: Method:	20170928 ExclusionSOP_TargetingScreening				•		Sample			2017	-00469, 3, blo	<u>od</u>
Inst. Method: Acquired:	9/28/2017 23:50						Comment	·			······································	········
Sample Type:	Unknown		Lab Name:	FBI Laborator	y		File	:			20170928	36
Vial Position	1:D,8		Аскау:	Exclusionary	Screening TOX	(215						
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		
	dextromethorphan	+	N/A	N/A (N/A)	272.2009	N/A	N/A	N/A	N/A			•
***************************************	dextrorphan	+	N/A	N/A (N/A)	258.1852	N/A	N/A	N/A	N/A		 	
	diphenhydramine	+	N/A	N/A (N/A)	256.1696	N/A	N/A	N/A	N/A		·····	
	doxylamine	+	N/A	N/A (N/A)	271.1805	N/A	N/A	N/A	N/A			
	hydroxyzine	+	N/A	N/A (N/A)	375.1834	N/A	N/A	N/A	N/A		······	
	norchlorcyclizine	+	N/A	N/A (N/A)	287.1310	N/A	N/A	N/A	N/A.	·····		·····
	pheniramine	+	N/A	N/A (N/A)	241.1699	N/A	N/A	N/A	N/A		·····	
	tetrahydrozoline	+	N/A	N/A (N/A)	201.1386	N/A	N/A	N/A	N/A	***************************************	······································	***************************************
	zaleplon	+	N/A	N/A (N/A)	306.1349	N/A	N/A	N/A	N/A	***************************************	***************************************	**********
	zolpidem	+	N/A	N/A (N/A)	308,1757	N/A	N/A	N/A	N/A	······	······	~~~~
	zopiclone	+	N/A	N/A (N/A)	389.1123	N/A	N/A	N/A	N/A	······		
	duloxetine	+	N/A	N/A (N/A)	298.1260	N/A	N/A	N/A	N/A			<u> </u>
					·····	***************************************	***************************************			~		

1000000

\$000000

d3-benzoylecgonine

b6 -1 b7C -1

File

NONZONO.

2002000-

1000000

20170928 36

4000000

2300303

d5-oxazepam

35

d5-diazepam

Acquired 9/28/2017 23:50 2017-00469, 3, blood d5-alprazolam d5-hydroxalprazolam d4-clonazepam d4-7-aminoclonazepam Compound: Compound. Compound: Compound: 3.1 RT(exp) 2.94 3.11 RT(exp) RT(exp) RT(exp) 2.07 3.07 (-0.03) RT(delta) 2.9 (~0.04) RT(delta) 3.07 (-0.04) 2.06 (-0.01) RT(delta) RT(delta) 16925000 2824400 Area: 525800 5369000 Area: Area: Агеа: 314.1220 330.1170 320.0739 290.0997 m/z: m/z: m/z: m/z: delta (mmu): 0.45 (mmu): 0.58 delta delta (mmu): 0.46 (mmu): 0.43 delta RT 3.07 AA: 16925030.65 RT 2.80 AA: 2024234.15 RT 3.07 RA 525800.04 RT 1.06 AA: \$268955.72 2430230 4500000 14000000 72372000 A 4000000 130000000 40000000 2003000 120000003 303302 **000002-1200000 3820000 100000000 3000000-160000007-30000000 90000000 1400000 20000000 2820000 1000000 7000000 2000003-20000000 60000000 10000000 SONOW. 1500003-*030000 6000000

30000

d6-zolpidem


3/

company.	- }	COMPONIA		Componed:	1		ar nonzoy.cogonino	b6 -1
RT(exp)	3.75	RT(exp)	3	RT(exp)	2.37	RT(exp)	1.97	b7C −1
RT(delta)	3.7 (-0.05)	RT(delta)	2.98 (-0.02)	RT(delta)	2.35 (-0.02)	RT(delta)	1.96 (-0.01)	
Area:	11461000	Агеа:		Area:	9359900	Area:	72241000	
m/z:	290.1106	m/z:	292.0901	m/z:	314.2136	m/z:	293.1577	
delta	(mmu): 0.3	delta	(mmu): 0.52	delta	(mmu): 0.16	delta	(mmu): 0.17	
500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 50000000 - 500000000	#T 5.70 An (1980) 2:	200000 - 780000 - 780000 - 780000 - 8000000 - 800000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 80000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 8000000 - 80000000 - 80000000 - 800000000	XY 7.88 An 365376:5	705000 905000 905000 905000 1005000 1005000 1005000 1005000 1005000 1005000 1005000 1005000 1005000 1005000 1005000 1005000 100500 10	97: 2.25 AM 9339982.4:	650,00000 - 600,000 - 600,0	** FBI(20-cv-0	3 4 5)-1215

File 20170928_36 Acquired 9/28/2017 23:50

2017-00469, 3, blood

Compound:	d3-diphenhydramine	Compound:	d6-oxycodone	Compound:	d3-morphine	Compound:	d3-hydrocodone
RT(exp)	2.73	RT(exp)	1.72	RT(exp)	0.56	RT(exp)	1.83
RT(delta)	2.73 (0)	RT(delta)	1.71 (-0.01)	RT(delta)	0.56 (0)	RT(delta)	1.8 (-0.03)
Area:	4555100	Area:	13352000	Area:	13113000	Area:	11897000
m/z:	259.1889	m/z:	322.1924	m/z:	289.1630	m/z:	303.1786
delta	(mmu): 0.45	delta	(mmu): 0.35	delta	(mmu): 0.36	delta	(mmu): 0.34
2500000 2500000 2500000 2500000 2500000 7500000	PT 1.72 AA. 455507.60	15030302 15030302 26030302 70030302 56030302 46030302 16030303	ST 127 AA 1225242.52	\$550060 5500000 \$500000 4000000 \$5000000 \$5000000	87.0.8 AX 13712877 81	:CESTEDT	ST 1 85 AA 11827D24.33



Page 6 of 12

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


File 20170928 36 Acquired 9/28/2017 23:50

ಯಾ

ထာ

ಯು

2017-00469, 3, blood



FBI(20-ev-0545)-1218

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_36
Acquired 9/28/2017.23


~**

(1) (1) (2) (3) (4) (4) (5) (4) (5) (5)

~~3

2017

32




32

2.5

File 20170928_36 9/28/2017 23:50 Acquired

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

2017-00469, 3, blood



Compound:	prazepam	Compound:	temazepam	Campound:	tetrazepam	Compound:	triazolam	b6 -1
RT(exp)	5.33	RT(exp)	3.27	RT(exp)	3.68	RT(exp)	3.12	b7C -1
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
m/z:		m/z:		m/z:		m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A.	
	977 5.35 AA 0.020 5.3 S.5 S.5	23700 - 3000 - 23700 - 23700 - 24700 - 24700 - 24700 - 3500 - 350	50° 2.17 AA 50° S2 35 32	330 350 75 550 550 550 550 550 550 550 550 55	87 3.63 A4 2.02 38 37 38	25 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	₹ 2:12 \$\frac{2}{2}\$ \$\frac{2}{2}\$\$ \$\frac{2}{2}\$\$	45)-1219


b6 -1 b7C -1

ा FBI(20-cv-0\$45)-1220

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_36 Acquired 9/28/2017 23:50

2017-00469, 3, blood



Compound:	EDDP	Compound:	hydrocodone	Gompound:	hydromorphone	Compound:	norcodeine
RT(exp)	2.87	RT(exp)	1.8	RT(exp)	0.86	RT(exp)	1.46
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	 RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z:		m/z:		m/z:		m/z:	
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
400.03 -;		13003 9010 5033	<u> </u>	100 J 80 J 80 J		82 - 82 -	

800 0.86 AA 0.00

SONO-

KONI-2000

2000

<u>دده</u> \$~ 600 600 1827-2817

POXIC-19000-

100000

2000

File 20170928_36 Acquired 9/28/2017 23:50

2017-00469, 3, blood

Compound:	normorphine	Compound:	noroxycodone	Compound:	oxycodone	Compound:	oxymorphone	
RT(exp)	0.44	RT(exp)	1.69	RT(exp)	1.72	RT(exp)	0.64	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
m/z:		m/z:		m/z:		m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	
6003 - 50	7. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.	5000 - 50	PET 1.800 Adv 2.200	200000 20000 20000		50000 - 50000 - 50000 - 50000 - 30000	77.022 77.022 77.022 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.02 78.0	b6 -1
Compound:	ecgonine methyl ester	Compound:	benzoylecgonine	Compound:	cocaethylene	Compound:	cocaine	b7C −1
RT(exp)	0.26	RT(exp)	1.96	RT(exp)	2.5	RT(exp)	2.3	
RT(delta)	N/A (N/A)	RT(delta)	1.96 (0)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	109330	Area:	N/A	Area:	N/A	
m/z:		m/z:	290.1387	m/z:		m/z:		
delta	(mmu): N/A	delta	(mmu): 0.02	delta	(mmu): N/A	delta	(mmu): N/A	
1.00000 - 1.00000 - 9.0000 - 9.0000 -		2020- 2000- 2000- 2000- 2000-	57 136 AN 139377.35	24000 - 72500 - 8000 - 9000 - 9000 -		92705 - 92705 - 92705 - 92705 - 92705 -	2 CONTRACTOR CONTRACTO	

File 20170928 36 TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS 9/28/2017 23:50 Acquired 2017-00469, 3, blood brompheniramine chlorpheniramine dextromethorphan dextrorphan Compound: Compound: Compound: Compound: 2.5 2.43 RT(exp) RT(exp) 2.65 RT(exp) 2.11 RT(exp) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) RT(delta) N/A N/A Агеа: N/A Area: N/A Area: Area: m/z: m/z: m/z: m/z delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta 002 12000 53~ 933000 11003-82. some. 90000. 10000 9000 222022 NOSS. 2000 1000000 20033-W. 53. 2000000 500000 SEC. 6320327 4000 -30000 030303 XXXX-202003-XCOX. 32. XXXXX 800 3.800 AA: 0.000 87 2.42 86 0.00 1000 800 3.15 AA 0.00 b6 -1 diphenhydramine doxylamine hydroxyzine norchlorcyclizine Compound: Compound Compound: Compound b7C -1 2.73 RT(exp) RT(exp) 1.94 2.98 RT(exp) 2.98 RT(exp) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A Area: N/A Area: Area: N/A N/A Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 8003 4000G-6000 SONO-AXXX-2007 2002 1500 2000 1000 1000-SWA RT 2.59 AA: 0:00 972 2.88 AA: 0.00 2.5 3.5 FBI(20-cv-0545)-1222 File

zopiclone

Compound:

20170928 36 9/28/2017 23:50 Acquired 2017-00469, 3, blood pheniramine tetrahydrozoline zaleplon zolpidem Compound: Compound: Compound: Compound: 1.93 1.87 RT(exp) 2.86 RT(exp) RT(exp) RT(exp) 2.35 RT(delta) N/A (N/A) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A (N/A) RT(delta) N/A Area: N/A N/A N/A Area: Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta 2000 *SSS32.* SANON. 11033 3000 5.5000 433333 7000 :2003-9000 STATE. 11003 KUM. :0000 8000 50000-3000 7023 axe. ww. 2300 exx. 2000 50003 8000 3003 ROSS. 4000 4000 20003 2000 3000 DEC-2023 1000 12223 907 1.53 AA 0.00 1003 87 2.88 AA 6.00 1000 AN 2.38 AN 2.22

		noonpound.	<u></u>
RT(exp)	2.13	RT(exp)	3.02
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A
n/z:		m/z:	
delta	(mmu): N/A	delta	(mmu); N/A
20	RF 2-03 AA 5-00 2: 22 23	25	RT: 3.02 AA: 0.05 S 35 3. 22

duloxetine



b6 -1

b7C -1

Batch:	20170928						Sample					sb
Method:	ExclusionSOP_TargetingScreening	ng					Campio		***************************************	***************************************	************	
Inst. Method:							Comment					
Acquired:	9/28/2017 23:39								***************************************	***************************************	•••••••••••••••••••••••••••••••••••••••	
Sample Type:	Unknown		Lab Name:	FBI Laborator	у		File				201	70928_35
Vial Position	1:D,7		Assay:	Exclusionary	Screening TOX	(215						
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		
	d5-alprazolam	+	N/A	N/A (N/A)	314.1215	N/A	N/A	N/A	N/A			
	d5-hydroxalprazolam	+	N/A	N/A (N/A)	330,1165	N/A	N/A	N/A	N/A	•••••		
	d4-clonazepam	+	N/A	N/A (N/A)	320.0735	N/A	N/A	N/A	N/A	***************************************	***************************************	
	d4-7-aminoclonazepam	+-	N/A	N/A (N/A)	290.0993	N/A	N/A	N/A	N/A	*********		
	d5-diazepam	+	N/A	N/A (N/A)	290.1103	N/A	N/A	N/A	N/A	***************************************		
	d5-oxazepam	4 .	N/A	N/A (N/A)	292.0896	N/A	N/A	N/A	N/A			
	d6-zolpidem	+	N/A	N/A (N/A)	314.2134	N/A	N/A	N/A	N/A			
	d3-benzoylecgonine	+	N/A	N/A (N/A)	293.1575	N/A	N/A	N/A	N/A			***************************************
	d3-diphenhydramine	+	N/A	N/A (N/A)	259.1884	N/A	N/A	N/A	N/A			
	d6-oxycodone	+.	N/A	N/A (N/A)	322.1920	N/A	N/A	N/A	N/A			
	d3-morphine	+	N/A	N/A (N/A)	289,1626	N/A	N/A	N/A	N/A	***************************************		
	d3-hydrocodone	+	N/A	N/A (N/A)	303.1783	N/A	N/A	N/A	N/A			
	morphine	+ .	N/A	N/A (N/A)	286,1438	N/A	N/A	N/A	N/A	***************************************		
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A	N/A	N/A			······································
	hydroxymidazolam	+	N/A	N/A (N/A)	342.0804	N/A	N/A	N/A	N/A		***************************************	***************************************
	hydroxytriazolam	+	N/A	N/A (N/A)	359.0461	N/A	N/A	N/A	N/A	7		
	7-aminoclonazepam	+	N/A	N/A (N/A)	286.0742	N/A	N/A	N/A	N/A	_	·	***************************************
	7-aminoflunitrazepam	+	N/A	N/A (N/A)	284.1194	N/A	N/A	N/A	N/A	7		
	alprazolam	+	N/A	N/A (N/A)	309,0902	N/A	N/A	N/A	N/A			
	bromazepam	+	N/A	N/A (N/A)	316.0080	N/A	N/A	N/A	N/A	~		
	chlordiazepoxide	4	N/A	N/A (N/A)	300.0898	N/A	N/A	N/A	N/A		***************************************	
	clonazepam	+	N/A	N/A (N/A)	316.0484	N/A	N/A	N/A	N/A		***********	
	desalkylflurazepam	+	N/A	N/A (N/A)	289.0539	N/A	N/A	N/A	N/A		***************************************	······································
	desmethylflunitrazepam	+	N/A	N/A (N/A)	300.0779	N/A	N/A	N/A	N/A	······································	***************************************	
	diazepam	4	N/A	N/A (N/A)	285.0789	N/A	N/A	N/A	N/A			
	estazolam	+	N/A	N/A (N/A)	295.0745	N/A	N/A	N/A	N/A	••••••	······································	
	etizolam	+	N/A	N/A (N/A)	343.0779	N/A	N/A	N/A	N/A			······································
	flunitrazepam	+	N/A	N/A (N/A)	314.0936	N/A	N/A	N/A	N/A	·	·····	***************************************
	flurazepam	+	N/A	N/A (N/A)	388,1586	N/A	N/A	N/A	N/A		······································	

b7E -2

Batch:	20170928						Sample					sb
Method:	ExclusionSOP_TargetingScreening	ng							***************************************	·····		
Inst. Method:							Comment					
Acquired:	9/28/2017 23:39									***************************************	······	······································
Sample Type:	Unknown		Lab Name:	FBI Laborator	У		File				2017	0928_35
Vial Position	1:D,7		Assay:	Exclusionary	Screening TOX	(215						
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		
	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A	N/A	N/A	N/A		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	***************************************
***************************************	lormetazepam	+	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A		***************************************	
	medazepam	+	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A	·······	······	***************************************
	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A	***************************************		
-	nordiazepam	+	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A			~~~~
	oxazepam	+	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A	***************************************	······································	······
	phenazepam	+	N/A	N/A (N/A)	348.9738	N/A	N/A	N/A	N/A	······		······································
	prazepam	4	N/A	N/A (N/A)	325.1102	N/A	N/A	N/A	N/A	·····		***************************************
	temazepam	+	N/A	N/A (N/A)	301.0738	N/A	N/A	N/A	N/A	·····	·····	······································
	tetrazepam	+	N/A	N/A (N/A)	289.1102	N/A	N/A	N/A	N/A		_	·····
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A		~	
	6-acetylmorphine	+	N/A	N/A (N/A)	328.1543	N/A	N/A	N/A	N/A		***************************************	
	codeine	+	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A		•••••	
	dihydrocodeine	+	N/A	N/A (N/A)	302.1751	N/A	N/A	N/A	N/A			
	dihydromorphone	+	N/A	N/A (N/A)	288.1594	N/A	N/A	N/A	N/A		<u> </u>	······
	EDDP	+	N/A	N/A (N/A)	278.1903	N/A	N/A	N/A	N/A			***************************************
	hydrocodone	*	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A	~~		
	hydromorphone	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	·····		
	norcodeine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A		***************************************	
	normorphine	+	N/A	N/A (N/A)	272.1281	N/A	N/A	N/A	N/A			***************************************
	noroxycodone	+	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A	•	•••••	***************************************
	oxycodone	+	N/A	N/A (N/A)	316.1543	N/A	N/A	N/A	N/A	***************************************	***************************************	***************************************
	oxymorphone	+	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A	***************************************		***************************************
	ecgonine methyl ester	4	N/A	N/A (N/A)	200.1281	N/A	N/A	N/A	N/A	***************************************	***************************************	······································
	benzoylecgonine	+	N/A	N/A (N/A)	290.1387	N/A	N/A	N/A	N/A			
~~~~	cocaethylene	+	N/A	N/A (N/A)	318.1700	N/A	N/A	N/A	N/A		***************************************	
<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	cocaine	+	N/A	N/A (N/A)	304.1543	N/A	N/A	N/A	N/A	·····		······································
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	brompheniramine	+	N/A	N/A (N/A)	319.0804	N/A	N/A	N/A	N/A			***************************************
:	chlorpheniramine	+	N/A	N/A (N/A)	275.1310	N/A	N/A	N/A	N/A		•••••	

ኤ7፱ _

3atch:	20170928						Sam	ile				sb
Aethod:	ExclusionSOP_TargetingScreening	ı									***********	•
nst. Method:							Comme	int				
cquired:	9/28/2017 23:39											
ample Type:			Lab Name:	FBI Laborator	ý		F	ile	*********	***********	2	0170928_35
'ial Position	1:D,7		Assay:	Exclusionary	Screening TOX	215						

Detected	Target Name	+1-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		
	dextromethorphan	+	N/A	N/A (N/A)	272.2009	N/A	N	A N/A	N/A			
	dextrorphan	+	N/A	N/A (N/A)	258.1852	N/A	N	A N/A	N/A	***************************************		
	diphenhydramine	+	N/A	N/A (N/A)	256.1696	N/A	N	A N/A	N/A		***************************************	
	doxylamine	+	N/A	N/A (N/A)	271.1805	N/A	N	A N/A	N/A			
	hydroxyzine	+	N/A	N/A (N/A)	375.1834	N/A	N	A N/A	N/A			
	norchlorcyclizine	+	N/A	N/A (N/A)	287.1310	N/A	N	A N/A	N/A	**********		
	pheniramine	+	N/A	N/A (N/A)	241.1699	N/A	N	A N/A	N/A			
***************************************	tetrahydrozoline	+	N/A	N/A (N/A)	201.1386	N/A	N	A N/A	N/A			
	zaleplon	+	N/A	N/A (N/A)	306.1349	N/A	N	A N/A	N/A			
***************************************	zolpidem	+	N/A	N/A (N/A)	308.1757	N/A	N	A N/A	N/A	······	······	······
***************************************	zopiclone	+	N/A	N/A (N/A)		N/A	N/	A N/A	N/A			
	duloxetine	+	N/A	N/A (N/A)	298.1260	N/A	N	A N/A	N/A			

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_35 Acquired 9/28/2017 23:39

2017-80460 1877-9817

Compound:	9/28/2017 23:39 d5-alprazolam	Compound:	d5-hydroxalprazolam	Compound:	d4-clonazepam		sb d4-7-aminoclonazepam	
RT(exp)	3.1	RT(exp)	2.94	RT(exp)	3.11	Compound: RT(exp)	2.07	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	3}	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	RT(delta)		
m/z:		m/z:	133/7	7,	BN/A	Area:	N/A	
delta	(mmu): N/A	delta	(mmu): N/A	m/z: delta	(mmú): N/A	m/z: delta	(mmu): N/A	
	RT.3 % AV. 6 % 28 24 22 23	25 - 25 - 25 - 25 - 25 - 25 - 25 - 25 -	877.284 AA 5300 28 20 31	25 - 25 - 25 - 25 - 25 - 25 - 25 - 25 -	ST 2.41 AA 355	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	977 1.577 A-8 0.582	
Compound: RT(exp)	d5-diazepam	Compound:	d5-oxazepam	Compound:	d6-zolpidem	Compound:	d3-benzoylecgonine	b6
T(delta)	N/A (N/A)	RT(exp)	3	RT(exp)	2.37	RT(exp)	1.97	b70
******************************	N/A	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
rea:	IN/M	Area:	N/A	Area:	N/A	Area	N/A	
/z: elta	(mmu): N/A	m/z: delta	(mm): N/A	m/z:	/##### 35 NUA	m/z:		
	Italia). WA	ueila	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	
2502 - 5000 - 4632 - 4033 - 3230 -		25. 25.		78 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8		1000000 - 1000000 - 1000000 - 1000000 - 1000000 - 1000000 - 10000000 - 10000000 - 10000000 - 10000000 - 10000000 - 10000000 - 100000000	A	

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

3-88 چــ دي دي

File 20170928 35


9/28/2017 23:39 Acquired dz d3-diphenhydramine d3-hydrocodone d6-oxycodone d3-morphine Compound: Compound: Compound: Compound: 2.73 1.72 0.56 1.83 RT(exp) RT(exp) RT(exp) RT(exp) RT(delta) N/A (N/A) RT(delta) N/A (N/A) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A Area: N/A N/A N/A Area: Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A (mmu): N/A (mmu): N/A delta delta 87 0.56 AA 0.00 3700 exen. 9000 4330 @XX3-**6863**-50003 5580. **40003** 6003eces. ÷523 7000 3500 4953. 6003 3000 4500. 5000 3820 2500 3330-NNS3 4000 2500 3933 2003-3330 1930 1500 2000 icos. 1000 RT 1.72 84:0.00 R12. SONmorphine hydroxyalprazolam hydroxymidazolam hydroxytriazolam Compound: Compound: Compound: Compound: 0.56 2.9 RT(exp) 2.67 2.9 RT(exp) RT(exp) RT(exp)

~~~~~~~~~	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	45		·				ş.
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	b6 −1
m/z:		m/z:		m/z:		m/z:		b7C −1
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	
1300	97 2.56 AA 630	25 25 25 25 25 25 25 25 25 25 25 25 25 2		900 - 80 - 90 -		2	mmummummumm	
502- 502- 502- 502- 503-		# # # # # # # # # # # # # # # # # # #		20- 20- 20- 20-		27- 27- 27- 27- 27- 27- 27- 27- 27- 27-		
200-	2	5	RT 290 4x 5300 32 35 30 35	*** - 2 5	57.187 AA:507 28 27 28	5	25 FBF(20-cv)-05	45)-1228

b6 -1

b7C -1

File 20170928 35



File

20170928_35


9/28/2017 23:39 Acquired sb diazepam estazolam Compound: etizolam flunitrazepam Compound: Compound: Compound: 3.7 RT(exp) RT(exp) 3.25 3.22 RT(exp) RT(exp) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A Area: N/A N/A Area: Area: N/A Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 33 3000 32. 78. €0. 2003 30-1000 33. 802 RT 3.70 AN 0.00 20. 20.2 TW 30.2 AA #07 3.22 AM 0.00 37 flurazepam lorazepam Compound: lormetazepam medazepam Compound: Compound: Compound 2.71 RT(exp) 3.04 3.43 RT(exp) 2.71 RT(exp) RT(exp) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A N/A Area: Area: N/A N/A Area: Агеа: b6 -1 m/z: m/z: m/z: m/z: b7C -1 delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A ×2. 62-53~ 30~ 22. 10. AC 0.000 907 3.42 AA: 0.00 800 2.74 AA 0.00 23 32 FBI(20-ev-0\$45)-1230

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

20170928_35 File Acquired

8,000

9/28/2017 23:39




TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_35 Acquired 9/28/2017 23:39

Compound:	6-acetylmorphine	Campound:	codeine	Compound:	dihydrocodeine	Compound:	dihydromorphone
RT(exp)	1.77	RT(exp)	1.54	RT(exp)	1.5	RT(exp)	0.49
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A:	Area:	N/A	Area:	N/A
n/z:		m/z:		m/z:		m/z:	
lelta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
2000 2000 2000 2000 2000 2000 2000 200	## 5 8 8 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	2000 - 4500 - 4500 - 2500 - 2500 - 2500 - 1500 - 1500 -		1900 - 1900 - 19	#07 1.800 AN 2.000	20	67.2.78 44.278
	EDDP	13	hydrocodone	13	i i i	1 3 3	84 38 2 <u>6</u>

Campound:	EDDP	Compound:	hydrocodone	Compound:	hydromorphone	Compound:	norcodeine
RT(exp)	2.87	RT(exp)	1.8	RT(exp)	0.86	RT(exp)	1.46
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z:		m/z:		m/z:		m/z:	
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A



2817-88468 1827-2817

Page 10 of 12

4223

0000 00000

CONT.

8223


1827-2817


File 20170928_35 Acquired 9/28/2017 23:39


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


sb normorphine noroxycodone oxycodone oxymorphone Compound. Compound: Compound: Compound: 0.44 1.69 1.72 0.64 RT(exp) RT(exp) RT(exp) RT(exp) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A N/A Area: N/A N/A Area: Area: Area: m/z: m/z: m/z: m/z: (mmu): N/A (mmu): N/A delta (mmu): N/A delta delta (mmu): N/A delta 2400 30000 3330 1383-2463 3886 ∞ಜನೆ XXXX 2282 2800 1000 1800 2400 2002 m. \$00. 16000 DOM: £300 1693 400-1883 1493 600 1200-1393 ASS. 1000 1333 1032 800-1003 230 2003 633 230ew. 453 302 430 400 323, 972 0.44 AA: 0.00 577. 1.695 AA: 0.003 RT 172 840 000 230-393 22

Campound:	ecgonine methyl ester	Compound:	benzoylecgonine	Compound:	cocaethylene	Compound:	cocaine
RT(exp)	0.26	RT(exp)	1.96	RT(exp)	2.5	RT(exp)	2.3
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z:		m/z:		m/z:		m/z:	
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A









TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928_35 9/28/2017 23:39 Acquired

6223 6222


8000 8000

ch

b6 -1

b7C -1

RT(exp) 2.5	Compound:	brompheniramine	Compound:	chlorpheniramine	Compound:	dextromethorphan	Compound:	dextrorphan
RT(delta) N/A (N/A) Area: N/A Area: N/A M/Z: delta (mmu): N/A delta (mmu): N/A RT(delta) N/A (N/A) RT(delta) N/A (N/A) Area: N/A Area: N/A M/Z: delta (mmu): N/A RT(delta) N/A (N/A) Area: N/A Area: N/A Area: N/A Area: N/A Area: N/A M/Z: delta (mmu): N/A RT(delta) N/A (N/A) Area: N/A Are	RT(exp)	2.5		2.43	18			-
Area: N/A m/z: delta (mmu): N/A	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	}}			······································
m/z:	Area:	N/A	Area:	N/A	Area:			~ _
800 - 100 -					m/z:			
## 5.55C 155C 155C	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
No. 1 No. 2 No.	22- 23- 23-	***************************************	5600 - 5600 - 4000 - 4000 - 20	24 29 26	7000- 5500- 7600- 7600- 7600- 7600- 7600- 7600- 7600- 7600- 7600- 7600-	AA 630	92. 33. 53. 53. 43. 33.	AA: 5.00




Compound:

File 20170928_35 Acquired 9/28/2017 23:39

Compound:	pheniramine	Compound:	tetrahydrozoline	Compound:	zalepion	Compound:	zolpidem
RT(exp)	1.93	RT(exp)	1.87	RT(exp)	2.86	RT(exp)	2.35
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A
	977 138 AA 033 15 20 20	2503 - 25	50 : 35 AA 200	2500 - 25	97.2 SE A 152	10002 9000 5000 5000 5000 4000 1000	### 12 #### 12 #### 12 #### 12 #### 12 #### 12 ########

RT(exp)	2.13		RT(exp)	3.02		
RT(delta)	N/A (N/A)		RT(delta)	N/A (N/A)		
Area:	N/A		Area:	N/A		
m/z:			m/z:			
delta	(mmu): N/A		delta	(mmu): N/	Ά	
	RE 2.12 AA 838 2 22	22		\$2.5.7% \$4.00 \$2.50	ì.	22



b7E -2

b6 -1 b7C -1

Exclusionary Screening by UPLC/FTMS

Batch:	20170928						Sample					ncb
Method:	ExclusionSOP_TargetingScreening	ng					Campie	····		·····		1100
Inst. Method:							Comment					
Acquired:	9/28/2017 23:16						00000000	~~~~	······································		***********	****************
Sample Type:	Unknown		Lab Name:	FBI Laborator	ý		File					20170928 33
Vial Position	1:D,5		Assay:	Exclusionary	-	C 215			***************************************	***************************************		
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		
•	d5-alprazolam	*	1.79E+07	3.07 (-0.03)314.1215	314.1221	0.57	100.00	7 of 7	************************	**********	***************************************
•	d5-hydroxalprazolam	+	3.30E+06	2.91 (-0.03	330.1165	330.1169	0.49	100.00	4 of 6	······		······
•	d4-clonazepam	+	6.82E+05	3.08 (-0.03)320.0735	320.0739	0.49	100.00	5 of 5	·····		
	d4-7-aminoclonazepam	+	2.85E+06	2.06 (-0.01)290.0993	290.0997	0.40	100.00	4 of 5		~;~~;~~;~~	
•	d5-diazepam	+	1.41E+07	3.7 (-0.05)	290.1103	290,1107	0.36	100.00	7 of 7	······································	~~~~~	***************************************
•	d5-oxazepam	+	1.56E+06	2.99 (-0.01)292.0896	292.0900	0.43	100.00	4 of 5	***************************************	***************************************	·····
•	d6-zolpidem	+	9.83E+06	2.36 (-0.01)	314.2134	314.2136	0.19	100.00	3 of 3	***************************************		***************************************
•	d3-benzoylecgonine	+	6.69E+07	1.96 (-0.01)293.1575	293.1579	0.42	100.00	4 of 4	***************************************	·	
•	d3-diphenhydramine	+	5.49E+06	2.73 (0)	259.1884	259,1887	0.30	100.00	3 of 3			
•	d6-oxycodone	+	2.92E+07	1.71 (-0.01	322.1920	322.1925	0.47	100,00	4 of 5	***************************************		
•	d3-morphine	+	2.48E+07	0.56 (0)	289.1626	289.1629	0.30	100.00	5 of 5			
•	d3-hydrocodone	+	2.60E+07	1.8 (-0.03)	303.1783	303.1787	0.49	100.00	3 of 4			······································
	morphine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	***************************************		
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A	N/A	N/A		***************************************	
	hydroxymidazolam	+	N/A	N/A (N/A)	342.0804	N/A	N/A	N/A	N/A			·····
	hydroxytriazolam	+	N/A		359.0461	N/A	N/A	N/A	N/A		<u> </u>	······································
	7-aminoclonazepam	+	N/A	N/A (N/A)	286.0742	N/A	N/A	N/A	N/A	•••••		·····
	7-aminoflunitrazepam	+	N/A	N/A (N/A)	284.1194	N/A	N/A	N/A	N/A		***************************************	······
	alprazolam	+	N/A	N/A (N/A)	309.0902	N/A	N/A	N/A	N/A		····	······································
	bromazepam	+	N/A	N/A (N/A)	316.0080	N/A	N/A	N/A	N/A		Ì	·····
	chlordiazepoxide	+	N/A	N/A (N/A)	300.0898	N/A	N/A	N/A	N/A		ľ	·····
	clonazepam	+	N/A		316.0484	N/A	N/A	N/A	N/A		1	·····
- 1	desalkylflurazepam	+	N/A	N/A (N/A)	289.0539	N/A	N/A	N/A	N/A		ľ	
	desmethylflunitrazepam	+	N/A		300.0779	N/A	N/A	N/A	N/A		Ì	
	diazepam	+	N/A		285.0789	N/A	N/A		N/A	luuuuu		
	estazolam	+	N/A		295.0745	N/A	N/A		N/A		***************************************	······································
· ·	etizolam	+	N/A		343.0779	N/A	N/A		N/A	···		·····
1	flunitrazepam	+	N/A		314.0936	N/A	N/A		N/A	*******		
	flurazepam	+	N/A		388.1586	N/A	N/A		N/A	***************************************		
				~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		~~~~	••••••••••••	·····	·····		

Baten:	20170928						Sample						ncb
Method:	ExclusionSOP_TargetingScree	ening					Oumpio		*******	***************************************	***************************************		***************************************
Inst. Method:							Comment						
Acquired:	9/28/2017 23:16							************	Probabilitation de la constitution de la cons titution de la constitution de la constitu		***************************************		
Sample Type:			Lab Name:	FBI Laborator	ry		File					2017092	8 33
Vial Position	1:D.5			Exclusionary	Screening TO	K 215							
L						····		·····					
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes			
	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A	N/A		N/A	***************************************	***************************************		
	lormetazepam	+	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A	***************************************		***************************************	
	medazepam	+	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A	***************************************		***************************************	
	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A		***************************************	-	
	nordiazepam	+	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A		***************************************	***************************************	
	oxazepam	4	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A	······································	***************************************		***************************************
	phenazepam	+	N/A	N/A (N/A)	348.9738	N/A	N/A	N/A	N/A	···········			***************************************
	prazepam	4	N/A	N/A (N/A)	325,1102	N/A	N/A	N/A	N/A				······································
	temazepam	4	N/A	N/A (N/A)	301.0738	N/A	N/A	N/A	N/A	***************************************			
	tetrazepam	4	N/A	N/A (N/A)	289,1102	N/A	N/A	N/A	N/A	***************************************			
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A	***************************************	***************************************		••••••
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	6-acetylmorphine	+	N/A	N/A (N/A)	328,1543	N/A	N/A	N/A	N/A			***************************************	
	codeine	4	N/A.	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A			***************************************	
	dihydrocodeine	+	N/A	N/A (N/A)	302.1751	N/A	N/A	N/A	N/A				***************************************
	dihydromorphone	+	N/A	N/A (N/A)	288.1594	N/A	N/A	N/A	N/A	***************************************			
	EDDP	+	N/A	N/A (N/A)	278.1903	N/A	N/A	N/A	N/A			1	
	hydrocodone	+	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A	·····			
	hydromorphone	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	~			***************************************
	norcodeine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	~	ľ		
	normorphine	+	N/A	N/A (N/A)	272,1281	N/A	N/A	N/A	N/A	7	Ī		<del></del>
	noroxycodone	+	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A			***************************************	
	oxycodone	+	N/A	N/A (N/A)	316.1543	N/A	N/A	N/A	N/A	~	ľ		************************
	oxymorphone	+	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A			***************************************	
	ecgonine methyl ester	+	N/A	N/A (N/A)	200.1281	N/A	N/A	N/A	N/A	<del>~~;~;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>		-	
	benzoylecgonine	+	N/A	N/A (N/A)	290.1387	N/A	N/A	N/A	N/A	<del></del>	******************		***************************************
	cocaethylene	+	N/A	N/A (N/A)	318.1700	N/A	N/A	N/A	N/A	***************************************		***************************************	
	cocaine	+	N/A	N/A (N/A)	304.1543	N/A	N/A	N/A	N/A	···		***************************************	************
	brompheniramine	+	N/A	N/A (N/A)	319.0804	N/A	N/A	N/A	N/A				
	chlorpheniramine	+	N/A	N/A (N/A)	275.1310	N/A	N/A	N/A	N/A	***************************************	*****************	<del></del>	***************************************
								~~~~~~	<del>~~~~~~~~</del>		***************************************	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	·····

b7E -2

7-88 455 55 1827-2811

				EXCIUSION	iary Screei	ning by UF	'LC/FINS	.			
Batch:	20170928						Sample	3 .			nct
Method:	ExclusionSOP_TargetingScreening						σα,ρ			······································	
Inst. Method:							Commen	ŧ			
Acquired:	9/28/2017 23:16							***************************************	Milledische Berlinder der der der der geregenen geb	~~~~	***************************************
Sample Type:			Lab Name:	FBI Laborator	У		File				20170928_33
Vial Position	1:D,5		<u>As</u> say:	Exclusionary	Screening TOX	X 215					
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes	
-	dextromethorphan	+	N/A	N/A (N/A)	272.2009	N/A	N/A	N/A	N/A		
	dextrorphan	+	N/A	N/A (N/A)	258.1852	N/A	N/A	N/A	N/A		
	diphenhydramine	+	N/A	N/A (N/A)	256.1696	N/A	N/A	N/A	N/A		
	doxylamine	+	N/A	N/A (N/A)	271.1805	N/A	N/A	N/A	N/A	***************************************	
	hydroxyzine	+	N/A	N/A (N/A)	375.1834	N/A	N/A	N/A	N/A	***************************************	
	norchlorcyclizine	*	N/A	N/A (N/A)	287.1310	N/A	N/A	N/A	N/A	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
	pheniramine	+	N/A	N/A (N/A)	241.1699	N/A	N/A	N/A	N/A	····	
	tetrahydrozoline	+	N/A	N/A (N/A)	201.1386	N/A	N/A	N/A	N/A	······································	
	zaleplon	+	N/A	N/A (N/A)	306.1349	N/A	N/A	N/A	N/A	***************************************	
	zolpidem	+	N/A	N/A (N/A)	308.1757	N/A	N/A	N/A	N/A	······································	·····
	zopiclone	+	N/A	N/A (N/A)	389.1123	N/A	~~~~~~~~~	N/A	N/A	·····	
	duloxetine	+	N/A	N/A (N/A)			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	N/A	N/A		

		b6 -1 b7C -:	1

40000000

3500000

3000000

2500000

TOXXXXXX

1503003 10000000

F000000

730030

5300330

\$03003

COCCO.

3000000

2000000

100000

25

File 20170928 33 Acquired 9/28/2017 23:16 ncb d5-alprazolam d5-hydroxalprazolam d4-clonazepam d4-7-aminoclonazepam Compound: Compound: Compound: Compound: 3.1 2.94 RT(exp) RT(exp) RT(exp) 3.11 RT(exp) 2.07 RT(delta) 3.07 (-0.03) RT(delta) 2.91 (-0.03) RT(delta) 3.08 (-0.03) 2.06 (-0.01) RT(delta) 17902000 3299500 Area: Area: 682290 Area: 2849200 Area: 314.1221 330,1169 320.0739 290,0997 m/z: m/z: m/z: m/z: delta (mmu): 0.57 delta (mmu): 0.49 delta (mmu): 0.49 delta (mmu): 0.4 FC 3.07 RT: 2.91 AA: 229653672 50.258 AX 682290.51 FET 2.06 A4: 3846244.76 140300000 28000000 2400000 130000000 30000G 2602360. 2230233 120000000 450000 24000000 20000000 410000000 22000003-400000 NOON ON THE 19000000 2000000 2223300 SCORGO 16000001 18030003-\$030000 200000 15000000. 1400000 70000000 14302300-1200000 2500003 EDXCOX(3) 200000 (00)(00) 2002203 20000000 10033003 2302300 40000000 8000003 150000-E00000 30000000 E033303 :00005-2000000 403360 4000000 50000-10000003 200000 2000XI 32 3 d5-diazepam d5-oxazepam d6-zolpidem d3-benzoylecgonine Compound: Compound Compound: Compound: 3.75 RT(exp) RT(exp) 2.37 RT(exp) RT(exp) 1.97 3.7 (-0.05) RT(delta) RT(delta) 2.99 (-0.01) RT(delta) 2.36 (-0.01) RT(delta) 1.96 (-0.01) 14103000 1557100 Area: Area: Area: 9834400 66943000 Area: 290,1107 292.0900 314.2136 293,1579 m/z: m/z: m/z: m/z: delta (mmu): 0.36 delta (mmu): 0.43 delta (mmu): 0.19 delta (mmu): 0.42 FCT: 3:70 80.2.38 RT: 2.36 AA: 5834448.50 PR: 1.96 AAC 86543447.85 \$6000000c 75030003 1300000 SECOCIOCO . 70000000 KCOXXXX EREXXXI. 520000000 1103003 70000003 COXXXXXX 50000000 :0000000 SSTOOMO. 600000 900000 450000000 SDOODSC-800000 ATTENDED ! 45000005-5000000J

4230233

1000001~

200000000

10000000

22

25 FBI(20-cv-0545)-1239

35000000

30000000

22000000

2000000

15000000

100000000

5803000

b6 -1

b7C -1

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928 33

Annuland	20170928_55		TOX 215 EXCLUSIONARY SC	SCREENING BY UPLC/FIMS				
Acquired Compound:	9/28/2017 23:16 d3-diphenhydramine	Compound:	d6-oxycodone	Compound:	d3-morphine	Compound:	ncb d3-hydrocodone	
RT(exp)	2.73	RT(exp)	1.72	RT(exp)	0.56	RT(exp)	1.83	
RT(delta)	2.73 (0)	RT(delta)	1.71 (-0.01)	RT(delta)	0.56 (0)	RT(delta)	1.8 (-0.03)	
Area:	5490500	Area:	29195000	Area:	24774000	Area:	25954000	
m/z:	259.1887	m/z:	322.1925	m/z:	289.1629	m/z:	303.1787	
delta	(mmu): 0.3	delta	(mmu): 0.47	delta	(mmu): 0.3	delta	(mmu): 0.49	
4500000 - 4600000 - 5500000 - 2500000 - 1500000 - 1500000 - 1500000 -	## 1.72 AV: 5650498.25	28600093 - 2060093 - 2060093 - 2060093 - 1500093 - 1500093 - 10000093 - 10000093 - 10000093 - 20600093 - 20600093 - 2060000000000000000000000000000000000	87:1.71 AX 28194627.73	166900001 148600001 126900001 169600001 269600001 269600001	FR 0.45 An 24773 and 200	223967000 - 207607000 - 160760700 - 16076000 - 1607600 - 1607600 - 1607600 - 1607600 - 1607600 - 1607600 - 16076000 - 1607600 - 1607600 - 1607600 - 1607600 - 1607600 - 16	5T 1.80 AA 2Z/S 3E7 92	
Compound:	morphine	Compound:	hydroxyalprazolam	Compound:	hydroxymidazolam	Compound:	hydroxytriazolam	
RT(exp)	0.56	RT(exp)	2.9	RT(exp)	2.67	RT(exp)	2.9	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
1 .	,		ı	44	,	IK .	. (

<u> </u>	~ 	Compound.		NODITIO CON CO.	COMPORIO.			RCOMPORNO:			
RT(exp)	0.56	RT(exp)	2.9	RT(exp)	2.67		RT(exp)	2.9			
(T(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	11	•••••	N/A (N/A)			
rea:	N/A	Area:	N/A	Area:	N/A [Area:	N/A			
n/z:		m/z:		m/z:			m/z:				
lelta	(mmu): N/A	delta (mmu); N/A		delta	delta (mmu): N/A			(mmu): N/A			
14000 14000 13000 13000 4000 4000 3000	FILLS AA DAS 25 2≥ 47	102 90 103 103 104 105 105 105 105 105 105 105 105	FT 2.55 AA 8 8 8 2 5 7 8 7 7	102 - 93 - 39 - 103 - 52 - 30 - 103	RT: 2.57 At: 5.00 25 27		1005 - 100 -	RT 250 AN DSE 25 FBI(20-EV			

1027-2017

20170928_33

Acquired	9/28/2017 23:16								ncb
Compound:	7-aminoclonazepam	Compound:	7-aminoflunitrazepam	Compaund:	alprazolam		Compound:	bromazepam	
RT(exp)	2.07	RT(exp)	2.27	RT(exp)	3.1		RT(exp)	2.66	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)		RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A		Area:	N/A	
m/z:		m/z:		m/z:			m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A		delta	(mmu): N/A	
103 - 103 -	585 3-07 AA: 2:05 3:5 2:5 2:5	92001 1898 2600 2600 2000 2000 1900 1600 1600 1600 1600 1600 1600 1	907 2.27 AX 8:00 2.2 2.3 2.4	102 - 102 -	8E 3,10 AA 94E 25 3: 22	23	103 - 99 - 103 - 1	77 2.65 AV 2.55 Zk 27 28	b6 -1 b7C -1
Compound:	chlordiazepoxide	Compound:	clonazepam	Compound:	desalkylfluraze	pam	Compound:	desmethylflunitrazep	am
RT(exp)	2.46	RT(exp)	3.07	RT(exp)	3.19		RT(exp)	2.95	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)		RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	L	Area:	N/A	
<u>m/z:</u>		m/z:		m/z:			m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	L	delta	(mmu): N/A	
92	572.2-46 AA: 800: 24 25 25:	92	875 2 57 AA 6 665 30 3.4 2.2	1000 - 200 -	87, 1.13 AA: 900 24 22 33		730502 220003 115205 70000 93003 93000 90000 90000 90000 90000 90000 90000 90000	FT 255	

File 20170928_33 9/28/2017 23:16 Acquired ncb diazepam estazolam etizolam flunitrazepam Compound: Compound: Compound: Compound: 3.7 RT(exp) RT(exp) 3.25 3.22 RT(exp) RT(exp) RT(delta) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A N/A Area: N/A Area: N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta (mmu): N/A delta 18000 9000 16003 SD50-14000 7000 120000 60X3-200000 50001-2003 4000 60003 2000 4000 2002 20 1003-RE 3.70 AA: 0.00 500 \$ 000 AA 6000 FER 3.22 AA: 6000 3.4 flurazepam lormetazepam lorazepam medazepam Compound: Compound: Compound: Compound: 2.71 RT(exp) RT(exp) 3.04 3.43 2.71 RT(exp) RT(exp) N/A (N/A). RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A N/A Area: Area: N/A Area: N/A Area: m/z: m/z: m/z: m/z delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 50 23~ 80-70-8X~ **8**3~ 23-43. **2**0-12 ۲ij., 10-570 3.54 AC 3.42

33

75

FBI(20-cv (0545)-1242

b6 -1

b7C -1

b6 -1 b7C -1

File

20170928 33 Acquired 9/28/2017 23:16 ncb midazolam nordiazepam oxazepam Compound: phenazepam Compound: Compound: Compound: 2.67 RT(exp) RT(exp) 3,19 2.98 RT(exp) 3.45 RT(exp) RT(delta) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A N/A Area: Area: N/A Area: N/A Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A RT 3.19 33-80... 70000 ম্য-70-SEXXES. ₹C~ 3000 SOCO. 1000 13. 970, 2, 977 AA: 8,000 13. 87.292 88.600 PTC 2.46 AAL 8.00 25 prazepam temazepam tetrazepam triazolam Compound: Compound: Compound: Compound: 5.33 RT(exp) RT(exp) 3.27 3.12 RT(exp) 3.68 RT(exp) RT(delta) N/A (N/A) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A (N/A) RT(delta) N/A Area: N/A Area: Area: N/A N/A Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 34003 53 -90-20 200000 70-15000 72-16000 60-E3~ 14000 5X--CHOCK! 100000 32-3000 30 6000 23-**3**0~ 23-4000 ₩. 12. 3000 RC 3.27 12-FEE: 2.65 AA: 8.00 RE3,12 AA 360 -55 FBI(20-cv-0545)-1243

0000 0000

em em


දක කා

~~

2000

3.8

ncb



400

577: 0.86 AA: 0.00 500

4200

2000

3.6

3 FBI(20-cv-0545)-1244

b6 -1

b7C -1

ಯಾ

~

*

ಯಾ


ೕ

12

9/28/2017 23:16

ncb


(20-ev 0545)-1245





File


20170928 33 Acquired 9/28/2017 23:16 ncb brompheniramine chlorpheniramine dextromethorphan Compound: Compound: dextrorphan Compound: Compound: RT(exp) 2.5 2.43 2.65 RT(exp) RT(exp) 2.11 RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A N/A Area: Area: N/A N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A *60000 40000 \$5000 200000 50000 <200000 · 7000003 46000 100000 6000000 43000-3000X0 SOEKSE-30200 4900003 X30X 40000 XJ. 5030 3933003 182800-32333 2 572 2.500 AA: 0.000 1302XXX RT 2.43 64: 0.00 RC 266 AN 200 9330-801.211 84.5.00 diphenhydramine doxylamine hydroxyzine Compound: norchlorcyclizine Compound: Compound: Compound: 2.73 1.94 RT(exp) RT(exp) 2.98 RT(exp) 2.98 RT(exp) b6 -1 N/A (N/A) N/A (N/A) RT(delta) RT(delta) RT(delta) N/A (N/A) N/A (N/A) b7C -1 RT(delta) N/A N/A Area: Area: N/A Area: N/A Area m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 92. 83-10-1 870.2.73 AA 6.00 FTC 1.34 AA: 0.00 ST: 2.93 FR 1.56 AA: 0.00 AA: 8.00 FBI(20-cv-0545)-1246 File 20170928_33 Acquired 9/28/2017 23:16

Acquired	9/28/2017/23:16							ncb
Compound:	pheniramine	Compound:	tetrahydrozoline	Compound:	zalepion	Compound:	zolpidem	
RT(exp)	1.93	RT(exp)	1.87	RT(exp)	2.86	RT(exp)	2.35	
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
m/z:		m/z:		m/z:		m/z:		
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	
193 43 -		50000		100		755-7		











FBI(20-cv-0545)-1247

Batch:	20170929						Commis			2017.	00469, 2, ui	rino
Method:	ExclusionSOP_TargetingScreen	ing					oanipie		·····	A-0:37	00700, E, UI	
Inst. Method:		-					Comment	:				
Acquired:	9/29/2017 10:28						Commen	·		·····	***************************************	
Sample Type:			Lab Name:	FBI Laborator	y		File				20170929	9 04
Vial Position	2:A,7		Asay:	Exclusionary	Screening TO)	¢ 215		***************************************				
Detected	Target Name	<i>≯/</i> -	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		**********
	d5-alprazolam	+	N/A	N/A (N/A)	314.1215	N/A	N/A	N/A	N/A		~····	***************************************
•	d5-hydroxalprazolam	+	3.58E+06	2.9 (-0.04)	330,1165	330.1173	0.86	92.00	4 of 6			
•	d4-clonazepam	-+-	7.35E+05	3.07 (-0.04	320.0735	320.0742	0.74	100.00	4 of 4		······	
•	d4-7-aminoclonazepam	+	1.67E+06	2.03 (-0.04)290.0993	290.1002	0.92	70.00	4 of 5	***************************************		
····	d5-diazepam	4.	N/A	N/A (N/A)	290.1103	N/A	N/A	N/A	N/A	***************************************		***************************************
•	d5-oxazepam	+	1.62E+06	2.98 (-0.02)292.0896	292.0902	0.64	100.00	4 of 5			
•	d6-zolpidem	+	6.63E+06	2.34 (-0.03	314.2134	314.2141	0.74	100.00	3 of 3		7	····
<u> </u>	d3-benzoylecgonine	+	3.13E+07	1.96 (-0.01)293.1575	293,1583	0.82	99.00	3 of 4	***************************************	<u> </u>	***************************************
•	d3-diphenhydramine	+	7.17E+06	2.72 (-0.01)259.1884	259.1893	0.85	95.00	3 of 3			
	d6-oxycodone	+	1.20E+07	1.69 (-0.03)322.1920	322.1928	0.78	100.00	3 of 4	······································		***************************************
	d3-morphine	+	7.12E+06	0.54 (-0.02)289.1626	289.1633	0.73	100.00	3 of 3			····
•	d3-hydrocodone	+	5.27E+06	1.79 (-0.04)303.1783	303.1786	0.37	100.00	3 of 3			*******
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	morphine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	***************************************		
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A	N/A	N/A	***************************************		
	hydroxymidazolam	+	N/A	N/A (N/A)	342.0804	N/A	N/A	N/A	N/A	***************************************	·····	······
	hydroxytriazolam	4	N/A	N/A (N/A)	359.0461	N/A	N/A	N/A	N/A		····	***************************************
	7-aminoclonazepam	+	N/A	N/A (N/A)	286.0742	N/A	N/A	N/A	N/A	***************************************	······	***************************************
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	7-aminoflunitrazepam	4	N/A	N/A (N/A)	284.1194	N/A	N/A	N/A	N/A	······································	***************************************	
	alprazolam	+	N/A	N/A (N/A)	309.0902	N/A	N/A	N/A	N/A		***************************************	·····
~~~~~~~~~~	bromazepam	+	N/A	N/A (N/A)	316.0080	N/A	N/A	N/A	N/A		***************************************	~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	chlordiazepoxide	+.	N/A	N/A (N/A)	300.0898	N/A	N/A	N/A	N/A			
	clonazepam	+	N/A	N/A (N/A)	316.0484	N/A	N/A	N/A	N/A	***************************************		
	desalkylflurazepam	+	N/A	N/A (N/A)	289.0539	N/A	N/A	N/A	N/A	***************************************		
	desmethylflunitrazepam	+	N/A	N/A (N/A)	300.0779	N/A	N/A	N/A	N/A	***************************************		
	diazepam	4	N/A	N/A (N/A)	285.0789	N/A	N/A	N/A	N/A	······································		
	estazolam	+	N/A	N/A (N/A)	295.0745	N/A	N/A	N/A	N/A	***************************************		
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	etizolam	+	N/A	N/A (N/A)	343.0779	N/A	N/A	N/A	N/A	***************************************		
	flunitrazepam	+	N/A	N/A (N/A)	314.0936	N/A	N/A	N/A	N/A			***************************************
······································	flurazepam	+	N/A	N/A (N/A)	388.1586	N/A	N/A	N/A	N/A	·····		··········

Batch:	20170929						Sample	i.		2017	-004	69, 2, urine	
Method:	ExclusionSOP_TargetingScreening	}					4477			~~~~			
Inst. Method:							Comment	{					
Acquired:	9/29/2017 10:28							***************************************					
Sample Type:	Unknown		Lab Name:	FBI Laborator	У		File					20170929_04	
Vial Position	2:A,7		Assay:	Exclusionary	Screening TOX	(215							1.75
*******************************				*******************************									b7E
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes			
	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A		N/A	N/A				
	lormetazepam	*	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A				
	medazepam	- <b>+</b> -	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A				
	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A				_
	nordiazepam	+	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A				
	oxazepam	+	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A				
***************************************	phenazepam	+	N/A	N/A (N/A)	348.9738	N/A	N/A	N/A	N/A				
	prazepam	+	N/A	N/A (N/A)	325.1102	N/A	N/A	N/A	N/A				
	temazepam	+	N/A	N/A (N/A)	301.0738	N/A	N/A	N/A	N/A				•
	tetrazepam		N/A	N/A (N/A)	289,1102	N/A	N/A	N/A	N/A				•
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A		ľ		`
	6-acetylmorphine	+	N/A	N/A (N/A)	328,1543	N/A	N/A	N/A	N/A				
	codeine	+	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A		ľ		•
	dihydrocodeine	+	N/A	N/A (N/A)	302.1751	N/A	N/A	N/A	N/A		ſ		
	dihydromorphone	+	N/A	N/A (N/A)	288.1594	N/A	N/A	N/A	N/A				
	EDDP	+	N/A	N/A (N/A)	278.1903	N/A	N/A	N/A	N/A				•
	hydrocodone	+	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A	***************************************			•
***************************************	hydromorphone	+	N/A	N/A (N/A)	286,1438	N/A	N/A	N/A	N/A		••••		•
	norcodeine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	***************************************	*********		LC 1
	normorphine	+	N/A	N/A (N/A)	272.1281	N/A	N/A	N/A	N/A				b6 -1 b7C -1
	noroxycodone	+	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A				1- 3/d
	oxycodone	+	N/A	N/A (N/A)	316.1543	N/A	N/A	N/A	N/A		*******		•
	oxymorphone	+	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A		**********		
	ecgonine methyl ester	+	N/A	N/A (N/A)	200.1281	N/A	N/A	N/A	N/A	~~~~			•
***************************************	benzoylecgonine	+	N/A	N/A (N/A)	290.1387	N/A	N/A	N/A	N/A				
	cocaethylene	+	N/A	N/A (N/A)	318.1700	N/A	N/A	N/A	N/A				<b>.</b> :
	cocaine	+	4.68E+06	2.31 (0.01)	304,1543	304.1554	1.03	90.00	3 of 3	,			
************************	brompheniramine	+	N/A	N/A (N/A)	319.0804	N/A	N/A	N/A	N/A				•
	chlorpheniramine	+	N/A	N/A (N/A)	275.1310	N/A	N/A	N/A	N/A		~~~~		-

b7E -2

b6 -1 b7C -1

				w/\~\w\	a. y a	nng by Ur	~~, c , 183~				
Batch:	20170929						Sample			201	7-00469, 2, urine
Method:	ExclusionSOP_TargetingScreening	E.					Gampio	,	***************************************		
Inst. Method:							Comment				
Acquired:	9/29/2017 10:28						Common	·	***************************************		***************************************
Sample Type:	Unknown		Lab Name:	FBI Laborator	y		File				20170929_04
Vial Position	2:A,7		Assay:	Exclusionary S	Screening TOX	(215		~~~~		***************************************	***************************************
Detected	Target Name	+/-	Area	RT (Measured	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern	Num Isotopes	Notes	
	dextromethorphan	+	N/A	and Delta)	272.2009	N/A	8 E/A	Score (%)	~~~~~~~	·	
	dextrorphan	<del>-</del>	N/A	N/A (N/A)		·····		N/A	N/A		
	diphenhydramine	+	·····	N/A (N/A)	258.1852	N/A	~~~	N/A	N/A		
			N/A	N/A (N/A)	<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	N/A		N/A	N/A		
	doxylamine	<del></del>	N/A			N/A	N/A	<del></del>	N/A		
	hydroxyzine	+	N/A	N/A (N/A)	375.1834	N/A		N/A	N/A		
	norchlorcyclizine	+	N/A	N/A (N/A)	<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	N/A	N/A		N/A	••••	
	pheniramine	+	N/A	N/A (N/A)		N/A	N/A	N/A	N/A		
	tetrahydrozoline	+	2.28E+06	1.89 (0.02)	201.1386	201.1392	0.61	79.00	1 of 4		
	zalepion	+	N/A	N/A (N/A)	306.1349	N/A	N/A	N/A	N/A	***************************************	
•	zolpidem	+	1.18E+05	2.35 (0)	308.1757	308.1766	0.90	67.00	1 of 2	***************************************	***************************************
	zopiclone	+	N/A	N/A (N/A)	389.1123	N/A	N/A	N/A	N/A	····	
	duloxetine	<del>}</del>	N/A	N/A (N/A)	298,1260	N/A	N/A	N/A	N/A _	~~~~~	

File 20170929 04 9/29/2017 10:28 Acquired


ccco

~

**c** 

233

-



File 20170929_04 Acquired 9/29/2017 10:2

\$2000

22


CON


ees

622

٠...

~~2






erro erro 20170929_04 9/29/2017 10:28

#### TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 6 of 12

2017-00469, 2, urine



Compound:	chlordiazepoxide	Compound:	clonazepam	Compound:	desalkylfluraze	epam		Compound:	desmethylflunitrazepam	Ĭ.
RT(exp)	2.46	RT(exp)	3.07	RT(exp)	3.19	***************************************		RT(exp)	2.95	1
RT(delta)	N/A (N/A)	RT(delta)	1	\$\$	N/A (N/A)	***************************************	}	18	N/A (N/A)	
Area:	N/A	Area:	N1/A		N/A				N/A	d
m/z:		m/z:		m/z:				m/z:		b6 -1
delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	1 1		·	(mmu): N/A	b7C −1
42502 - 12503	2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	122 30 22 70 53 45 45 25 25 26 27 28 29 20 20 20 20 20 20 20 20 20 20	RT:207 AA:000 30 33 32	100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 -	767 X.12 AA: 202 25 32 32			70000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 450000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 450000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 450000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 45000 - 450	28 28FBI(20-cv-0)	545)-125:

Page 7 of 12

N/A (N/A)

N/A

RT(delta)


CON NO <del>س</del>ہ

RT(delta)

Area:

N/A (N/A)

N/A



······································	<del></del>	7.17.00x.	(417)	m ca.	13.412.7		12	Mica.	1 W/M	!!
n/z: elta	(mmu): N/A	m/z: delta	(mmu): N/A	m/z: delta	(mmu): N/A			m/z: delta	(mmu): N/A	b6 b70
20020 - 25005 - 2003 - 2000 - 2000 - *2000 - *2000 - *3000 -	FR 2.71 AK 0.50 26 27 29 33	200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 -	FT 2.04 44 5.02 35 2° 22	105 - 40 - 85 - 70 - 80 -	97.3.42 50:200	38		\$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022 \$2022	#7.27: AN 200 28 27 FB1(20-€v-0	545)-1

RT(delta)

Area

N/A (N/A)

N/A

N/A (N/A)

N/A

RT(delta)

Area:

1

File 20170929 04

#### TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 8 of 12

Acquired 9/29/2017 10:28 2017-00469, 2, urine midazolam nordiazepam oxazepam phenazepam Compound: Compound: Compound: Compound: 2.67 RT(exp) RT(exp) 3.19 2.98 3.45 RT(exp) RT(exp) N/A (N/A) RT(delta) N/A.(N/A) RT(delta) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A N/A Area: Area: N/A N/A Area: Area m/z: m/z m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta 500003 53-450003-80.-43003 73, MON. 33300 25700 zoxe. 30 -:DXX 23-22. :0000 A 8712.67 600.000 AT: 3.19 AA: 0.00 RT 2.56 prazepam temazepam tetrazepam triazolam Compound: Compound: Compound: Compound 5.33 RT(exp) 3.68 RT(exp) 3.27 RT(exp) 3.12 RT(exp) N/A (N/A) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A Area: Area: N/A N/A N/A Area: Area m/z: m/z: m/z: b6 -1 delta (mmu): N/A (mmu): N/A delta delta (mmu): N/A delta (mmu): N/A 30000 52-23~ 45000 400000 70. 22000 æ. 207/02 55. 42. 20000 32.4 22~ 10000 20.4 DXC. AR 3.37 AA 0.00 70. 3.65 FBI(20-cv-0\$45)-1255

b7C -1

b6 -1


b7C -1

FBI(20-cv-0\$45)-1256

# TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170929 04 Acquired

2017-00469, 2, urine



2000

700002-

50000

90000

**90003** -

300000

333003

100000

35


273373

2350550

930330

430000

200000



35032

XXXX-

25003

200000

150550

10000-

5000

Page 10 of 12


File 20170929_04 9/29/2017 10:28 Acquired

~ 00

#~~ ##

#### TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

2017-00469, 2, urine




Compound:	ecgonine methyl ester	Compound:	benzoylecgonine	Compound:	cocaethylene	Compound:	cocaine	
RT(exp)	0.26	RT(exp)	1	18	2.5	RT(exp)	2.3	1
RT(delta)	N/A (N/A)	RT(delta)		3[	N/A (N/A)		2.31 (0.01)	
Area:	N/A	Area:	6376	1	N/A	Area:	4681300	
m/z:		m/z:		m/z:		m/z:	304.1554	1
delta	(mmu): N/A	delta		delta	(mmu): N/A		(mmu): 1.03	b6 -1 b7C -1
3-1		1203005 1000000 10020000 1002000 1002000 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 100200 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 10020 100	\$ 1.55 \$ 1.55 \$ 2.55	550002 500005 450002 400005 150005 250005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005 150005		250000000 250000000 250000000 250000000 150000000 100000000 20000000	22 23 FBI(20-cv-0	545)-1257

Page 11 of 12

File 20170929_04

#### TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Acquired							2017-00469, 2, urir
Compound:	brompheniramine	Compound:	chlorpheniramine	Compound:	dextromethorphan	Compound:	dextrorphan
RT(exp)	2.5	RT(exp)	2.43	RT(exp)	2.65	RT(exp)	2.11
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A
niz:		m/z:		m/z:		m/z:	***************************************
ielta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A	delta	(mmu): N/A
16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000 - 16000	87:180 AA:300 24 28 28 27	1220202 180000 180000 180000 190000 190000 190000 190000 190000	757 2-15 AA 5-20 23 23 28	750783 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 2297837 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 22978 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 22978 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 - 229787 -	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	190000 140000 100000 10000 10000 10000 10000 10000 10000	AA 5 22 23
ompound:	diphenhydramine	Compound:	doxylamine	Compound:	hydroxyzine	Compound:	norchlorcyclizine



ന്നു സ 25~ C339 File 20170929_04 Acquired 9/29/2017 10:28 pheniramine Compound: 1.93 RT(exp)

N/A

RT(delta)


Compound:


Area: m/z: delta N/A (N/A)

(mmu): N/A


#### TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


***************************************						2017-00469, 2, urine	8
ne	Compound:	tetrahydrozoline	Compound:	zalepion	Compound:	zolpidem	٦
	RT(exp)	1.87	RT(exp)	2.86	RT(exp)	2.35	1
	RT(delta)	1,89 (0.02)	RT(delta)	N/A: (N/A)	RT(delta)	2.35 (0)	1
	Area:	2283000	Area:	N/A	Area:	117530	1
***************************************	m/z:	201.1392	m/z:		m/z:	308,1766	
	delta	(mmu): 0.61	delta	(mmu): N/A	delta	(mmu): 0.9	7





duloxetine





RT(exp)	2.13	RT(exp)	3.02
RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)
Area:	N/A	Area:	N/A
n/z:		m/z:	
delta	(mmu): N/A	delta	(mmu): N/A
3836000 3830600 4830600 4830000 803000	\$77.2.45 AA 0.000 SS 21 22 25	25 - 25 - 25 - 25 - 25 - 25 - 25 - 25 -	877 3.52 844 3.50 25 2.5



b6 -1 b7C -1

b6 -1 b7C -1

FBI(20-cv-0545)-1259

b7E -2

b6 -1 b7C -1

Batch:	20170929						Sample				hydrolys	sis check	
Method:	ExclusionSOP_TargetingScreeni	ng					Campic			***************************************			
Inst. Method:							Comment						
Acquired:	9/29/2017 10:39						4.0	~~~~~		·····		······································	•
Sample Type:			Lab Name:	FBI Laborator	у		File				20	170929_05	
Vial Position	2:8,6		Assay:	Exclusionary :	Screening TO)	(215						***************************************	
				~~~									
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	isotopic Pattern Score (%)	Num Isotopes Matched	Notes			
	d5-alprazolam	+	N/A	N/A (N/A)	314,1215	N/A		N/A	N/A	*******			
	d5-hydroxalprazolam	+	2.64E+06	2.91 (-0.03	330.1165	330.1173	0.86	100.00	6 of 6	······································	***************************************	**********	
	d4-clonazepam	+	5.27E+05	3.08 (-0.03	320.0735	320.0743	0.83	100.00	5 of 5		***************************************	······································	
•	d4-7-aminoclonazepam	+	2.85E+06	2.04 (-0.03	290.0993	290.1000	0.77	100.00	5 of 6		······································	*************************************	
	d5-diazepam	4.	N/A	N/A (N/A)	290.1103	N/A	N/A	N/A	N/A		***************************************		~~~~
•	d5-oxazepam	+	9.16E+05	2.98 (-0.02)292.0896	292.0905	0.88	97.00	5 of 6		***************************************	~~~	
•	d6-zolpidem	+	6.22E+06	2.35 (-0.02	314.2134	314.2140		100.00	2 of 3		·····		
•	d3-benzoylecgonine	+	6.51E+07)293,1575		~~~~	100.00	4 of 4			**************************************	
•	d3-diphenhydramine	+	9.77E+06	2.72 (-0.01				100.00	3 of 4		······		~~~~
•	d6-oxycodone	+	1.60E+07	1.7 (-0.02)	····			100.00	4 of 4	~~~~		***************************************	
•	d3-morphine	+	1.23E+07	0.55 (-0.01		***************************************	***************	100.00	3 of 4		***************************************		
•	d3-hydrocodone	+	1.57E+07	1.79 (-0.04				100.00	3 of 4		····		
•	morphine	+	7.51E+07	0.55 (-0.01		286,1445		100.00	4 of 5				
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A		N/A		<u>-</u>	***************************************	
	hydroxymidazolam	+	N/A	N/A (N/A)	342.0804	N/A	N/A		N/A			*********************	
	hydroxytriazolam	+	N/A	N/A (N/A)	359.0461	N/A	N/A		N/A	~			
	7-aminoclonazepam	+	N/A	N/A (N/A)	286.0742	N/A	N/A		N/A	······		***************************************	*****
	7-aminoflunitrazepam	+	N/A	N/A (N/A)	284.1194	N/A	N/A		N/A	Г			
	alprazolam	+	N/A	N/A (N/A)	309.0902	N/A	N/A		N/A	·····-		•••••••••••••••••••••••••••••••••••••••	
	bromazepam	+	N/A	N/A (N/A)	316.0080	N/A	N/A		N/A	·····	•••••••••••••••••••••••••••••••••••••••		
	chlordiazepoxide	+	N/A	N/A (N/A)	300.0898	N/A	N/A		N/A		·····	•••••	
	clonazepam	+	N/A	N/A (N/A)	316.0484	N/A	N/A		N/A		·····	······	
	desalkylflurazepam	+	N/A	N/A (N/A)	289.0539	N/A	N/A		N/A		***************************************	·····	
	desmethylflunitrazepam	4	N/A	N/A (N/A)	300.0779	N/A	N/A		N/A		······································		
	diazepam	*	N/A		285,0789	N/A	N/A		N/A			•••••	
	estazolam	+	N/A		295.0745	N/A	N/A		N/A		·		
	etizolam	- } -	N/A		343.0779	N/A	N/A	******	N/A	~~~~			
	flunitrazepam	+	N/A		314.0936	N/A	N/A		N/A			~~~	
	flurazepam	+	N/A	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		N/A	N/A		N/A		•••••	······	

				exclusion	iary screen	ning by Or	LL LINIS					
Batch:	20170929						Sample	}			hydrolysis	check
Method:	ExclusionSOP_TargetingScreeni	ng					,	***************************************				
Inst. Method:							Comment	t				
Acquired:	9/29/2017 10:39											
Sample Type:			Lab Name:	FBI Laborator	rý		File				2017	0929 05
Vial Position	2:8.6		Δesay:	Exclusionary	Screening TOX	(215						
Detected	Target Name	+1-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes	•••••	
	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A	N/A	N/A	N/A			
	lormetazepam	+	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A			
	medazepam	÷.	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A			
	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A			
	nordiazepam	+	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A			
	oxazepam	+.	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A			
	phenazepam	+	N/A	N/A (N/A)	348.9738	N/A	N/A	N/A	N/A	***************************************		
	prazepam	+	N/A	N/A (N/A)	325.1102	N/A	N/A	N/A	N/A			
	temazepam	+	N/A	N/A (N/A)	301.0738	N/A	N/A	N/A	N/A			•••••
	tetrazepam	+	N/A	N/A (N/A)	289.1102	N/A	N/A	N/A	N/A			
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A			
	6-acetylmorphine	+	N/A	N/A (N/A)	328.1543	N/A	N/A	N/A	N/A			
	codeine	+	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A		T	
	dihydrocodeine	+	N/A	N/A (N/A)	302.1751	N/A	N/A	N/A	N/A		7 ~ ~	~~~~~
	dihydromorphone	+	N/A	N/A (N/A)	288.1594	N/A	N/A	N/A	N/A		7 -	
	EDDP	+	N/A	N/A (N/A)	278.1903	N/A	N/A	N/A	N/A		7 [
	hydrocodone	4	N/A	N/A (N/A)	300.1594	N/A	N/A	N/A	N/A		~	
	hydromorphone	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A	***************************************	7 ~	
	norcodeine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A			
	normorphine	+	N/A	N/A (N/A)	272.1281	N/A	N/A	N/A	N/A			
	noroxycodone	4	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A			
	oxycodone	+	N/A	N/A (N/A)	316.1543	N/A	N/A	N/A	N/A			
	oxymorphone	4	N/A	N/A (N/A)	302.1387	N/A	N/A	N/A	N/A			
	ecgonine methyl ester	+	N/A	N/A (N/A)	200.1281	N/A	N/A	N/A	N/A			
	benzoylecgonine	+	N/A	N/A (N/A)	290.1387	N/A	N/A	N/A	N/A			
	cocaethylene	+	N/A	N/A (N/A)	318.1700	N/A	N/A	N/A	N/A	······		
	cocaine	+	N/A	N/A (N/A)	304.1543	N/A	N/A	N/A	N/A			
	brompheniramine	+	N/A	N/A (N/A)	319.0804	N/A	N/A	N/A	N/A	***************************************		
	chlorpheniramine	+	N/A	N/A (N/A)	275.1310	N/A	N/A	N/A	N/A			

b6 -1 b7C -1

Exclusionary Screening by UPLC/FTMS

Batch: Method:	20170929 ExclusionSOP_TargetingScreening	<u>.</u> .			•	•	Sample	·		ŀ	ydroly	sis chec	k
Inst. Method: Acquired:	9/29/2017 10:39	}					Comment						
Sample Type: Vial Position	Unknown		Lab Name:	FBI Laborator	y Screening TOX	(215	File		······································		<u> </u>	0170929_0	<u>)5</u>
Detected	Target Name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes		·····	•••
	dextromethorphan	+	N/A	N/A (N/A)	272.2009	N/A	N/A	N/A	N/A		•••••		-
	dextrorphan	+	N/A	N/A (N/A)	258.1852	N/A	~~~~~~~	N/A	N/A	~~~~		***************************************	
	diphenhydramine	+	N/A	N/A (N/A)	256.1696	N/A	N/A	N/A	N/A	•••••••••••••••••••••••••••••••••••••••	وعومو فو هوه و آنو هو		
·	doxylamine	+	N/A	N/A (N/A)	271.1805	N/A	N/A	N/A	N/A	***************************************			
	hydroxyzine	+-	N/A	N/A (N/A)	375.1834	N/A	N/A	N/A	N/A	***************************************		***	
	norchlorcyclizine	4	N/A	N/A (N/A)	287.1310	N/A	N/A	N/A	N/A	~~~~~	****************	***************************************	~~~~
	pheniramine	+	N/A	N/A (N/A)	241.1699	N/A	N/A	N/A	N/A	•••••			
	tetrahydrozoline	+	1.31E+06	1.9 (0.03)	201.1386	201,1393	0.65	84.00	2 of 4 s	Inotel			
	zaleplon	+	N/A	N/A (N/A)	306.1349	N/A	N/A	N/A	N/A	~~~~~~		***************************************	
	zolpidem	4	N/A	N/A (N/A)	308,1757	N/A	N/A	N/A	N/A	***************************************		***************************************	~~~~
***************************************	zopiclone	+	N/A	N/A (N/A)	389.1123	N/A	N/A	N/A	N/A _	·····			
	duloxetine	+	N/A	N/A (N/A)	298,1260	N/A	N/A	N/A	N/A				~~~~
													

b6 -1 b7C -1

(22)

537

850

File

20170929 05 9/29/2017 10:39


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 4 of 12

b6 -1

b7C -1

2 FBI(20-cv-0\$45)-1263



~3

25


File

20170929_05 9/29/2017 10:39

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 5 of 12

hydrolysis check



Compound:	morphine	Compound:	hydroxyalprazolam	Compound:	hydroxymid	lazolam	Compound:	hydroxytriazolam	
RT(exp)	0.56	RT(exp)	2.9	RT(exp)	2.67		RT(exp)	2.9	
RT(delta)	0.55 (-0.01)	RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)		RT(delta)	N/A (N/A)	
Area:	75059000	Area:	N/A	Area:	N/A		Area:	N/A	
m/z	286.1445	m/z:		m/z:			m/z:		b6 -1
delta	(mmu): 0.7	delta	(mmu): N/A	delta	(mmu): N/A	1	delta	(mmu): N/A	b7C -1
\$50000000 \$50000000 \$5000000 \$5000000 \$5000000 \$6000000 \$6000000 \$5000000 \$5000000	77 77 11	50 50 50 50 50 50 50 50 50 50 50 50 50 5	777 2.50 AA. 0.00 25 29 50 54	200 - 200 -	70, 2,57 AA, 570 24	22	100 - 100 -	₩ 2.50 Αλ.030 23 25 FB∲(20-cV-0)	45)-126

File 20170929 05 9/29/2017 10:39 Acquired


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


Page 6 of 12

b6 -1

b7C -1

hydrolysis check





25

Page 7 of 12 File 20170929 05 TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS 9/29/2017 10:39 Acquired hydrolysis check diazepam estazolam etizolam Compound. flunitrazepam Compound: Compound Compound: RT(exp) 3.7 RT(exp) 3.25 RT(exp) 3.22 RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A Area: Area: N/A N/A N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 8800 -150000 6000 1,00000 **%** 5303 130000 :20000 J 20. 5000 112000 4903 100002-42223-500000 16272 -60000 XXX MAKKES . 3500 exce. 53370-3002 30. 43320 :500-30000-22 20-4 :000-20000 ÷33-801 3,70 AA 0,00 10. 1004))((()) #07 3.25 AA: 0.00 3.4 flurazepam lorazepam lormetazepam Compound: medazepam Compound: Compound: Compound: RT(exp) 2.71 RT(exp) 3.04 3.43 2.71 RT(exp) RT(exp) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A Агеа: N/A Area: N/A N/A Area: Area: m/z: m/z: b6 -1 m/z: m/z delta (mmu): N/A delta (mmu): N/A delta b7C -1 (mmu): N/A (mmu): N/A delta 155. ×0-80-23. 70.₄ 72 23. 33.-42-39~ 33.-:34 767.2.75 AA 000

887 3.42 88. 9.60

25


FBI(20-cv-0545)-1266


File 20170929 05 9/29/2017 10:39 Acquired

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 8 of 12

hydrolysis check





b6 -1 b7C -1 File 20170929_05 9/29/2017 10:39 Acquired


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


Page 9 of 12

hydrolysis check

b6 -1

b7C -1






File 20170929_05 Acquired 9/29/2017 10:39


3 17 80

ಜ್ಞಾ

œ-,

~ # # * hydrolysis check






File 20170929_05 9/29/2017 10:39 Acquired

دنته

hydrolysis check



b6 -1


b7C -1

b6 -1 b7C -1

20170929_05 File Acquired 9/29/2017 10:39


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

hydrolysis check pheniramine tetrahydrozoline zaleplon zolpidem Compound: Compound: Compound: Compound: RT(exp) 1.93 1.87 RT(exp) 2.86 RT(exp) RT(exp) 2.35 N/A (N/A) RT(delta) RT(delta) 1.9 (0.03) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A Area: 1315000 Area: N/A N/A Area: Area: 201.1393 m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): 0.65 delta (mmu): N/A delta (mmu): N/A





zopiclone

Compound:



duloxetine





RT(exp)	2.13		RT(exp)	3.02				
RT(delta)	N/A (N/A)		RT(delta)	N/A (N/A	s)			
Area:	N/A		Area:	N/A				
n/z:			m/z:					
delta	(mmu): N/A	(mmu): N/A		(mmu): N	V/A	***************************************		
52- 52- 52- 52- 52- 52- 52- 52- 52- 52-	707 4 f2 AA: 8:00	22 23	700 - 20 - 20 - 20 - 20 - 20 - 20 - 20 -	\$7.3 M.	1.50; 2005			
2/2	4.5	22 23	7	÷ 25	25	23		

Compound



FBI(20-cv-0545)-1271

Batch:	20170929						Sample					1	ncu
Method:	ExclusionSOP_TargetingScreen	ing					Campie			••••••	***************************************		
Inst. Method:							Comment	ł					
Acquired:	9/29/2017 10:17						24.111.271	`	*********************	***************************************	***************************************		
Sample Type:			Lab Name:	FBI Laborator	y		File	:			2	0170929	9 03
Vial Position	2:A.6		Accay:	Exclusionary S	Screening TOX	(215					***************************************		
Potential	Target Name					······	·····	t de de como constitue de const	~~~				
Detected	rarget name	+/-	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes			
	d5-alprazolam	1	1.47E+07	3.07 (-0.03	314.1215	314.1223	0.75	100.00	6 of 7	·····	****		~~~~
	d5-hydroxalprazolam	+	3.38E+06	2.91 (-0.03	330.1165	330.1173	0,86	100.00	6 of 6	***************************************	***************************************	***************************************	•••••••••••••••••••••••••••••••••••••••
	d4-clonazepam	+	6.27E+05	3,08 (-0.03	320.0735	320.0742	0.71	100.00	5 of 5			~~~~	~~~~
•	d4-7-aminoclonazepam	4	2.11E+06	2.04 (-0.03)290.0993	290.1000	0.74	100.00	5 of 6	*************			
	d5-diazepam	+	N/A	N/A (N/A)	290.1103	N/A	N/A	N/A	N/A	************	***************************************	······	
•	d5-oxazepam	+	1.33E+06	2.99 (-0.01)292.0896	292.0903	0.76	98.00	4 of 5		***************************************	····	
•	d6-zolpidem	+	6.89E+06	2.35 (-0.02			0.53	100.00	3 of 3	ter et en			~~~~~
	d3-benzoylecgonine	+	5.71E+07	1.96 (-0.01	293.1575	293.1582	0.69	100.00	3 of 4	-	***************************************	·····	
•	d3-diphenhydramine	+	4.06E+06	2.73 (0)	259.1884	259.1892	0.79	97.00	3 of 3				
•	d6-oxycodone	+	1.69E+07	1.7 (-0.02)	322.1920	322.1928	0.84	100.00	3 of 4	***********		, i	•••••
•	d3-morphine	+	1.16E+07	0.55 (-0.01	289.1626	289.1633	0.73	100.00	3 of 4			ı İ	·
•	d3-hydrocodone	+	1.40E+07	1.79 (-0.04	303.1783	303.1789	0.67	100.00	3 of 4			ı İ	
	morphine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A				
	hydroxyalprazolam	+	N/A	N/A (N/A)	325.0851	N/A	N/A		N/A	*************			
	hydroxymidazolam	4-	N/A	N/A (N/A)	342.0804	N/A	N/A	N/A	N/A	····	1		~~~~
	hydroxytriazolam	+	N/A	N/A (N/A)	359.0461	N/A	N/A	N/A	N/A		<u>-</u>		······
	7-aminoclonazepam	+	N/A	N/A (N/A)	286.0742	N/A	N/A		N/A	*********************	***************************************		~~~~
	7-aminoflunitrazepam	+	N/A	N/A (N/A)	284.1194	N/A	N/A	N/A	N/A				
	alprazolam	+	N/A	N/A (N/A)	309.0902	N/A	N/A	N/A	N/A	·····	***************************************		
	bromazepam	+	N/A	N/A (N/A)	316.0080	N/A	N/A	N/A	N/A		***************************************		•••••
	chlordiazepoxide	*	N/A	N/A (N/A)	300.0898	N/A	N/A	N/A	N/A	······	*******	~~~~	
	clonazepam	+	N/A	N/A (N/A)	316.0484	N/A	N/A	N/A	N/A		**************	***************************************	
	desalkylflurazepam	.+	N/A	N/A (N/A)	289.0539	N/A	N/A	N/A	N/A	•••••••••••••••••••••••••••••••••••••••			
	desmethylflunitrazepam	+	N/A	N/A (N/A)	300.0779	N/A	N/A		N/A				
	diazepam	+	N/A		285.0789	N/A	N/A		N/A	•••••		·····	
	estazolam	+	N/A	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	295.0745	N/A	N/A		N/A	~~~~	•	***************************************	
	etizolam	+	N/A		343.0779	N/A	N/A		N/A				
	flunitrazepam	+	N/A		314.0936	N/A	N/A		N/A	~~~~~~	*****		·····
	flurazepam	+	N/A	N/A (N/A)	388.1586	N/A	N/A	N/A	N/A		***************************************	*****************	

b7E -2

b6 -1 b7C -1

b6 -1 b7C -1

Batch:	20170929				-								2011
Method:	ExclusionSOP_TargetingScreening	g					Sample	·	·····	**********			ncu
nst. Method:		~					Comment						
Acquired:	9/29/2017 10:17						Commen	·	······································		***************************************		
Sample Type:	Unknown		Lab Name:	FBI Laborator	ry		File	r				2017092	29 03
/ial Position	2:A.6		^esay:		Screening TOX	(215		·			·····	2017002	
Detected	Target Name	<i>*/-</i>	Area	RT (Measured and Delta)	Expected m/z	Measured m/z	Delta MMU	Isotopic Pattern Score (%)	Num Isotopes Matched	Notes			•••••
~~~~~~~~~~~	lorazepam	+	N/A	N/A (N/A)	321.0192	N/A	N/A	N/A	N/A		***************************************	······································	
	lormetazepam	+	N/A	N/A (N/A)	335.0349	N/A	N/A	N/A	N/A	***************************************			
************************	medazepam	+	N/A	N/A (N/A)	271.0997	N/A	N/A	N/A	N/A	~~~~	***************************************		
····	midazolam	+	N/A	N/A (N/A)	326.0855	N/A	N/A	N/A	N/A				
***********	nordiazepam	4	N/A	N/A (N/A)	271.0633	N/A	N/A	N/A	N/A	***********	***************************************		
····	oxazepam	*	N/A	N/A (N/A)	287.0582	N/A	N/A	N/A	N/A		~~~~~	<del></del>	
····	phenazepam	+	N/A	N/A (N/A)	348,9738	N/A	N/A	N/A	N/A	~~~~~	•••••••••••••••••••••••••••••••••••••••	······································	
	prazepam	+	N/A	N/A (N/A)	325.1102	N/A	N/A	N/A	N/A	·····		***************************************	
	temazepam	+	N/A	N/A (N/A)	301.0738	N/A	N/A		N/A		······································	***************************************	
***************************************	tetrazepam	+	N/A	N/A (N/A)	289.1102	N/A	N/A	N/A	N/A	<u></u>	·····	<del></del>	······
	triazolam	+	N/A	N/A (N/A)	343.0512	N/A	N/A	N/A	N/A				
	6-acetylmorphine	+	N/A	N/A (N/A)	328.1543	N/A	N/A	N/A	N/A				
	codeine	+	N/A	N/A (N/A)	300.1594	N/A	N/A		N/A				
	dihydrocodeine	+	N/A	N/A (N/A)	302.1751	N/A	N/A	N/A	N/A				
	dihydromorphone	+	N/A	N/A (N/A)	288.1594	N/A	N/A		N/A			·	·····
	EDDP	+	N/A	N/A (N/A)	278.1903	N/A	N/A		N/A				
	hydrocodone	+	N/A	N/A (N/A)	300.1594	N/A	N/A		N/A				
	hydromorphone	+	N/A	N/A (N/A)	286.1438	N/A	N/A	******	N/A			····	
	norcodeine	+	N/A	N/A (N/A)	286.1438	N/A	N/A	N/A	N/A			·····	
	normorphine	+	N/A	N/A (N/A)	272.1281	N/A	N/A	N/A	N/A			······	
	noroxycodone	-\$-	N/A	N/A (N/A)	302.1387	N/A	N/A	<b></b>	N/A		······	······	
	oxycodone	+	N/A	N/A (N/A)	316,1543	N/A	N/A		N/A		·····	•••••	
	oxymorphone	+	N/A	N/A (N/A)		N/A	N/A		N/A		<del></del>	······································	
	ecgonine methyl ester	+	N/A	N/A (N/A)		N/A	N/A		N/A		······································	·····	
	benzoylecgonine	+	N/A	N/A (N/A)	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	N/A	N/A	******	N/A			·····	
	cocaethylene	+	N/A	N/A (N/A)		N/A	N/A	<b></b>	N/A		***************************************		
•	cocaine	+	1.91E+05			304.1553			2 of 2	1.0	purt	<del></del>	
	brompheniramine	+	N/A	N/A (N/A)		N/A	N/A		N/A			<u> </u>	
	chlorpheniramine	-f-	N/A		<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	N/A	N/A		N/A		·····		

b7E -2

b6 -1 b7C -1

# 2817-88488 1827-281)

				CACIUSION	ary screet	mig by ur	TC/ LIMI2	r-			
Batch:	20170929						Sample	>			no
llethod:	ExclusionSOP_TargetingScreening						~~,,,,,,,	·	***************************************	<del></del>	
nst. Method:							Commen	t			
cquired:	9/29/2017 10:17							*	************************	***************************************	······································
Sample Type:			Lab Name:	FBI Laborator	ý		File	,			20170929_0
ial Position	2:A.6		Assay:	Exclusionary	Screening TO	C 215					
Detected	Target Name	+/-	Area	RT	Expected	Measured	Delta	Isotopic	Num	Notes	
				(Measured and Delta)	m/z	m/z	MMU	Pattern Score (%)	Isotopes Matched		
************	dextromethorphan	4	N/A	N/A (N/A)	272.2009	N/A	N/A	N/A	N/A		
	dextrorphan	+	N/A	N/A (N/A)	258.1852	N/A	N/A	N/A	N/A		······································
	diphenhydramine	+	N/A	N/A (N/A)	256.1696	N/A	N/A	N/A	N/A		
	doxylamine	+	N/A	N/A (N/A)	271.1805	N/A	N/A	N/A	N/A		
	hydroxyzine	+	N/A	N/A (N/A)	375.1834	N/A	N/A	N/A	N/A	***************************************	······································
	norchlorcyclizine	+	N/A	N/A (N/A)	287.1310	N/A	N/A	N/A	N/A	***************************************	······································
	pheniramine	+	N/A	N/A (N/A)	241.1699	N/A	N/A	N/A	N/A		······································
•	tetrahydrozoline	+	1.13E+06	1.9 (0.03)	201.1386	201.1393	0.67	72.00	1 of 4	1	
	zalepion	+	N/A	N/A (N/A)	306.1349	N/A	N/A	N/A	N/A		
	zolpidem	+	N/A	N/A (N/A)	308.1757	N/A	N/A	N/A	N/A		······
	zopiclone	+	N/A	N/A (N/A)	389.1123	N/A	N/A	N/A	N/A		
	duloxetine	4	N/A	N/A (N/A)	298.1260	N/A	N/A	N/A	N/A		······

File 20170929 03 9/29/2017 10:17 Acquired


Compound:

233


crx

ccs

*




b7C -1



*****

File 20170929_03 Acquired 9/29/2017 10:17

Compound:	d3-diphenhydramine	Compound:	d6-oxycodone	Compound:	d3-morphine	Compound:	d3-hydrocodone
RT(exp)	2.73	RT(exp)	1.72	RT(exp)	0.56	RT(exp)	1.83
RT(delta)	2.73 (0)	RT(delta)	1.7 (-0.02)	RT(delta)	0.55 (~0.01)	RT(delta)	1.79 (-0.04)
Агеа:	4056700	Area:	16879000	Area:	11574000	Area:	13959000
m/z:	259.1892	m/z:	322.1928	m/z:	289.1633	m/z:	303.1789
delta	(mmu): 0.79	delta	(mmu): 0.84	delta	(mmu): 0.73	delta	(mmu): 0.67
23/23/265 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/25/26 - 1 25/2	25 25 25 25 25 25 25 25 25 25 25 25 25 2	20502003 - 20502005 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 150020000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 150020000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 15002000 - 150020000 - 150020000 - 150020000 - 150020000 - 150020000000 - 15002000000 - 15002000000000000000 - 150020000000000000000000000000000000000	80: 1-70 -04: 18579522.55	\$0200000 \$2000000 \$000000 \$000000 \$000000 \$000000 \$000000	RY U.SE AN 1957272.52	1.4230300 - 1.3030000 - 1.203300 - 1.203300 - 1.203200 - 1.203200 - 2.203200  2.203200 - 2.203200 - 2.203200 - 2.203200 - 2.203200 - 2.20320 - 2.20	97: 1.75 AA: 1395927012*



2.07 RT(exp) N/A (N/A) RT(delta) N/A Area: m/z: delta 50 -25 -70-

*--೯ ೧೦೦೨

**C** 

File

Compound:

20170929 03 Acquired 9/29/2017 10:17

7-aminoclonazepam

Compound:

RT(exp)

RT(delta)


Area:

m/z:

2.27

N/A

ncu 7-aminoflunitrazepam alprazolam bromazepam Compound: Compound: 3.1 RT(exp) 2.66 RT(exp) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A Area: Area: N/A m/z: m/z: (mmu): N/A delta delta (mmu): N/A



Compound:	chlordiazepoxide	Compound:	clonazepam	Compound:	desalkylflurazepam	Compound:	desmethylflunitrazepam	Ē
RT(exp)	2.46	RT(exp)	3.07	RT(exp)	3.19	RT(exp)	2.95	
RT(delta)	N/A (N/A)	RT(delta)		RT(delta)	N/A (N/A)	RT(delta)	N/A (N/A)	
Area:	N/A	Area:	N/A	Area:	N/A	Area:	N/A	
m/z:		m/z:		m/z:		m/z:		1-6-1
delta	(mmu): N/A	delta		delta	(mmu): N/A	della	(mmu); N/A	b6 -1 b7C -1
95 53 73 53 52 42 73 73 73 73 73 73 73 73 73 73 73 73 73	777.2.45 AA: 2.50 24 25 28	20 - 29 - 29 - 29	X7 3.07 AA. 2025 50 25 25	202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 - 202 -	70: 3.1% AA 5.20 3: 53 22	113093 - 12092 - 2002 -	్లోజీజీజీ * పి ►*FBI(20-cv-05	545)-1277


File 20170929 03 9/29/2017 10:17 Acquired

222

ncu

b6 -1

b7C -1



2.71 RT(exp) RT(exp) 3.04 2.71 3.43 RT(exp) RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A Area: N/A Area: N/A N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 10-32 FBI(20-cv-0\$45)-1278

#### File 20170929_03

ಯು

(CC) &~ ©73

~~~ ~~~ ~~~

~ ~ ~

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Acquired 9/29/2017 10:17 ncu midazolam nordiazepam oxazepam Compound: phenazepam Compound: Compound: Compound: 2.67 RT(exp) 3.19 RT(exp) 2.98 RT(exp) RT(exp) 3.45 N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A Area: N/A Area: N/A N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta delta (mmu); N/A 5C -**3**3~ 92. æ. ∞. 72.~ £3... 54.-43-22 32. 12. 10. 500:2.67 AA: 0:00 23. 8703.19 AA: \$50 80 0.80 AA 0.00 5.le 22 prazepam temazepam tetrazepam Compound: triazolam Compound:

| RT(exp) | 5.33 | RT(exp) | 3.27 | RT(exp) | 3.68 | RT(exp) | 3.12 | |
|---|------------------------------------|---|-----------------------------------|---|--------------------------------|---|---------------------------|------|
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | 1 |
| Area: | N/A | Area: | N/A | Area: | N/A | Area: | N/A | 1 |
| n/z | | m/z: | | m/z: | | m/z: | | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | b6 - |
| 20 - 20 - 20 - 20 - 20 - 20 - 20 - 20 - | 877.9.23
404.030
2 53 54 5.4 | 79000 - 70000 | #77 3.37
A4 5:30
52 3/3 3/4 | 20 - 20 - 20 - 20 - 20 - 20 - 20 - 20 - | %7 3.82
AA 8.02
28 27 22 | 20 - 20 - 20 - 20 - 20 - 20 - 20 - 20 - | ≈ 3:12
*** FBI(20-cv-(| |


Compound:

Compound:

File 20170929\_03 Acquired 9/29/2017 10:17

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


| Compound: | 6-acetylmorphine | Compound: | codeine | Compound: | dihydrocodeine | Compound: | dihydromorphone |
|---|------------------|---|------------|--|--------------------------------|--|-----------------|
| RT(exp) | 1.77 | RT(exp) | 1.54 | RT(exp) | 1.5 | RT(exp) | 0.49 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| Area: | N/A | Area: | N/A | Area: | N/A | Area: | N/A |
| m/z: | | m/z: | | m/z: | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A |
| 39000
39000
39000
39000
19000
19000
30 18 | 200 - 12 - 15 | 45000-
45000-
35000-
35000-
15000-
15000-
3000- | | 3530
3520
3520
3520
3520
3520
4530
4530
4530 | 87 1.50
A4 0.00
14 15 15 | 1500000
1600000
1700000
1700000
1700000
1700000
170000
170000
170000
170000
170000
170000
170000
170000
170000
170000 | 24 25 3t |





File 20170929\_03 Acquired 9/29/2017 10:17


ncu

| Compaund: | normorphine | Compound: | noroxycodone | Compound: | oxycodone | Compound: | oxymorphone |
|-------------|-------------|-----------|--------------|-----------|------------|-------------|-------------|
| RT(exp) | 0,44 | RT(exp) | 1.69 | RT(exp) | 1.72 | RT(exp) | 0.64 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | 1 | N/A (N/A) |
| Area: | N/A | Area: | N/A | Area: | N/A | Area: | N/A |
| m/z: | | m/z: | | m/z: | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A |
| <i>gama</i> | | | | , | | janiananan. | <u> </u> |










507, 3.21 AA: 191236.45

200203-


40000

2000

| Compound: | ecgonine methyl ester | Compound: | benzoylecgonine | Compound: | cocaethylene | *************************************** | Compound: | cocaine |
|--|-----------------------|---------------------------------------|--|-----------|--------------|---|-----------|-------------|
| RT(exp) | 0.26 | RT(exp) | 1.96 | RT(exp) | 2.5 | *************************************** | RT(exp) | 2.3 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | • | 1 | 2.31 (0.01) |
| Area: | N/A | Area: | N/A | Area: | N/A | | Area: | 191340 |
| m/z: | | m/z: | | m/z: | | | m/z: | 304.1553 |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | | delta | (mmu): 0.94 |
| ************************************* | | · · · · · · · · · · · · · · · · · · · | aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa | ~ | | | , | |





b6 -1 b7C -1




2017-00468

1827-2817






File 20170929\_03 9/29/2017 10:17 Acquired




File 20170929\_03 Acquired 9/29/2017 10:17

men

| Compound: | pheniramine | Compound: | tetrahydrozoline | Compound: | zaleplon | Compound: | zolpidem | nce |
|--|--|-----------|--|-----------|------------|-----------|------------|---|
| RT(exp) | 1.93 | RT(exp) | 1.87 | RT(exp) | 2.86 | RT(exp) | 2.35 | |
| RT(delta) | N/A (N/A) | RT(delta) | 1.9 (0.03) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | *************************************** |
| Area: | N/A | Area: | 1133800 | Area: | N/A | Area: | N/A | |
| m/z: | | m/z: | 201.1393 | m/z: | | m/z: | | *************************************** |
| delta | (mmu): N/A | delta | (mmu): 0.67 | delta | (mmu): N/A | delta | (mmu): N/A | |
| , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | ······································ | | and the second s | | | ; <u></u> | | |
| | | | 877: 1.50
68: 1032772: 47 | | | | | |



7-80 469



| | ************ | *************** | ******** |
|---|---|------------------|----------|
| 3 | | | |
| | | | |
| 3 | | | |
| 100.7 | | | |
| sc. | | | |
| ~~ | | | |
| 25~ | | | |
| 4 | | | |
| 70-4 | | | |
| l _ 1 | | | |
| 89- - | | | |
| [<sub>50</sub> .] | | | |
| { ~ } | | | |
| 204 | | | |
| 1 . | | | |
| 32- | | | |
| 20. | | | |
| 1~] | | | |
| 20 27 27 27 27 27 27 27 27 27 27 27 27 27 | | | |
| 1 1 | × × | 7:2.56
N 0:00 | |
| § 3-hanger | | | |
| 37 | 23 | 23 | 30 |
| Conservation contraction. | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | |

| 20200 | | į |
|--|---------|-----|
| 18000 -
18000 -
18000 -
14000 -
12000 -
10000 - | | |
| 180000- | | |
| *4000 | | |
| 12000 | | - |
| 19535 | | |
| 8000 | | |
| 5000- | | ľ |
| 4000 - | | |
| 2003-
2003- | #01# | |
| [] 3.] | AA 9700 | |
| 22 | 2.3 2.4 | 3.5 |

| RT(delta) N
Area: N
m/z:
delta (r | | Compound:
RT(exp) | 2.02 |
|--|------------------------------|---|----------------------------------|
| Area: N
m/z:
delta (r | N/A (N/A) | | 3.02 |
| m/z:
delta (r | | RT(delta) | N/A (N/A) |
| delta (r | V/A | Area: | N/A |
| <u> </u> | | m/z: | |
| 93- | mmu): N/A | delta | (mmu): N/A |
| 80 - 80 - 80 - 80 - 80 - 80 - 80 - 80 - | 27 242
AN 020
27 22 25 | 20 1 20 1 20 1 20 1 20 1 20 1 20 1 20 1 | 87: 1.02
AA: 0.00
20 30 32 |



b6 -1 b7C -1

| Batch: | 20170929 | | | | | | Sample | | | | | | sb |
|---|------------------------------|-------------|-----------|-------------------------------|---------------|-----------------|--------------|---|---|---|---|---|---|
| Method: | ExclusionSOP_TargetingScreen | ing | | | | | Sample | | | ······ | | | 283 |
| Inst. Method: | | | | | | | Comment | | | | | | |
| Acquired: | 9/29/2017 10:05 | | | | | | Comment | *************************************** | | *************************************** | ••••• | *************************************** | |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | y | | File | | | | 201 | 70929 | 02 |
| Vial Position | 2:A.5 | | Accay: | Exclusionary | Screening TOX | (215 | | ~~~~~~ | *************************************** | | | ······································ | |
| | | | | | | | | | | | | | |
| Detected | Target Name | <i>+}-</i> | Area | RT
(Measured
and Delta) | Expected m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | ••••• | *************************************** | - |
| | d5-alprazolam | + | N/A | N/A (N/A) | 314.1215 | N/A | N/A | | N/A | | *************************************** | | *************************************** |
| | d5-hydroxalprazolam | 4. | N/A | N/A (N/A) | 330.1165 | N/A | N/A | N/A | N/A | ****************** | ······································ | *************************************** | |
| | d4-clonazepam | + | N/A | N/A (N/A) | 320.0735 | N/A | N/A | N/A | N/A | ***** | | *************************************** | *************************************** |
| | d4-7-aminoclonazepam | + | N/A | N/A (N/A) | 290.0993 | N/A | N/A | N/A | N/A | *************************************** | | ••••• | |
| | d5-diazepam | + | N/A | N/A (N/A) | 290.1103 | N/A | N/A | N/A | N/A | **** | | | *************************************** |
| | d5-oxazepam | + | N/A | N/A (N/A) | 292.0896 | N/A | N/A | N/A | N/A | · | ······································ | ······ | |
| | d6-zolpidem | + | N/A | N/A (N/A) | 314.2134 | N/A | N/A | N/A | N/A | *************************************** | | *************************************** | |
| | d3-benzoylecgonine | +: | N/A | N/A (N/A) | 293.1575 | N/A | N/A | N/A | N/A | *********** | | ······································ | |
| | d3-diphenhydramine | 4. | N/A | N/A (N/A) | 259.1884 | N/A | N/A | N/A | N/A | - | ······································ | | *************************************** |
| | d6-oxycodone | + | N/A | N/A (N/A) | 322.1920 | N/A | N/A | N/A | N/A | | ~~~~ | | *************************************** |
| | d3-morphine | + | N/A | N/A (N/A) | 289.1626 | N/A | N/A | N/A | N/A | | *************************************** | | *********** |
| | d3-hydrocodone | + | N/A | N/A (N/A) | 303.1783 | N/A | N/A | N/A | N/A | · | | | |
| | morphine | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A | N/A | N/A | | | | |
| | hydroxyalprazolam | + | N/A | N/A (N/A) | 325.0851 | N/A | N/A | N/A | N/A | ~~~~ | | ····· | |
| | hydroxymidazolam | + | N/A | N/A (N/A) | 342.0804 | N/A | N/A | N/A | N/A | *************************************** | | | |
| | hydroxytriazolam | 4 | N/A | N/A (N/A) | 359.0461 | N/A | N/A | N/A | N/A | *************************************** | | | |
| *************************************** | 7-aminoclonazepam | + | N/A | N/A (N/A) | 286.0742 | N/A | N/A | N/A | N/A | *************************************** | | ······ | |
| | 7-aminoflunitrazepam | + | N/A | N/A (N/A) | 284.1194 | N/A | N/A | N/A | N/A | *************************************** | | ••••• | |
| | alprazolam | + | N/A | N/A (N/A) | 309.0902 | N/A | N/A | N/A | N/A | | | | |
| | bromazepam | + | N/A | N/A (N/A) | 316.0080 | N/A | N/A | N/A | N/A | | ***** | | *********** |
| | chlordiazepoxide | . ‡. | N/A | N/A (N/A) | 300,0898 | N/A | N/A | N/A | N/A | | | | |
| | clonazepam | + | N/A | N/A (N/A) | 316.0484 | N/A | N/A | N/A | N/A | ••••• | ****** | | |
| | desalkylflurazepam | + | N/A | N/A (N/A) | 289.0539 | N/A | N/A | N/A | N/A | ····· | | | |
| | desmethylflunitrazepam | + | N/A | N/A (N/A) | 300.0779 | N/A | N/A | N/A | N/A | ••••• | ····· | ******* | |
| | diazepam | + | N/A | N/A (N/A) | 285.0789 | N/A | N/A | N/A | N/A | | ••••• | | |
| | estazolam | + | N/A | N/A (N/A) | 295.0745 | N/A | N/A | | N/A | ••••• | *************************************** | ********** | |
| | etizolam | + | N/A | N/A (N/A) | 343.0779 | N/A | N/A | N/A | N/A | | ······································ | ~~~~~ | |
| | flunitrazepam | + | N/A | N/A (N/A) | 314.0936 | N/A | N/A | N/A | N/A | 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 | | *************************************** | |
| | flurazepam | + | N/A | N/A (N/A) | 388.1586 | N/A | N/A | N/A | N/A | ••••••••••••••••••••••••••••••••••••••• | *************************************** | | ********* |

Exclusionary Screening by UPLC/FTMS

| Batch: | 20170929 | | | | | | Sample | 23 | | | | sk | 3 |
|---------------------------|-----------------------------|-------|-----------|-------------------------------|--|-----------------|--------------|--|----------------------------|---|---|---|------|
| Method: | ExclusionSOP_TargetingScree | ining | | | | | Samp | ~····································· | ······ | *************************************** | ********* | | ~ |
| Inst. Method: | | | | | | | Commen | ıt | | | | | |
| Acquired: | 9/29/2017 10:05 | | | | | | 3 2 | · | | *************************************** | | ······································ | wa |
| Sample Type: | | | Lab Name: | FBI Laborator | ry . | | Pile | 3 | | | | 20170929 02 | 2 |
| Vial Position | 2:A,5 | | Assay: | Exclusionary | Screening TO) | (215 | | | | ~~~~ | | | _ |
| | | | | | | | | | | | | | |
| Detected | Target Name | +1- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | *************************************** | | - |
| ************************* | lorazepam | + | N/A | N/A (N/A) | 321.0192 | N/A | N/A | N/A | N/A | | | | |
| | lormetazepam | + | N/A | N/A (N/A) | 335.0349 | N/A | N/A | N/A | N/A | | | | |
| ************************ | medazepam | + | N/A | N/A (N/A) | 271.0997 | N/A | N/A | N/A | N/A | | *************************************** | | |
| | midazolam | + | N/A | N/A (N/A) | 326.0855 | N/A | N/A | N/A | N/A | | *************************************** | | |
| | nordiazepam | + | N/A | N/A (N/A) | 271.0633 | N/A | N/A | N/A | N/A | | *************************************** | | |
| | oxazepam | -+- | N/A | N/A (N/A) | 287.0582 | N/A | N/A | N/A | N/A | | | *************************************** | |
| | phenazepam | + | N/A | N/A (N/A) | 348.9738 | N/A | N/A | N/A | N/A | | *************************************** | | |
| | prazepam | + | N/A | N/A (N/A) | 325.1102 | N/A | N/A | N/A | N/A | | | | |
| | temazepam | + | N/A | N/A (N/A) | 301.0738 | N/A | N/A | N/A | N/A | *************************************** | | ••••••••••••••••••••••••••••••••••••••• | |
| | tetrazepam | +- | N/A | N/A (N/A) | 289,1102 | N/A | N/A | N/A | N/A | *************************************** | | *************************************** | |
| | triazolam | + | N/A | N/A (N/A) | 343.0512 | N/A | N/A | N/A | N/A | ······ | *************************************** | ···· | |
| | 6-acetylmorphine | + | N/A | N/A (N/A) | 328.1543 | N/A | N/A | N/A | N/A | | | ****************************** | |
| | codeine | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A | N/A | N/A | ~~~~~ | | | |
| | dihydrocodeine | + | N/A | N/A (N/A) | 302.1751 | N/A | N/A | N/A | N/A | | | | |
| | dihydromorphone | + | N/A | N/A (N/A) | 288.1594 | N/A | N/A | N/A | N/A | | 1 | *************************************** | |
| | EDDP | 4- | N/A | N/A (N/A) | 278.1903 | N/A | N/A | N/A | N/A | ····· | 1 | *************************************** | |
| | hydrocodone | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A | N/A | N/A | | 1 | | |
| | hydromorphone | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A | N/A | N/A | | 1 | | |
| | norcodeine | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A | N/A | N/A | | 1 | | |
| | normorphine | + | N/A | N/A (N/A) | 272.1281 | N/A | N/A | N/A | N/A | | 4 | | |
| | noroxycodone | + | N/A | N/A (N/A) | 302.1387 | N/A | N/A | N/A | N/A | | | *************************************** | |
| | oxycodone | + | N/A | N/A (N/A) | 316,1543 | N/A | N/A | N/A | N/A | · | | *************************************** | |
| | oxymorphone | + | N/A | N/A (N/A) | 302.1387 | N/A | N/A | N/A | N/A | *************************************** | | | |
| | ecgonine methyl ester | + | N/A | N/A (N/A) | 200.1281 | N/A | N/A | N/A | N/A | | **************** | | |
| | benzoylecgonine | 4 | N/A | N/A (N/A) | 290.1387 | N/A | | N/A | N/A | | | | |
| | cocaethylene | + | N/A | N/A (N/A) | 318.1700 | N/A | N/A | N/A | N/A | •••••• | | *************************************** | ~~~~ |
| | cocaine | + | N/A | N/A (N/A) | 304,1543 | N/A | N/A | N/A | N/A | | | | |
| | brompheniramine | 4- | N/A | N/A (N/A) | 319.0804 | N/A | N/A | N/A | N/A | | | | |
| ····· | chlorpheniramine | + | N/A | N/A (N/A) | 275.1310 | N/A | N/A | N/A | N/A | · | | | |
| | | | | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | ~~~~ | ····· | | | | | | |

2017-00 488 1027-2017

Exclusionary Screening by UPLC/FTMS

| Batch: | 20170929 | | | | | | Sample | × | | | | sb |
|---|---------------------------------|-----|-----------|-------------------------------|-----------------|-----------------|--------------|---|---|---|---|---|
| Method: | ExclusionSOP_TargetingScreening | | | | | | овици | | | ····· | ······································ | |
| Inst. Method: | | | | | | | Commen | ŧ | | | | |
| Acquired: | 9/29/2017 10:05 | | | | | | Outmon | · | *************************************** | ······································ | | ······· |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | ý | | File | 1 | | | 20170929 | 02 |
| Vial Position | 2:A,5 | | Assay: | Exclusionary | Screening TO) | (215 | | *************************************** | | **************** | | ************ |
| | | | | | ~ | | | | | | | |
| Detected | Target Name | +/~ | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | ······································ | |
| ~~~ | dextromethorphan | + | N/A | N/A (N/A) | 272.2009 | N/A | N/A | N/A | N/A | *************************************** | ······································ | *************************************** |
| *************************************** | dextrorphan | + | N/A | N/A (N/A) | 258.1852 | N/A | N/A | N/A | N/A | | | |
| | diphenhydramine | + | N/A | N/A (N/A) | 256.1696 | N/A | N/A | N/A | N/A | | | |
| | doxylamine | + | N/A | N/A (N/A) | 271.1805 | N/A | N/A | N/A | N/A | | ···· | |
| | hydroxyzine | + | N/A | N/A (N/A) | 375.1834 | N/A | N/A | N/A | N/A | | ······································ | · |
| | norchlorcyclizine | + | N/A | N/A (N/A) | 287.1310 | N/A | N/A | N/A | N/A | | | |
| | pheniramine | + | N/A | N/A (N/A) | 241.1699 | N/A | N/A | N/A | N/A | *************************************** | | |
| | tetrahydrozoline | + | N/A | N/A (N/A) | 201.1386 | N/A | N/A | N/A | N/A | | | |
| | zalepion | + | N/A | N/A (N/A) | 306.1349 | N/A | N/A | N/A | N/A | | | |
| | zolpidem | + | N/A | N/A (N/A) | 308.1757 | N/A | | N/A | N/A | ···· | ••••••••••••••••••••••••••••••••••••••• | *************************************** |
| | zopiclone | + | N/A | N/A (N/A) | 389.1123 | N/A | | N/A | N/A | ······································ | | |
| | duloxetine | + | N/A | N/A (N/A) | 298.1260 | N/A | | N/A | N/A | | | |
| | | | | | | | | | | | | |

File 20170929 02 9/29/2017 10:05 Acquired


ന്നു നോ


ထာ

~

b6 -1

b7C -1






File 20170929\_02 9/29/2017 10:05 Acquired

ಞಾ

con

4.EX

ست




b6 -1 b7C -1

FBI(20-cv-0545)-1288

File 20170929 02

| Compound: | 7-aminoclonazepam | Compound: | 7-aminoflunitrazepam | Compound: | alprazolam | | bromazepam |
|---|----------------------|---|----------------------|--|-----------------------|---|------------------|
| RT(exp) | 2.07 | RT(exp) | 2.27 | RT(exp) | 3.1 | Compound:
RT(exp) | 2.66 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| irea: | N/A | Area: | N/A | Area: | N/A | Area: | N/A |
| n/z: | | m/z: | | m/z: | · | m/z: | 1000 |
| leita | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A |
| 20 - 20 - 20 - 20 - 20 - 20 - 20 - 20 - | | 1685-
1687-
1482-
1280-
1083-
882-
588- | | 1402 -
1300 -
1320 -
1520 -
1520 -
260 -
2 | | 122 - | |
| 15. | 707 2.07
AA: 2.00 | 285 | 80 3.07
84 5.00 | 702 | 907 3.100
AA 0.202 | 10. | 80.256
84.600 |



2017-88 468 1827-2817

File

20170929 02

9/29/2017 10:05 Acquired diazepam estazolam etizolam flunitrazepam Compound: Compound: Compound: Compound: 3.7 RT(exp) RT(exp) 3.25 3.22 RT(exp) RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A Area: Area: N/A N/A N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta delta (mmu): N/A 92.-97200 5500 5000 48655 53. 250Z. 3023 42-2523 2500 322 1000 73. 887 3.70 AA 2200 :0. 500 AR 3.00 AA 0.00 AR 3.35 AA 0.00 24 flurazepam lorazepam lormetazepam medazepam Compound: Compound: Compound: Compound: 2.71 RT(exp) 3.04 RT(exp) RT(exp) 3.43 2.71 RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) N/A (N/A) RT(delta) RT(delta) Area: N/A N/A Area: Area: N/A N/A Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A b6 -1 b7C -1 23. 13... PP2 3:04 88 3.42 AA 0.00 32 FBI(20-ev-0\$45)-1290

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

~3 \*\*\*\* C33 KEX. File

20170929\_02 9/29/2017 10:05 Acquired midazolam nordiazepam Compound: oxazepam phenazepam Compound: Compound: Compound: RT(exp) 2.67 RT(exp) 3.19 RT(exp) 2.98 3.45 RT(exp) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A Area: N/A Area: N/A N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta delta (mmu): N/A 93~ ×. 80... æ. 32. 23~ 25. ATT 2.67 AA: 0.00 12. 12-207 3.13 AA: 0.00 801 2.50 AA 300 prazepam temazepam Compound: tetrazepam triazolam Compound: Compound: Compound 5.33 RT(exp) 3.27 RT(exp) RT(exp) 3.68 3.12 RT(exp) DTIMALIA NUA ANUAS NICK CALLAS


| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | |
|--|----------------------------------|--|--|--|------------------------------|---|---|--------|
| Area: | N/A | Area: | N/A | Area: | N/A | Area: | N/A | |
| m/z: | | m/z: | | m/z: | | m/z: | | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | b6 -1 |
| 223 - 22 - 22 - 22 - 22 - 22 - 22 - 22 | 977 5 32
404 7572
53 54 52 | 2200 - 20 | 80 3.0
80 3.0
80 3.2
80 3.2
80 3.2 | 50
50
50
50
50
50
50
12
12
12 | RT 262
AX 035
35 37 32 | 352
957
372
373
374
375
375
375
375
375
375
375
375
375
375 | 777 3.122
788 200
2° 2° FBI(20∓cv-0 | b7C −: |


File 20170929\_02 Acquired 9/29/2017 10:05

(C) (C) (C) (C) (C) (C) (C)

1027-2017


\_







File


9/29/2017 10:05 Acquired sb normorphine noroxycodone oxycodone Compound: oxymorphone Compound: Compound: Compound: 0.44 RT(exp) 1,69 RT(exp) 1.72 RT(exp) 0.64 RT(exp) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) N/A (N/A) RT(delta) RT(delta) N/A Area: N/A Area: N/A N/A Area: Area: m/z: m/z: m/z: m/z: (mmu): N/A delta delta (mmu): N/A (mmu): N/A delta delta (mmu): N/A




20170929\_02










| <u> </u> | · | <u> </u> | | 16 | | <u></u> | <u> </u> | |
|--|-----------------------|--|----------------------|--------------------------------------|--------------|---|---|-------------------|
| Compound: | ecgonine methyl ester | Compound: | benzoylecgonine | Compound: | cocaethylene | | Campound: | cocaine |
| RT(exp) | 0.26 | RT(exp) | 1.96 | RT(exp) | 2.5 | *************************************** | RT(exp) | 2.3 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | | RT(delta) | N/A (N/A) |
| Area: | N/A | Area: | N/A | Area: | N/A r | | Area: | N/A |
| m/z: | | m/z: | | m/z: | | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | | delta | (mmu): N/A |
| 5000 - 1
5000 - 1
3000 - 1
3000 - 1
3000 - 1 | | 20200-
18200-
19020-
19020-
19020- | 877:3 SG
AA: 2:35 | 2000
1500
1600
1200
1000 | | | 53200
52200
66730
45235
35000 | X 2.12
AA 2.22 |










File 20170929 02

b6 -1

b7C -1





*62*3.

2693


3003-

2000-

2000-

10000-

432-4



File 20170929\_02 Acquired 9/29/2017 10:05

zopiclone

Compound:

7-88 -56


1827-2017

sb

| Compound: | pheniramine | Compound: | tetrahydrozoline | Compound: | zalepion | Compound: | zolpidem |
|--|----------------------------------|--|-------------------------------------|---|-------------------------------------|--|---------------------|
| RT(exp) | 1.93 | RT(exp) | 1.87 | RT(exp) | 2.86 | RT(exp) | 2.35 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | | RT(delta) | N/A (N/A) |
| Area: | N/A | Area: | N/A | Area: | N/A | Area | N/A |
| m/z: | | m/z: | | m/z: | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A |
| 201-
201-
201-
201-
201-
201-
201-
201- | 987:1,92
AN 2.00
152 36 31 | 50-
50-
50-
50-
50-
50-
50-
50-
50-
50- | 3877.4.87
AAN ESSE
1.8 49 750 | 100 -
20 - | 877 2 58
40 E 837
238 238 320 | 19200
19200 m2 22 4 23 23 24 23 |

| RT(exp) | 2.13 | | RT(exp) | 3.02 | | |
|---|-------------------------------|----|--|-------------------------------|----|----|
| RT(delta) | N/A (N/A) | | RT(delta) | N/A (N/A) | | |
| Area: | N/A | | Area: | N/A | | |
| m/z: | | | m/z: | | | |
| delta | (mmu): N/A | | delta | (mmu): N// | ٩ | |
| 530 -
530 -
500 -
500 -
500 -
500 -
500 -
500 -
500 -
500 -
500 - | 707 2-13
AN: 2-23
: \$3 | 23 | 927
927
201
201
201
201
201
201
201
201 | 577 2.03
AV: 0.03
5 2 0 | 32 | 32 |

duloxetine



Exclusionary Screening by UPLC/FTMS

Sample

File

Batch: Method: Inst. Method: Acquired: Vial Position 2:B,1

ExclusionSOP\_TargetingScreening

2017-00469, 5, urine Comment

9/29/2017 4:45 Sample Type: Unknown

20170928

FBI Laboratory

20170928 62

Exclusionary Screening TOX 215

Lab Name:

| | Target Name | +/- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta isoto
MMU Patte
Score | n Isotope: | | ······································ |
|--|------------------------|-----|----------|-------------------------------|---|-----------------|-----------------------------------|------------|---|---|
| | d5-alprazolam | + | N/A | N/A (N/A) | 314.1215 | N/A | N/A N/A | N/A | | *************************************** |
| | d5-hydroxalprazolam | + | 3.00E+06 | 2.9 (-0.04) | 330.1165 | 330.1170 | 0.58 100. | 00 5 of 5 | *************************************** | ••••••••••••••••••••••••••••••••••••••• |
| | d4-clonazepam | + | 6.95E+05 | 3.07 (-0.04 |)320.0735 | 320.0737 | 0.28 99.0 | 3 of 4 | *************************************** | ····· |
| | d4-7-aminoclonazepam | + | 1.36E+06 | 2.05 (-0.02 | 290.0993 | 290.0999 | 0.61 76.0 | 3 of 4 | | *************************************** |
| | d5-diazepam | + | N/A | N/A (N/A) | 290.1103 | N/A | N/A N/A | N/A | | *************************************** |
| | d5-oxazepam | + | 1.47E+06 | 2.98 (-0.02 | 292.0896 | 292.0902 | 0.61 100. | | *************************************** | ····· |
| | d6-zolpidem | + | 9.52E+06 | 2.35 (-0.02 | 314.2134 | 314.2138 | 0.38 100.0 | | | ····· |
| *** | d3-benzoylecgonine | 4 | 2.91E+07 | 1.96 (-0.01 | 293.1575 | 293.1581 | 0.57 100.0 | | | |
| | d3-diphenhydramine | + | 9.65E+06 | 2.73 (0) | 259.1884 | 259,1889 | 0.48 100.0 | | | |
| (9) | d6-oxycodone | 4 | 1.12E+07 | 1.69 (-0.03) | 322.1920 | 322,1925 | 0.47 100.0 | | ····· | |
| | d3-morphine | + | N/A | | *************************************** | N/A | N/A N/A | N/A | ····· | |
| | d3-hydrocodone | + | 4.39E+06 | 1.79 (-0.04) | 303.1783 | 303,1783 | 0.09 100.0 | | ~~~~ | |
| ~~~ | morphine | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A N/A | N/A | | |
| | hydroxyalprazolam | + | N/A | N/A (N/A) | 325.0851 | N/A | N/A N/A | N/A | ······ | |
| | hydroxymidazolam | + | N/A | N/A (N/A) | 342.0804 | N/A | N/A N/A | N/A | | |
| | hydroxytriazolam | + | N/A | | 359.0461 | N/A | N/A N/A | N/A | | |
| ~~~ | 7-aminoclonazepam | + | N/A | N/A (N/A) | 286.0742 | N/A | N/A N/A | N/A | | |
| ~~~~ | 7-aminoflunitrazepam | 4 | N/A | N/A (N/A) | 284.1194 | N/A | N/A N/A | N/A | | |
| | alprazolam | + | N/A | N/A (N/A) | 309.0902 | N/A | N/A N/A | N/A | | |
| ~~~~ | bromazepam | 4 | N/A | | 316.0080 | N/A | N/A N/A | N/A | | |
| | chlordiazepoxide | + | N/A | N/A (N/A) | 300.0898 | N/A | N/A N/A | N/A | | ~~~~ |
| | clonazepam | + | N/A | N/A (N/A) | 316.0484 | N/A | N/A N/A | N/A | | |
| | desalkylflurazepam | + | N/A | N/A (N/A) | 289.0539 | N/A | N/A N/A | N/A | · | |
| ~~~~ | desmethylflunitrazepam | + | N/A | N/A (N/A) | 300.0779 | N/A | N/A N/A | N/A | | |
| ~~~~~~ | diazepam | 4 | N/A | | 285.0789 | N/A | N/A N/A | N/A | | *************************************** |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | estazolam | + | N/A. | ~~~ | 295.0745 | N/A | N/A N/A | N/A | · | ····· |
| | etizolam | + | N/A | | 343.0779 | N/A | N/A N/A | N/A | | |
| | flunitrazepam | -{- | N/A | N/A (N/A) | 314.0936 | N/A | N/A N/A | N/A | *************************************** | |
| ************************* | flurazepam | + | N/A | N/A (N/A) | 388.1586 | N/A | N/A N/A | N/A | | ······································ |

b6 -1 b7C -1

b7E -2

FTMS

| | | | | Exclusion | ary Screen | ning by UF | PLC/FTN | IS |
|---------------|---------------------------------|-----|-----------|-------------------------------|---------------|-----------------|-------------------------|------|
| Batch: | 20170928 | | | | | | Sam | ė. |
| Method: | ExclusionSOP_TargetingScreening | 3 | | | | | Jan | Þæ.~ |
| Inst. Method: | | | | | | | property and the second | فندت |
| Acquired: | 9/29/2017 4:45 | | | | | | Comme | sar_ |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | v | | ŧ | ile |
| Vial Position | 2:8,1 | | Accay: | | Screening TOX | C215 | , | |
| Detected | Target Name | +/- | Area | RT
(Measured
and Delta) | Expected m/z | Measured
m/z | Delta
MMU | 1 |
| | lorazepam | + | N/A | N/A (N/A) | 321.0192 | N/A | N/ | AI |
| | lormetazepam | + | N/A | N/A (N/A) | 335.0349 | N/A | | /A I |
| | medazepam | + | N/A | N/A (N/A) | 271.0997 | N/A | | AI |

2017-00469, 5, urine

20170928\_62

b7E -2

| Detected | Target Name | +}- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta Isotopic
MMU Pattern
Score (% | Isotopes | Notes | | | • |
|----------|-----------------------|----------------|----------|-------------------------------|---|-----------------|---|----------|---|---|---|---|
| | lorazepam | + | N/A | N/A (N/A) | 321.0192 | N/A | N/A N/A | N/A | ····· | | *************************************** | |
| ~~~~ | lormetazepam | + | N/A | N/A (N/A) | 335.0349 | N/A | N/A N/A | N/A | ······ | | ******* | |
| ~~~ | medazepam | + | N/A | N/A (N/A) | 271.0997 | N/A | N/A N/A | N/A | ······································ | | ************** | |
| | midazolam | + | N/A | N/A (N/A) | 326.0855 | N/A | N/A N/A | N/A | | *************************************** | | |
| | nordiazepam | + | N/A | N/A (N/A) | 271.0633 | N/A | N/A N/A | N/A | | ····· | | |
| | oxazepam | + | N/A | N/A (N/A) | 287.0582 | N/A | N/A N/A | N/A | | *************************************** | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | |
| | phenazepam | + | N/A | N/A (N/A) | 348.9738 | N/A | N/A N/A | N/A | | ~~ | | |
| | prazepam | + | N/A | N/A (N/A) | 325.1102 | N/A | N/A N/A | N/A | | | ~~~ | |
| | temazepam | + | N/A | N/A (N/A) | 301.0738 | N/A | N/A N/A | N/A | ······································ | | ······································ | |
| | tetrazepam | + | N/A | N/A (N/A) | 289.1102 | N/A | N/A N/A | N/A | ····· | *************************************** | | |
| | triazolam | + | N/A | N/A (N/A) | 343.0512 | N/A | N/A N/A | N/A | ····· | ···· | | |
| | 6-acetylmorphine | 4 | N/A | N/A (N/A) | 328.1543 | N/A | N/A N/A | N/A | ······ | | | |
| | codeine | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A N/A | N/A | ······································ | | | |
| | dihydrocodeine | + | N/A | N/A (N/A) | 302,1751 | N/A | N/A N/A | N/A | ······ | - | | |
| | dihydromorphone | + | N/A | N/A (N/A) | 288.1594 | N/A | N/A N/A | N/A | ••••••••••••••••••••••••••••••••••••••• | ووجوم مهدر دواند ند ندواند نداداد | | |
| | EDDP | + | N/A | N/A (N/A) | 278.1903 | N/A | N/A N/A | N/A | | | | |
| | hydrocodone | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A N/A | N/A | ······ | | | |
| | hydromorphone | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A N/A | N/A | *************************************** | - | | |
| | norcodeine | 4 . | N/A | N/A (N/A) | 286.1438 | N/A | N/A N/A | N/A | *************************************** | 1 | | |
| | normorphine | + | N/A | N/A (N/A) | 272.1281 | N/A | N/A N/A | N/A | ····· | 1 | | |
| | noroxycodone | 4 | N/A | N/A (N/A) | 302.1387 | N/A | N/A N/A | N/A | *************************************** | 1 | | |
| | oxycodone | .+ | N/A | N/A (N/A) | 316.1543 | N/A | N/A N/A | N/A | | | | |
| | oxymorphone | + | N/A | N/A (N/A) | 302.1387 | N/A | N/A N/A | N/A | ····· | | | |
| | ecgonine methyl ester | + | N/A | N/A (N/A) | 200.1281 | N/A | N/A N/A | N/A | | | | |
| | benzoylecgonine | + | N/A | N/A (N/A) | 290.1387 | N/A | N/A N/A | N/A | ······································ | | | |
| | cocaethylene | + | N/A | N/A (N/A) | ···· | N/A | N/A N/A | N/A | ····· | | | |
| • | cocaine | + | 4.68E+06 | 2.31 (0.01) | | 304.1550 | 0.67 100.00 | 3 of 3 | n.d | | ······ | |
| | brompheniramine | + | N/A | N/A (N/A) | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | N/A | N/A N/A | N/A | M.a. | | | |
| | chlorpheniramine | + | N/A | N/A (N/A) | | N/A | N/A N/A | N/A | | | | |

Exclusionary Screening by UPLC/FTMS

| | | | | | | mile na ni | | | | | |
|---------------------------|---------------------------------|-----|-----------------|-------------------------------|---------------|-----------------|--------------|---|----------------------------|---|--|
| Batch: | 20170928 | | | | | | Sample | , | | 2017- | -00469, 5, urine |
| Method: | ExclusionSOP_TargetingScreening | | | | | | . | *************************************** | | | ······································ |
| nst. Method:
Acquired: | 9/29/2017 4:45 | | | | | | Commen | | | ······ | |
| Sample Type: | | | Lab Name: | FBI Laborator | ý | | File | | | *************************************** | 20170928_6 |
| Vial Position | 2:8.1 | | a y: | Exclusionary | Screening TOX | (215 | | | | | |
| Detected | Target Name | +1- | Area | RT
(Measured
and Delta) | Expected m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | |
| | dextromethorphan | + | N/A | N/A (N/A) | 272.2009 | N/A | N/A | N/A | N/A | ~~~~ | ······································ |
| | dextrorphan | + | N/A | N/A (N/A) | 258.1852 | N/A | N/A | N/A | N/A | *************************************** | |
| | diphenhydramine | + | N/A | N/A (N/A) | 256.1696 | N/A | N/A | N/A | N/A | ···· | |
| | doxylamine | + | N/A | N/A (N/A) | 271.1805 | N/A | N/A | N/A | N/A | | |
| | hydroxyzine | + | N/A | N/A (N/A) | 375.1834 | N/A | N/A | N/A | N/A | | |
| | norchlorcyclizine | + | N/A | N/A (N/A) | 287.1310 | N/A | N/A | N/A | N/A | ************ | ······································ |
| | pheniramine | + | N/A | N/A (N/A) | 241,1699 | N/A | N/A | N/A | N/A | | |
| • | tetrahydrozoline | + | 2.99E+06 | 1.9 (0.03) | 201.1386 | 201.1391 | 0.42 | 98.00 | 2 of 4 | u-d. | |
| | zaleplon | + | N/A | N/A (N/A) | 306.1349 | N/A | N/A | N/A | N/A | | - |
| | zolpidem | + | N/A | N/A (N/A) | 308.1757 | N/A | N/A | N/A | N/A | **************** | ······ |
| | zopiclone | + | N/A | N/A (N/A) | 389.1123 | N/A | N/A | N/A | N/A | | |
| | duloxetine | + | N/A | N/A (N/A) | 298.1260 | N/A | N/A | N/A | N/A | | |

Page 4 of 12 File 20170928\_62 TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS 9/29/2017 4:45 Acquired 2017-00469, 5, urine d5-alprazolam d5-hydroxalprazolam d4-clonazepam d4-7-aminoclonazepam Compound: Compound: Compound: Compound: RT(exp) 3.1 RT(exp) 2.94 3.11 RT(exp) 2.07 RT(exp) N/A (N/A) 2.9 (-0.04) RT(delta) RT(delta) RT(delta) 3.07 (-0.04) 2.05 (-0.02) RT(delta) N/A 694530 Area: 2995300 Area: 1356300 Area: Area 330.1170 320.0737 m/z: 290.0999 m/z: m/z: m/z: delta (mmu): N/A delta (mmu): 0.58 delta (mmu): 0.28 delta (mmu): 0.61 RT: 2.50 AA: 2956346.20 50: 2:07 AA: 554532.57 97 175 AA: 1256324,59 30000000 02000300-9500000 v \*\*\*32335 26/23/20 600000-30000000 0400000 10300030 200000 27307300 70000000 3000000 500000 22033300 450000 207007~ 90000003 15332335-430000 733336-1600000 50000000 250000 1400000 600000 40000000 XXXXX 10000000 5200000 250000 10000000 300930930 4000000 233233 \$33033 3300330 1000000 1500003 6200000 200500 701.2.10 4A: 0.00 100000 100000 100030003 100000 5500 100000 d5-diazepam d5-oxazepam d6-zolpidem d3-benzovlecgonine

b6 -1


b7C -1

| Compound: | | Compound: | uo-oxazepann | Compound: | do-gothideili | Compound: | as-penzoyiecgonine | |
|--|--|---|---------------------------|--|--------------------------|--|--|---------|
| RT(exp) | 3.75 | RT(exp) | 3 | RT(exp) | 2.37 | RT(exp) | 1.97 | |
| RT(delta) | N/A (N/A) | RT(delta) | 2.98 (-0.02) | RT(delta) | 2.35 (-0.02) | RT(delta) | 1.96 (-0.01) | |
| Area: | N/A | Area: | 1470600 | Area: | 9522000 | Area: | 29060000 | |
| m/z: | | m/z: | 292.0902 | m/z: | 314.2138 | m/z: | 293.1581 | |
| delta | (mmu): N/A | delta | (mmu): 0.61 | delta | (mmu): 0.38 | delta | (mmu): 0.57 | |
| 6530000
570000
550000
550000
450000
450000
350000
350000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
300000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
30000
300 | ************************************** | 13/00000
13/00000
10/00000
10/00000
20/0000
20/0000
20/0000
20/0000
20/0000
20/0000
20/0000 | 977 7.86
A4 1970604.10 | ###################################### | X7 3.35
AA 5923216.52 | 1000000
2000000
2400000
2400000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
1000000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
100000
10 | 57.1.36
34.19660266.46
35.FBI(20-cv-0.54 | 5)-1299 |

(CC) ಜ್ಞಾ

20170928\_62 9/29/2017 4:45

2017-00469, 5, urine



| ₩ 15 15 15 b7C | | | a Brookl | b6 -
b7C |
|----------------|-----|--|----------|-------------|
| | 1.7 | ************************************** | | b7C |

-1

| Compound: | morphine | Compound: | hydroxyalprazolam | Compound: | hydroxymidazolam | ********** | Compound: | hydroxytriazolam | í |
|--|------------|--|-------------------|---------------------------------|------------------|------------|-----------|------------------|---|
| RT(exp) | 0.56 | RT(exp) | 2.9 | RT(exp) | 2.67 | | RT(exp) | 2.9 | |
| RT(delta) | N/A (N/A) | RT(delta) | NIIA WIIA | | N/A (N/A) | | RT(delta) | N/A (N/A) | |
| Area: | N/A | Area: | N/A | 7 | N/A | | Area | N/A | |
| m/z: | | m/z: | | m/z | | | m/z: | | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | - | delta | (mmu): N/A. | |
| \$120000 -
7000000 -
\$200000 -
\$000000 -
4000000 - | | 200 -
200 -
200 -
200 -
200 -
200 - | | ***

*** | | | 20 | | |

Page 6 of 12

desmethylflunitrazepam

File 20170928 62

chlordiazepoxide

2 46

Compound:

RT(eyn)

\*\*\*\*

5337 ಜಾ

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

9/29/2017 4:45 Acquired 2017-00469, 5, urine 7-aminoclonazepam 7-aminoflunitrazepam alprazolam Compound: bromazepam Compound: Compound: Compound: 2.07 2.27 RT(exp) RT(exp) 3.1 2.66 RT(exp) RT(exp) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A Area: N/A N/A Area N/A Area: Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A (mmu): N/A delta (mmu): N/A delta 200000 1000000 1200000 3400203 490000 110000 900000-2200000 20000 40X80 809X0-232320 97007 35000 1800550 XXXXX ... 20020 160000 33002 40000 20003 90000 20020 1000000 20023 1000000 4572 13000 20200 30200-\$3000° 10000 20223 40000 20000 5000 707.2-07 24.300 200200 R7 3.27 AA 0.00 10000 88 3.10 AA 0.00 32

| L'Hexb) | 12.40 | KI(exp) | 3.07 | RT(exp) | 3.19 | RT(exp) | 2.95 | |
|--|---------------------------------|---|-------------------------------|--|---------------------------------|-----------|--|-----------|
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | |
| Area: | N/A | Area: | N/A | Area: | N/A | Агеа: | N/A | |
| m/z: | | m/z: | | m/z: | | m/z: | | b6 -1 |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | b7C -1 |
| \$5000-
45000-
45000-
35000-
25000-
25000-
15000-
15000-
15000-
17000-
5000-
23 | 777 2.46
AA 0.00
24 25 25 | 100 - | 97.3.27
Aè 020
22 2: 32 | 200
200
200
200
200
200
200
200
200
200 | 7F 3.15
Ac 1575
3.5 22 22 | 22 | 577.2.55
44.0.005
28 20 FBI(220-CV-0 | 545)-1301 |

desalkylflurazepam

clonazepam

Compound:

File 20170928\_62 Acquired 9/29/2017 4:45

\*\*\*

| Acquired | 9/29/2017 4:45 | | CON ELD ENCLOSIONARI DE | | | | 2017-00469, 5, urine |) |
|---|------------------------------------|---|-------------------------|---|--|--|--|----------|
| Compound: | diazepam | Compound: | estazolam | Compound: | etizolam | Compound: | flunitrazepam | 1 |
| RT(exp) | 3.7 | RT(exp) | 3 | RT(exp) | 3.25 | RT(exp) | 3.22 | 1 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | |
| Area: | N/A | Area: | N/A | Area: | N/A | Area: | N/A | |
| m/z: | | m/z: | | m/z: | | m/z: | | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | |
| 302
302
303
303
303
303
303
303
303
303 | 867.2.70
AV 0.00
36 37 33 35 | 100000 -
50000 -
50000 -
10000 -
50000 -
50000 -
20000 -
10000 - | 23 22 3: 22 | 300 - | 877.2.225
444.0.000
2 <sup>1</sup> 2 2 <sup>1</sup> 2 2 <sup>1</sup> 4 | 100
32
53
52
52
53
54
53
54
55
56
57
58
58
58
58
58
58
58
58 | 777.325
AA 2200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.200
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3.000
3. | |
| Compound: | flurazepam | Compound: | lorazepam | Compound: | lormetazepam | Compound: | medazepam | I |
| RT(exp) | 2.71 | RT(exp) | 3.04 | | 3.43 | RT(exp) | 2.71 | |
| RT(delta) | N/A (N/A) | RT(delta) | | | N/A (N/A) | RT(delta) | N/A (N/A) | |
| Area: | N/A | Area: | N/A | | N/A | Area: | N/A | b6 -1 |
| n/z: | | m/z: | | m/z: | 2.77. | m/z: | 373 | b7C - |
| delta | (mmu): N/A | delta | | delta | (mmu): N/A | | (mmu): N/A | |
| 50020 - 46020 - 25005 - 25005 - 25000 - 15000 | 50°2.74
Ax 500:
26 27 28 35 | 20 - 20 - 20 - 20 - 20 - 20 - 20 - 20 - | 977: 3,24
A4, 6700- | 200 - | 87 3.42
A6 5.20 | 80000 - 1
80000 - 1 | 57, 2-7 ;
AA, 0:00 | |

`₽BI('2'0₹ĉv-0|545)-1303

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


File 20170928 62

(333) **Anno**

ಜಾ ಜಾ

œ-

و....ه و....ه



b7C -1

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


File 20170928 62 9/29/2017 4:45 Acquired


23.2 22.~

5

5~~3 ~~3

2017-00469, 5, urine






MOMON.

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928\_62 9/29/2017 4:45 Arguired

| Acquirea | | | | | | | 2017-00469, 5, urine |
|---|----------------------|--|--------------|--|------------|--|------------------------|
| Compound: | normorphine | Compound: | noroxycodone | Compound: | oxycodone | Compound: | oxymorphone |
| RT(exp) | 0.44 | RT(exp) | 1.69 | RT(exp) | 1.72 | RT(exp) | 0.64 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| Area: | N/A | Area: | N/A | Area: | N/A | Area: | N/A |
| m/z: | | m/z: | | m/z: | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A |
| \$50000 -
760000 -
760000 -
860000 -
860000 -
850000 -
450000 -
450000 -
450000 -
250000 -
250000 -
250000 -
250000 - | 70° 0.24
44. 0.55 | 30000000
18200000
18200000
18200000
18200000
12200000
90000000
8000000
8000000 | | 232000000
230000000
230000000
230000000
150000000
150000000 | | ************************************** | 577.6 644
JAA: 3:00 |



~ ردي دي

SCRICKS ...

b6 -1

b7C -1


File 20170928\_62 9/29/2017 4:45 Acquired


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 11 of 12

b6 -1

b7C -1





File 20170928\_62 Acquired 9/29/2017 4:45

| Compound: | pheniramine | Compound: | tetrahydrozoline | Compound: | zaleplon | Compound: | 2017-00469, 5, urine zolpidem |
|---|-------------------------------|--|---|--------------|--|---|-------------------------------|
| RT(exp) | 1.93 | RT(exp) | 1.87 | RT(exp) | 2.86 | RT(exp) | 2.35 |
| RT(delta) | N/A (N/A) | RT(delta) | 1.9 (0.03) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| ۱rea: | N/A | Area: | 2988500 | Area: | N/A | Area: | N/A |
| n/z: | | m/z: | 201.1391 | m/z: | ······································ | m/z: | 1307 |
| ielta | (mmu): N/A | delta | (mmu): 0.42 | delta | (mmu): N/A | delta | (mmu): N/A |
| 100
52
23
43
44
33
24
33
34
35
36
37
48
48
48
48
48
48
48
48 | 80.4.83
AX.200
48 24 24 | 12000000
12000000
1800000
1800000
1800000
1000000
1000000
1000000
1000000
1000000 | \$7.35
\$4.352427.35
\$\int_{1}^{2} \int_{1}^{2} \ldots \ldot | 270500 - 277 | \$7.2.56
A4.0.20
29 23 28 | 2400202
220000
200000
1800000
1600000
100000
100000
100000
100000
100000
100000
100000
100000 | 77.7.55
W. 2000 |

| RT 1.56
AA-9.00 | |
|--------------------|-------------|
| | b6 -
b7C |
| | |

| Compound: | zopiclone | Compound: | duloxetine |
|---|---------------------------------|--|----------------------|
| RT(exp) | 2.13 | RT(exp) | 3.02 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| Area: | N/A | Area: | N/A |
| n1/z: | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A |
| *85002-
*85002-
*45002-
*30002-
*20002-
*50002-
*50002- | 27 1/2
AA 5/3C
22 2/2 1/3 | 60572
25205
35100
25002
15000
10000
5003 | PRT 3.02
AA 0.022 |



FBI(20-cv-0545)-1307

b6 -1 b7C -1

| Batch: | 20170928 | | | | | | Camula | | | | hydrol | ysis che | nk |
|---------------|------------------------------|-----|-----------|--|-----------------|-----------------|--------------|---|----------------------------|---|---|---|----------|
| Method: | ExclusionSOP_TargetingScreen | ing | | | | | Sample | | ······ | ····· | ny ar or | y 313 CITE | |
| Inst. Method: | | - | | | | | Comment | | | | | | |
| Acquired: | 9/29/2017 5:42 | | | | | | Common | | | ••••••••••••••••••••••••••••••••••••••• | *************************************** | | |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | ý | | File | | | | - | 20170928 | 67 |
| Vial Position | 2:B,6 | | _^esay: | Exclusionary | Screening TO) | (215 | | *************************************** | ************** | | | | |
| | | | | | | | | | | | | | |
| Detected | Target Name | +}- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | | | |
| • | d5-alprazolam | + | 1.34E+07 | 3.07 (-0.03 | 314.1215 | 314.1221 | 0.54 | 100.00 | 6 of 7 | | | | |
| • | d5-hydroxalprazolam | + | 2.58E+06 | 2.91 (-0.03 | 330.1165 | 330,1171 | | 100.00 | 5 of 6 | ······ | ······ | | ····· |
| | d4-clonazepam | + | N/A | N/A (N/A) | 320.0735 | N/A | N/A | N/A | N/A | | ····· | | |
| | d4-7-aminoclonazepam | + | 2.64E+06 | 2.06 (-0.01 |)290.0993 | 290.0998 | | 100.00 | 5 of 6 | | | | ······ |
| | d5-diazepam | + | N/A | N/A (N/A) | 290.1103 | N/A | N/A | | N/A | | *************************************** | ***** | ······ |
| • | d5-oxazepam | + | 8.60E+05 | 2.98 (~0.02 | | | ~~~~ | 100.00 | 5 of 6 | | | | |
| • | d6-zolpidem | + | 8.38E+06 | 2.36 (-0.01 | 314.2134 | 314.2136 | | 100.00 | 2 of 3 | | | | |
| • | d3-benzoylecgonine | + | 6.46E+07 | 1.96 (-0.01 | | | | 100.00 | 4 of 4 | | | | |
| • | d3-diphenhydramine | + | 1.13E+07 | 2.73 (0) | 259.1884 | | ***** | 100.00 | 3 of 4 | ······ | *********** | | |
| • | d6-oxycodone | + | 9.18E+06 | 1.71 (-0.01 | | . | | 100.00 | 4 of 4 | *************************************** | | | |
| • | d3-morphine | + | 1.05E+07 | 0.56 (0) | 289.1626 | 289.1630 | | 100.00 | 3 of 4 | ····· | | | |
| • | d3-hydrocodone | + | 1.71E+07 | 1.8 (-0.03) | | 303.1787 | | 100.00 | 3 of 4 | *************************************** | | | |
| • | morphine | + | 6.96E+07 | 0.56 (0) | 286.1438 | 286.1442 | ~~~~ | 100.00 | 4 of 5 | ····· | | | |
| | hydroxyalprazolam | + | N/A | N/A (N/A) | 325.0851 | N/A | N/A | | N/A | ~~~~~~ | | | |
| | hydroxymidazolam | + | N/A | N/A (N/A) | 342.0804 | N/A | N/A | | N/A | ····· | *************************************** | | |
| | hydroxytriazolam | + | N/A | N/A (N/A) | 359.0461 | N/A | N/A | | N/A | | | | |
| | 7-aminoclonazepam | + | N/A | N/A (N/A) | 286.0742 | N/A | N/A | | N/A | ····· | | | |
| | 7-aminoflunitrazepam | + | N/A | N/A (N/A) | ~~~ | N/A | N/A | | N/A | ····· | | ······ | ····· |
| | alprazolam | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | | | | |
| | bromazepam | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | | | ····· | |
| | chlordiazepoxide | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | •••••• | *************************************** | | |
| | clonazepam | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | ······ | *************************************** | ······································ | |
| | desalkylflurazepam | + | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | | N/A | N/A | | N/A | | ***** | | |
| | desmethylflunitrazepam | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | ······ | *********** | | |
| | diazepam | + | N/A | ~~~~ | | N/A | N/A I | ~~~ | N/A | | ······································ | - | |
| | estazolam | + | N/A | ~~~~~~ | **** | N/A | N/A | | N/A | | | *************************************** | |
| | etizolam | +. | N/A | | | N/A | N/A I | | N/A | *************************************** | | | |
| | flunitrazepam | + | N/A | | ***** | N/A | N/A I | | N/A | | ••••••••••••••••••••••••••••••••••••••• | | ******** |
| | flurazepam | + | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | ************* | N/A | N/A I | | N/A | **** | | ••••• | |
| | | | | | | | | | | | | | |

b6 -1 b7C -1

| Batch: | 20170928 | | | | | - | | | | بريا عمالم بريا | -111- |
|---|---------------------------------|-----|----------------|--|---|-----------------|-----------|--|---|---|---|
| Method: | ExclusionSOP_TargetingScreening | ia | | | | | Sample | ······································ | | nyuronys | sis check |
| Inst. Method: | <u> </u> | ~ | | | | | O-5 | | | | |
| Acquired: | 9/29/2017 5:42 | | | | | | Comment | ····· | | | |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | ~ | | File | | | or. | 1170000 e7 |
| Vial Position | 2:8.6 | | <u>^</u> -вау: | | Screening TO | X 216 | 7.112 | | ····· | | 0170928 67 |
| | | | Ť | , <u>.</u> | | | | | | | |
| Detected | Target Name | +/- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | MMU Patt | opic Num
ern Isotopes
re (%) Matched | | | |
| *************************************** | lorazepam | + | N/A | N/A (N/A) | 321.0192 | N/A | N/A N/A | | | ********** | *************************************** |
| | lormetazepam | + | N/A | N/A (N/A) | 335.0349 | N/A | N/A N/A | | **** | ····· | |
| | medazepam | + | N/A | N/A (N/A) | 271.0997 | N/A | N/A N/A | N/A | | <u> </u> | |
| | midazolam | + | N/A | N/A (N/A) | 326.0855 | N/A | N/A N/A | N/A | | 1 F | *************************************** |
| ····· | nordiazepam | + | N/A | N/A (N/A) | 271.0633 | N/A | N/A N/A | N/A | | 1 F | ****************************** |
| | oxazepam | + | N/A | N/A (N/A) | 287.0582 | N/A | N/A N/A | N/A | | 1 - | |
| | phenazepam | + | N/A | N/A (N/A) | 348.9738 | N/A | N/A N/A | N/A | *************************************** | 1 | |
| *************************************** | prazepam | + | N/A | N/A (N/A) | 325.1102 | N/A | N/A N/A | | • | | |
| | temazepam | + | N/A | N/A (N/A) | 301.0738 | N/A | N/A N/A | | | | *************************************** |
| ~~~~ | tetrazepam | + | N/A | N/A (N/A) | 289.1102 | N/A | N/A N/A | N/A | | *************************************** | |
| ···· | triazolam | + | N/A | N/A (N/A) | 343.0512 | N/A | N/A N/A | | | *************************************** | |
| | 6-acetylmorphine | + | N/A | N/A (N/A) | 328.1543 | N/A | N/A N/A | | | | |
| | codeine | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A N/A | | | | *************************************** |
| | dihydrocodeine | + | N/A | N/A (N/A) | 302.1751 | N/A | N/A N/A | | | *************************************** | · |
| | dihydromorphone | + | N/A | N/A (N/A) | 288.1594 | N/A | N/A N/A | | | | |
| | EDDP | + | N/A | N/A (N/A) | 278.1903 | N/A | N/A N/A | N/A | | | |
| | hydrocodone | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A N/A | N/A | | | *************************************** |
| | hydromorphone | + | N/A | N/A (N/A) | 286,1438 | N/A | N/A N/A | N/A | | *************************************** | |
| | norcodeine | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A N/A | N/A | | | |
| | normorphine | + | N/A | | 272.1281 | N/A | N/A N/A | N/A | | ···· | |
| | noroxycodone | +- | N/A | N/A (N/A) | 302.1387 | N/A | N/A N/A | N/A | | *************************************** | |
| | oxycodone | -}- | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | ***************** | N/A | N/A N/A | N/A | | | |
| | oxymorphone | + | N/A | | | N/A | N/A N/A | N/A | ····· | ······································ | |
| ···· | ecgonine methyl ester | -f- | N/A | | | N/A | N/A N/A | N/A | | | |
| • | benzoylecgonine | + | 1.03E+05 | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | ~~~~ | 290.1388 | 0.11 100. | | | | |
| | cocaethylene | + | N/A | | ···· | N/A | N/A N/A | N/A | *************************************** | ····· | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | cocaine | + | N/A | | ~~~~~ | N/A | N/A N/A | N/A | | ····· | |
| | brompheniramine | + | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | N/A | N/A N/A | N/A | | | |
| | chlorpheniramine | + | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | 275.1310 | N/A | N/A N/A | N/A | | | |

b6 -1 b7C -1

| Batch: | 20170928 | | | | | | Campla | | | | hydra | olysis d | hock |
|---------------|---------------------------------|-----------------|-----------|-------------------------------|-----------------|-----------------|--------------|---|---|---|---|---|---|
| Method: | ExclusionSOP_TargetingScreening | | | | | | Sample | · | ····· | *************************************** | | 31y313 C | 11000 |
| Inst. Method: | | | | | | | Comment | | | | | | |
| Acquired: | 9/29/2017 5:42 | | | | | | Comment | · | *************************************** | ••••• | - | | |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | v | | File | ſ | | | | 201709 | 128 67 |
| Vial Position | 2:8,6 | | Aesay: | Exclusionary : | Screening TOX | C 215 | | | ~~~~ | ····· | *************************************** | | |
| Detected | Target Name | +/ <sub>~</sub> | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | | | |
| | dextromethorphan | 4 | N/A | N/A (N/A) | 272.2009 | N/A | N/A | N/A | N/A | | | | |
| | dextrorphan | + | N/A | N/A (N/A) | 258.1852 | N/A | N/A | N/A | N/A | ••••• | ******* | | |
| | diphenhydramine | + | N/A | N/A (N/A) | 256,1696 | N/A | N/A | N/A | N/A | ····· | - | | |
| | doxylamine | + | N/A | N/A (N/A) | 271.1805 | N/A | N/A | N/A | N/A | **** | | | |
| | hydroxyzine | + | N/A | N/A (N/A) | 375.1834 | N/A | | N/A | N/A | ····· | ******* | | |
| | norchlorcyclizine | + | N/A | N/A (N/A) | 287.1310 | N/A | N/A | N/A | N/A | | *************************************** | | • |
| | pheniramine | + | N/A | N/A (N/A) | 241.1699 | N/A | | N/A | N/A | | | | ······ |
| • | tetrahydrozoline | + | 1.31E+06 | 1.91 (0.04) | 201.1386 | 201.1392 | - | 100.00 | 2 of 4 | | inal | 7 | T |
| | zaleplon | + | N/A | N/A (N/A) | 306.1349 | N/A | ~~~~~ | N/A | N/A | | *************************************** | | |
| | zolpidem | 7 | N/A | N/A (N/A) | 308,1757 | N/A | N/A | *************************************** | N/A | | | | ····· |
| | zopiclone | + | N/A | N/A (N/A) | 389.1123 | N/A | N/A | ~~~~~ | N/A | | | ************ | |
| | duloxetine | + | N/A | N/A (N/A) | 298,1260 | N/A | N/A | | N/A | | | *************************************** | ••••••••••••••••••••••••••••••••••••••• |
| | | | | | | | | *************************************** | ····· | | | *************************************** | |

303703 ·

#81 0.75 #41 2.00

130000

50000

File 20170928\_67 9/29/2017 5:42 Acquired


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 4 of 12

b6 -1


b7C -1

FBI(20-cv-0545)-1311



10030000

3000000



| 3 23 | 32 35 22 32 | 3,1, | 23 25 25 | 3 | 32 32 32 | 20320- | 25 25 22 |
|--|--|---|----------------------------|--|------------------------------|---|---------------------------|
| Compound: | d5-diazepam | Compound: | d5-oxazepam | Compound: | d6-zolpidem | Compound: | d3-benzoylecgonine |
| RT(exp) | 3.75 | RT(exp) | 3 | RT(exp) | 2.37 | RT(exp) | 1.97 |
| RT(delta) | N/A (N/A) | RT(delta) | 2.98 (-0.02) | RT(delta) | 2.36 (-0.01) | RT(delta) | 1.96 (-0.01) |
| Area: | N/A | Area: | 859560 | Area: | 8380600 | Area: | 64588000 |
| m/z: | ······································ | m/z: | 292.0902 | m/z: | 314.2136 | m/z: | 293.1579 |
| delta | (mmu): N/A | delta | (mmu): 0.61 | delta | (mmu): 0.16 | delta | (mmu): 0.39 |
| \$5000500 -
4900000 -
4000000 -
3500000 -
2500000 -
2500000 -
1500000 -
1500000 - | | 750000 -
70000 -
55000 -
50000 -
50000 -
50000 -
45000 -
45000 -
15000 -
15000 -
15000 -
15000 - | RT. 2.83
Av. 2695623 13 | 30X00X0-
10X10X0-
50X00X0-
50X00X0-
40X00X0-
300X005-
20X00X0- | 970. 2.32
9A: 3520599; 07 | 60000000 55000000 55000000 55000000 55000000 55000000 55000000 15000000 | RT 1.36
An 54537639.12 |

File 20170928 67 9/29/2017 5:42 Acquired


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 5 of 12

b6 -1

b7C -1

hydrolysis check



| Compound: | morphine | Compound: | hydroxyalprazolam | Compound: | hydroxymidazolam | Compound: | hydroxytriazolam | |
|---|-------------|-----------|---------------------------------------|---|--------------------|--|---------------------------------------|------|
| RT(exp) | 0.56 | RT(exp) | 2.9 | RT(exp) | 2.67 | RT(exp) | 2.9 | |
| RT(delta) | 0.56 (0) | RT(delta) | }********* | 31 | N/A (N/A) | } | N/A (N/A) | |
| Area: | 69562000 | Area | N/A | 1 | N/A | 1 | N/A | |
| m/z: | 286.1442 | m/z: | | m/z: | | m/z: | | |
| delta | (mmu): 0.46 | delta | (mmu): N/A | | (mmu): N/A | delta | (mmu): N/A | |
| 25030000
25000000
15000000
15000000
5000000 | | 88.8 | 87: 2.90
44: 5.00
22: 25 35 3.1 | 200 - | #F 2-67
AX 0-22 | 100 - 50 - 50 - 50 - 50 - 50 - 50 - 50 - | ##################################### | 5)-1 |

b6 -1 b7C -1

| Batch: | 20170928 | | | | , | | , | | | | | |
|--|-----------------------------------|--------|-----------|-------------------------------|---|--|--|---|----------------------------|---|---|--|
| Method: | ExclusionSOP_TargetingScreen | ina | | | | | Sample | *************************************** | | **** | • | ncu |
| Inst. Method: | Exolusion Cor _ range in goot een | mg | | | | | | | | | | |
| Acquired: | 9/29/2017 4:11 | | | | | | Comment | ····· | | | | |
| Sample Type: | | | Lab Name: | FBI Laborator | M. | | File | | | | 0047000 | 10 50 |
| Vial Position | | ∆ssay; | | y
Screening TO) | ¥ 915 | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | 2017092 | 28 59 | | | | |
| | | | 1 | zitorainoriai j | oorooming ro | α & CD. | | | | | | |
| Detected | Target Name | +/- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | MMU | Isotopic
Pattern | Num
Isotopes
Matched | Notes | | nn nananananani |
| • | d5-alprazolam | + | 1.53E+07 | 3.07 (-0.03 | 314.1215 | 314.1221 | | 100.00 | 7 of 7 | | | |
| • | d5-hydroxalprazolam | + | 3.02E+06 | 2.91 (-0.03 | | | | 100.00 | 4 of 6 | | | |
| • | d4-clonazepam | + | 6.63E+05 | 3.07 (-0.04 | | | | 100.00 | 4 of 5 | | ······································ | |
| | d4-7-aminoclonazepam | + | 2.49E+06 | 2.06 (-0.01 | 290.0993 | 290.0998 | | 100.00 | 4 of 6 | | ····· | |
| | d5-diazepam | 4 | N/A | N/A (N/A) | 290.1103 | N/A | N/A | | N/A | ···· | | ~~~~~ |
| • | d5-oxazepam | + | 1.37E+06 | 2.98 (-0.02 | | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | 100.00 | 5 of 5 | | ····· | |
| | d6-zolpidem | + | 8.53E+06 | 2.35 (-0.02 | 314.2134 | 314.2137 | ******* | 100.00 | 3 of 3 | | | |
| • | d3-benzoylecgonine | + | 5.91E+07 | 1.96 (-0.01 | | | | 100.00 | 4 of 4 | | | ······································ |
| • | d3-diphenhydramine | + | 4.40E+06 | 2.73 (0) | 259.1884 | | | 100.00 | 3 of 3 | | | ···· |
| • | d6-oxycodone | 4 | 8.81E+06 | 1.7 (-0.02) | 322.1920 | 322.1927 | ~~~~ | 100.00 | 3 of 4 | ····· | | ····· |
| | d3-morphine | 4 | 1.09E+07 | 0.56 (0) | ~~~~~~ | 289.1631 | | 100.00 | 3 of 4 | | | |
| | d3-hydrocodone | + | 1.51E+07 | 1.8 (-0.03) | 303.1783 | 303.1789 | 0.61 | 100.00 | 3 of 4 | | *************************************** | |
| | morphine | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A I | | N/A | *************************************** | | |
| | hydroxyalprazolam | + | N/A | N/A (N/A) | 325.0851 | N/A | N/A I | V/A | N/A | | *************************************** | ······································ |
| **** | hydroxymidazolam | 4 | N/A | N/A (N/A) | 342,0804 | N/A | N/A I | | N/A | | | |
| and the second s | hydroxytriazolam | + | N/A | N/A (N/A) | 359.0461 | N/A | N/A I | N/A | N/A | ······································ | | |
| | 7-aminoclonazepam | + | N/A | N/A (N/A) | 286.0742 | N/A | N/A I | V/A | N/A | · | | |
| | 7-aminoflunitrazepam | + | N/A | N/A (N/A) | 284.1194 | N/A | N/A I | ****** | N/A | | *************************************** | |
| | alprazolam | + | N/A | N/A (N/A) | 309.0902 | N/A | N/A I | V/A | N/A | *************************************** | | |
| | bromazepam | + | N/A | N/A (N/A) | 316.0080 | N/A | N/A N | | N/A | | | |
| | chlordiazepoxide | + | N/A | N/A (N/A) | 300.0898 | N/A | N/A N | V/A | N/A | *************************************** | ······ | ~~~~~ |
| | clonazepam | + | N/A | N/A (N/A) | 316.0484 | N/A | N/A N | | N/A | | *************************************** | |
| | desalkylflurazepam | + | N/A | N/A (N/A) | 289.0539 | N/A | N/A N | | N/A | ************ | ······································ | |
| | desmethylflunitrazepam | + | N/A | N/A (N/A) | 300.0779 | N/A | N/A N | V/A | N/A | | | ~~~~~ |
| | diazepam | + | N/A | N/A (N/A) | 285.0789 | N/A | N/A N | *********** | N/A | *************************************** | | |
| *************************************** | estazolam | 4 | N/A | | 295.0745 | N/A | N/A N | ************ | N/A | ····· | | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | etizolam | + | N/A | N/A (N/A) | 343.0779 | N/A | N/A N | | N/A | *************************************** | | |
| | flunitrazepam | + | N/A | N/A (N/A) | 314.0936 | N/A | N/A N | ~~~~ | N/A | ~~~~ | | |
| 1 | flurazepam | + | N/A | N/A (N/A) | 388.1586 | N/A | N/A N | | N/A | | *************************************** | ····· |


b6 -1 b7C -1

2017-80468 1617-16-7

| Batch: | 20170928 | | | | | | ~ | | | | | ****** |
|---|---|------|-----------|--|---|-----------------|--------------|---|----------------------------|---|---|---|
| Method: | ExclusionSOP_TargetingScreer | nina | | | | | Sample | ····· | ····· | | *************************************** | ncu |
| Inst. Method: | _ · · · · · · · · · · · · · · · · · · · | | | | | | @ | | | | | |
| Acquired: | 9/29/2017 4:11 | | | | | | Comment | | | ····· | *************************************** | *************************************** |
| Sample Type: | Unknown | | Lab Name: | FBI Laborato | rv: | | File | | | | 201 | 70928_59 |
| Vial Position | 2.4.6 | | - pay: | | Screening TO | C 215 | . 110 | *************************************** | | | <u> </u> | 10920_39 |
| | | | | | | | | | | | | |
| Detected | Target Name | +{- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | | |
| ····· | lorazepam | + | N/A | N/A (N/A) | 321.0192 | N/A | N/A | N/A | N/A | ***************** | | |
| *************************************** | lormetazepam | + | N/A | N/A (N/A) | 335.0349 | N/A | N/A | N/A | N/A | ~~~~~~~~~ | *************************************** | |
| | medazepam | 4 | N/A | N/A (N/A) | 271.0997 | N/A | N/A | N/A | N/A | | *************************************** | ····· |
| | midazolam | + | N/A | N/A (N/A) | 326.0855 | N/A | N/A | N/A | N/A | ····· | ······ | *************************************** |
| | nordiazepam | 4. | N/A | N/A (N/A) | 271.0633 | N/A | N/A | | N/A | | | *************************************** |
| | oxazepam | + | N/A | N/A (N/A) | 287.0582 | N/A | N/A | N/A | N/A | ···· | | ····· |
| | phenazepam | + | N/A | N/A (N/A) | 348.9738 | N/A | N/A | N/A | N/A | | | ······································ |
| | prazepam | + | N/A | N/A (N/A) | 325.1102 | N/A | N/A | ***** | N/A | | | |
| | temazepam | + | N/A | N/A (N/A) | 301.0738 | N/A | N/A | | N/A | | | |
| | tetrazepam | + | N/A | N/A (N/A) | 289.1102 | N/A | N/A | | N/A | | | |
| | triazolam | + | N/A | N/A (N/A) | 343.0512 | N/A | N/A | | N/A | | | ······ |
| | 6-acetylmorphine | 4 | N/A | N/A (N/A) | 328.1543 | N/A | N/A | | N/A | | *************************************** | |
| | codeine | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A | | N/A | | *************************************** | |
| | dihydrocodeine | + | N/A | N/A (N/A) | 302,1751 | N/A | N/A | | N/A | | ······································ | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ |
| | dihydromorphone | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | | | |
| | EDDP | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | | | |
| | hydrocodone | + | N/A | N/A (N/A) | | N/A | N/A | | N/A | | ····· | |
| | hydromorphone | + | N/A | N/A (N/A) | *************************************** | N/A | N/A | ******** | N/A | | | |
| | norcodeine | + | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | | N/A | N/A | | N/A | | | |
| | normorphine | + | N/A | | | N/A | N/A | | N/A | ···· | ···· | *************************************** |
| | noroxycodone | + | N/A | N/A (N/A) | | N/A | N/A I | | N/A | *************************************** | | ····· |
| | oxycodone | + | N/A | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | N/A | N/A I | | N/A | ····· | | *************************************** |
| | oxymorphone | + | N/A | ~~~~ | *************************************** | N/A | N/A I | | N/A | *************************************** | | ······ |
| | ecgonine methyl ester | + | N/A | | ···· | N/A | N/A I | | N/A | ······ | | ····· |
| | benzoylecgonine | + | N/A | | | N/A | N/A I | | N/A | | *************************************** | |
| | cocaethylene | + | N/A | | | N/A | N/A I | | N/A | | *************************************** | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | cocaine | + | N/A | | | N/A | N/A I | | N/A | | | . |
| | brompheniramine | + | N/A | ~~~~~ | ****************** | N/A | N/A I | | N/A | | | |
| (| chlorpheniramine | + | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | | N/A | N/A I | | N/A | | *************************************** | |
| | ······ | ~~~~ | | | | · · · · · | 3.316.3.3 | 201 1 | 1 4/ /·) | | | |

b6 -1 b7C -1

| Batch:
Method: | 20170928 | | Sample | | | | | | | | ncu | | | | |
|-------------------|---------------------------------|------------------|-----------|-------------------------------|-----------------|-----------------|--|----------------------------------|----------------------------|---|---|---|----------|---|--|
| Inst. Method: | ExclusionSOP_TargetingScreening | | | | | | | | | | | | | - | |
| Acquired: | 9/29/2017 4:11 | | | | | | Commen | <u> </u> | ····· | | | - | | ~ | |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | v: | | File | 6 | | | | 204700 | nn ~ | ^ | |
| Vial Position | Lub (tallie: | | | Exclusionary (| * | C215 | | | | | 201709 | 28 58 | <u>1</u> | | |
| Detected | Target Name | +/- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | | | ······ | ~ | |
| | dextromethorphan | + | N/A | N/A (N/A) | 272.2009 | N/A | N/A | N/A | N/A | | **** | | | | |
| | dextrorphan | + | N/A | N/A (N/A) | 258.1852 | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | N/A | N/A | | | | ····· | | |
| | diphenhydramine | + | N/A | N/A (N/A) | 256.1696 | N/A | ~~~~~~~~~~ | N/A | N/A | ••••• | | |] | | |
| | doxylamine | + | N/A | N/A (N/A) | 271.1805 | N/A | | N/A | N/A | | | | | | |
| | hydroxyzine | 4 | N/A | N/A (N/A) | 375.1834 | N/A | | N/A | N/A | *************************************** | | | | | |
| | norchlorcyclizine | . + . | N/A | N/A (N/A) | 287.1310 | N/A | | N/A | N/A | ······ | | | | | |
| | pheniramine | + | N/A | N/A (N/A) | 241.1699 | N/A | | N/A | N/A | | | | | · | |
| • | tetrahydrozoline | + | 1.17E+06 | 1.91 (0.04) | 201.1386 | 201.1391 | | 82.00 | 1 of 4 | | L | 0. | Ь— | T | |
| | zaleplon | + | N/A | N/A (N/A) | 306.1349 | N/A | N/A | ~~~~~ | N/A | | | | | J | |
| | zolpidem | + | N/A | N/A (N/A) | 308.1757 | N/A | N/A | ···· | N/A | | | | | | |
| | zopiclone | + | N/A | N/A (N/A) | 389.1123 | N/A | N/A | | N/A | | | ···· | | | |
| | duloxetine | + | N/A | N/A (N/A) | 298.1260 | N/A | N/A | | N/A | | *************************************** | *************************************** | | | |



E00000

EVENT.

7.7

S2225 COX. شن ، جسر:

87.3.75 AA: 0200

38 FBI(20-cv-0545)-1316


b6 -1

b7C -1

20170928\_59

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 5 of 12



2817-88469 1827-2817


(CC)


CO

\*\*\*\*


TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 6 of 12





117-111 488 1827-2817



8222 82228


ಯ

~

~⇒

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 9 of 12



b6 -1 b7C -1

File 20170928\_59 Acquired 9/29/2017 4:11

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

ncu normorphine noroxycodone oxycodone Compound: oxymorphone Compound: Compound: Compound: RT(exp) 0.44 1.69 RT(exp) 1.72 RT(exp) RT(exp) 0.64 N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) RT(delta) N/A (N/A) N/A Area: N/A Area: N/A Area: N/A Area: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 150000-:4000 2230 130003 30000 120000 70295-\*\*000 9000 10000 3000 3000 2707 7000 4330 1555001-6000 95723-MEN. ACKIG-2003 2000 3000-3003 1000. 1000 767 1.89 AA: 0.00 800 1,72 846 0,000 900 0.84 84: 0.88

| Compound: | ecgonine methyl ester | Compound: | benzoylecgonine | Compound: | cocaethyler | 1e | ******* | Compound: | cocaine |
|----------------------|-----------------------|-----------------------|-----------------|-----------|---|---|---------|-----------|------------|
| RT(exp) | 0.26 | RT(exp) | 1.96 | RT(exp) | 2.5 | *************************************** | | RT(exp) | 2.3 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | ****************** | ******* | RT(delta) | N/A (N/A) |
| Area: | N/A | Area: | N/A | Area: | N/A | | 7 | Area: | N/A |
| m/z: | | m/z: | | m/z: | | | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu); N/A | 1 | | delta | (mmu): N/A |
| 180000 -
160000 - | / L | :40000 -
1:50000 - | | 75000- | *************************************** | 30000000 | | 90000 | <u>l</u> |



14000C-


120000

\*3335330~

30200-

SOEGE-

400000



FBI(20-cv-0545)-1323

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

ncu brompheniramine chlorpheniramine dextromethorphan Compound: Compound: dextrorphan Compound: Compound: 2.5 RT(exp) 2.43 RT(exp) 2.65 RT(exp) 2.11 RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A Area: N/A Area: N/A Area: N/A Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A 1200000 750000 92-11:0000 7000003 EZGERG. \*000003 **33**-18000 GOODOGI. 93020 79. ¥90000 SOEXCE-500000 12000 70000 4930001~ 4000000-83000 3500X0 -500000° 9000000 ~ anno. 290000-RE 2.45 30000 2000000-8500003-200000 7000000 v 577:2.50 545:550 100000 J 2003 RT: 2.65 AV: 0.00 50000 -837 2.11 AA: 0:00 23 diphenhydramine doxylamine hydroxyzine Compound: Compound: norchlorcyclizine Compound: Compound: 2.73 RT(exp) RT(exp) 1.94 RT(exp) 2.98 2.98 RT(exp) N/A (N/A) N/A (N/A) RT(delta) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A Area: N/A Area: Area: N/A N/A b6 -1 Area: m/z: m/z: b7C -1 m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A FCC: 2.73 AA: 0.00 870 1,94 .4A: 0.000 900.2.98 AA: 8.00 RE 2.38 AA: 0.00

817-88489 1827-28

pheniramine

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Acquired 9/29/2017 4:11

1.93

N/A

N/A (N/A)

(mmu): N/A

Compound:

RT(exp)

RT(delta)

Area: m/z:


delta


ಜ್ಞಾ


\_\_\_\_ \_\_\_\_\_

27-2917

| *************************************** | · | | | | | | ıcu |
|---|-----------|------------------|-----------|------------|-----------|--|------|
| | Compound: | tetrahydrozoline | Compound: | zalepion | Compound: | zolpidem | |
| | RT(exp) | 1.87 | RT(exp) | 2.86 | RT(exp) | 2.35 | |
| | RT(delta) | 1.91 (0.04) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | ···· |
| | Area: | 1166500 | Area: | N/A | Area: | N/A | ~~~ |
| | m/z: | 201.1391 | m/z: | | m/z: | ************************************** | |
| ····· | delta | (mmu): 0.5 | delta | (mmu): N/A | delta | (mmu): N/A | |
| | | GET 7 dis | | | | | |








| 200000-1 | | | | | |
|----------|----|--------|-------|-----|------|
| 30000 | | | | | |
| 180007 | | | | | |
| 190000 | | | | | |
| 14000 | | | | | |
| 12020 | | | | | |
| 120020 | | | | | |
| 2002 | | | | | |
| 90000 | | | | | |
| 4000 | | | | | |
| 2000 | | 120 | 1.36 | | |
| 3.1 | | ₩
₩ | OCC C | | |
| 1 | 25 | 33 | 2.4 | 2.5 | **** |

| b6 | _ | 1 | |
|-----|---|---|--|
| b7C | | - | |

| Compound: | zopiclone | Compound: | duloxetine |
|--|----------------------------------|---|-------------------------------------|
| RT(exp) | 2.13 | RT(exp) | 3.02 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| Агеа: | N/A | Area: | N/A |
| m/z: | | m/z: | |
| delta | (mmu): N/A | delta | (mmu): N/A |
| 200 - 20
200 - 20
200 - 20
200 - 20
200 - 20 | RT: 2.13
AX: 0.05
25 22 23 | 300 - | FIT: 2.02
AV: 2.00
SIG 25 3.2 |



b7E -2

b6 -1 b7C -1

2017-00 4 88 1027-2017

Exclusionary Screening by UPLC/FTMS

| Batch: | 20170928 | | | | • | • | <u> </u> | | | | | ما م | |
|---|--|----------|----------------------|-------------------------------|--------------|-----------------|----------|---|----------------------------|---|---|--|--------------------|
| Method: | ExclusionSOP_TargetingScreen | ina | | | | | Sample | | | | | sb | }
~- |
| Inst. Method: | 2 • • • • • • • • • • • • • • • • • • • | | | | | | O'4 | | | | | | |
| Acquired: | 9/29/2017 4:34 | | | | | | Comment | | | | | ······································ | Na. |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | rv | | File | | | | | 20170928 61 | |
| Vial Position | 2:A.8 | | - ^g say: | | Screening TO | C 215 | 7 46 _ | | | *************************************** | | 20170926 61 | _ |
| | | | | • | | | | | | | | | |
| Detected | Target Name | +/- | Area | RT
(Measured
and Delta) | Expected m/z | Measured
m/z | UMM | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | *************************************** | *************************************** | ~ |
| | d5-alprazolam | + | N/A | N/A (N/A) | 314.1215 | N/A | N/A | N/A | N/A | ··········· | - | | ~~~ |
| ····· | d5-hydroxalprazolam | + | N/A | N/A (N/A) | 330.1165 | N/A | N/A | N/A | N/A | | | | |
| *************************************** | d4-clonazepam | + | N/A | N/A (N/A) | 320.0735 | N/A | N/A | N/A | N/A | ********* | | *************************************** | ********** |
| ~~~~ | d4-7-aminoclonazepam | + | N/A | N/A (N/A) | 290.0993 | N/A | N/A I | N/A | N/A | *************************************** | | ····· | |
| ····· | d5-diazepam | + | N/A | N/A (N/A) | 290.1103 | N/A | N/A I | N/A | N/A | | | | |
| ····· | d5-oxazepam | + | N/A | N/A (N/A) | 292.0896 | N/A | N/A I | N/A | N/A | ************* | ~~~~~ | *************************************** | |
| *************************************** | d6-zolpidem | 4 | N/A | N/A (N/A) | 314.2134 | N/A | N/A I | V/A | N/A | | | | |
| ····· | d3-benzoylecgonine | + | N/A | N/A (N/A) | 293.1575 | N/A | N/A I | V/A | N/A | · | | | |
| | d3-diphenhydramine | + | N/A | N/A (N/A) | 259.1884 | N/A | N/A I | | N/A | | | | |
| | d6-oxycodone | +- | N/A | N/A (N/A) | 322.1920 | N/A | N/A.1 | V/A | N/A | | | | |
| | d3-morphine | + | N/A | N/A (N/A) | 289.1626 | N/A | N/A I | | N/A | | | | |
| *************************************** | d3-hydrocodone | + | N/A | N/A (N/A) | 303,1783 | N/A | N/A I | V/A | N/A | | | *************************************** | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | morphine | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A I | | N/A | | | | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | hydroxyalprazolam | + | N/A | N/A (N/A) | 325.0851 | N/A | N/A I | V/A | N/A | | | | |
| ····· | hydroxymidazolam | * | N/A | N/A (N/A) | 342.0804 | N/A | N/A I | V/A | N/A | | | | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | hydroxytriazolam | + | N/A | N/A (N/A) | 359.0461 | N/A | N/A N | V/A | N/A | ******* | | ····· | |
| | 7-aminoclonazepam | + | N/A | N/A (N/A) | 286.0742 | N/A | N/A N | V/A | N/A | | | | |
| | 7-aminoflunitrazepam | + | N/A | N/A (N/A) | 284.1194 | N/A | N/A N | V/A | N/A | | | *************** | ~~~ |
| | alprazolam | + | N/A | N/A (N/A) | 309.0902 | N/A | N/A N | 1/A | N/A | | | · | |
| | bromazepam | 4 | N/A | N/A (N/A) | 316.0080 | N/A | N/A N | V/A | N/A | | | | |
| | chlordiazepoxide | + | N/A | N/A (N/A) | 300.0898 | N/A | N/A N | ************ | N/A | | •••••• | *************************************** | |
| | clonazepam | + | N/A | N/A (N/A) | 316.0484 | N/A | N/A N | | N/A | | | *************************************** | |
| | desalkylflurazepam | + | N/A | N/A (N/A) | 289.0539 | N/A | N/A N | | N/A | | | *************************************** | |
| ····· | desmethylflunitrazepam | + | N/A | N/A (N/A) | 300.0779 | N/A | N/A N | | N/A | | ~~~~~ | | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | diazepam | + | N/A | | 285.0789 | N/A | N/A N | | N/A | | | | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | estazolam | + | N/A | | 295.0745 | N/A | N/A N | | N/A | ····· | | ····· | |
| | etizolam | + | N/A | | 343.0779 | N/A | N/A N | | N/A | | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | |
| | flunitrazepam | + | N/A | | 314.0936 | N/A | N/A N | | N/A | | | *************************************** | |
| | flurazepam | + | N/A | N/A (N/A) | 388.1586 | N/A | N/A N | *************************************** | N/A | | | | |
| | | | | | | | | | ~~~~ | | | | |

2017-88 488 1827-26.

Exclusionary Screening by UPLC/FTMS

| Batch: | 20170928 | | | | | | Ö | | sb |
|---------------|---------------------------------|-----|-----------|--|-----------------|-----------------|---|----------------------------------|---|
| Method: | ExclusionSOP_TargetingScreening | 1g | | | | | Sample | | 30 |
| Inst. Method: | | - | | | | | Comment | | |
| Acquired: | 9/29/2017 4:34 | | | | | | Commen | ······ | ······································ |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | v. | | File | | 20170928_61 |
| Vial Position | 2:A.8 | | Acsay: | | Screening TOX | (215 | # (*) | | 20110020 |
| | | | | | | | | | |
| Detected | Target Name | +/- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta Isotopic
MMU Pattern
Score (% | Num Notes
Isotopes
Matched | ······································ |
| | lorazepam | * | N/A | N/A (N/A) | 321.0192 | N/A | N/A N/A | N/A | |
| | lormetazepam | + | N/A | N/A (N/A) | 335.0349 | N/A | N/A N/A | N/A | |
| - | medazepam | + | N/A | N/A (N/A) | 271.0997 | N/A | N/A N/A | N/A | |
| | midazolam | + | N/A | N/A (N/A) | 326.0855 | N/A | N/A N/A | N/A | |
| | nordiazepam | + | N/A | N/A (N/A) | 271.0633 | N/A | N/A N/A | N/A | |
| | oxazepam | 4 | N/A | N/A (N/A) | 287.0582 | N/A | N/A N/A | N/A | ······································ |
| ~ | phenazepam | + | N/A | N/A (N/A) | 348.9738 | N/A | N/A N/A | N/A | ······ |
| | prazepam | 4 | N/A | N/A (N/A) | 325.1102 | N/A | N/A N/A | N/A | |
| | temazepam | + | N/A | N/A (N/A) | 301.0738 | N/A | N/A N/A | N/A | |
| | tetrazepam | + | N/A | N/A (N/A) | 289.1102 | N/A | N/A N/A | N/A | *************************************** |
| | triazolam | + | N/A | N/A (N/A) | 343.0512 | N/A | N/A N/A | N/A | ······································ |
| | 6-acetylmorphine | + | N/A | N/A (N/A) | 328.1543 | N/A | N/A N/A | N/A | |
| | codeine | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A N/A | N/A | ······································ |
| | dihydrocodeine | + | N/A | N/A (N/A) | 302.1751 | N/A | N/A N/A | N/A | *************************************** |
| | dihydromorphone | + | N/A | N/A (N/A) | 288.1594 | N/A | N/A N/A | N/A | ······ |
| | EDDP | + | N/A | N/A (N/A) | 278.1903 | N/A | N/A N/A | N/A | |
| | hydrocodone | + | N/A | N/A (N/A) | 300.1594 | N/A | N/A N/A | N/A | *************************************** |
| | hydromorphone | + | N/A | N/A (N/A) | 286.1438 | N/A | N/A N/A | N/A | *************************************** |
| | norcodeine | + | N/A | N/A (N/A) | 286,1438 | N/A | N/A N/A | N/A | ······································ |
| | normorphine | 4 | N/A | ~~~~~~ | 272.1281 | N/A | N/A N/A | N/A | ····· |
| | noroxycodone | + | N/A | N/A (N/A) | 302.1387 | N/A | N/A N/A | N/A | ······································ |
| | oxycodone | 4 | N/A | N/A (N/A) | 316.1543 | N/A | N/A N/A | N/A | ······································ |
| | oxymorphone | 4 | N/A | N/A (N/A) | 302.1387 | N/A | N/A N/A | N/A | |
| | ecgonine methyl ester | + | N/A | | 200.1281 | N/A | N/A N/A | N/A | ······································ |
| | benzoylecgonine | + | N/A | ~~~~ | 290.1387 | N/A | N/A N/A | N/A | |
| | cocaethylene | + | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | | N/A | N/A N/A | N/A | |
| | cocaine | + | N/A | | | N/A | N/A N/A | N/A | |
| | brompheniramine | + | N/A | | 319.0804 | N/A | N/A N/A | N/A | *************************************** |
| | chlorpheniramine | + | N/A | | 275,1310 | N/A | N/A N/A | N/A | ······································ |
| | | | | ····· | | | | ······ | *************************************** |

Exclusionary Screening by UPLC/FTMS

| Batch: | 20170928 | | | | | | Camala | | | | | sb |
|---|---------------------------------|----------------|-----------|-------------------------------|--------------------|-----------------|--------------|--|----------------------------|--|---|-------------|
| Method: | ExclusionSOP_TargetingScreening | | | | | | Sample | | | ······ | | 30 |
| Inst. Method: | | | | | | | Comment | . | | | | |
| Acquired: | 9/29/2017 4:34 | | | | | | Commen | | | | ····· | ******* |
| Sample Type: | Unknown | | Lab Name: | FBI Laborator | v | | File | | | | 20170928 | 61 |
| Vial Position | 2:A,8 | | Accay; | | ,
Screening TOX | (215 | | | | | 20170020 | |
| | | | | , | | | | | | | | |
| Detected | | +/- | Area | RT
(Measured
and Delta) | Expected
m/z | Measured
m/z | Delta
MMU | Isotopic
Pattern
Score (%) | Num
Isotopes
Matched | Notes | *************************************** | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | dextromethorphan | + | N/A | N/A (N/A) | 272.2009 | N/A | N/A | N/A | N/A | ***************** | | |
| | dextrorphan | + | N/A | N/A (N/A) | 258.1852 | N/A | N/A | N/A | N/A | | *************************************** | |
| | diphenhydramine | ÷ | N/A | N/A (N/A) | 256.1696 | N/A | N/A | N/A | N/A | | *************************************** | |
| | doxylamine | + | N/A | N/A (N/A) | 271.1805 | N/A | N/A | N/A | N/A | | | |
| | hydroxyzine | + | N/A | N/A (N/A) | 375.1834 | N/A | N/A | N/A | N/A | ······································ | ····· | |
| | norchlorcyclizine | + | N/A | N/A (N/A) | 287.1310 | N/A | N/A | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | N/A | ····· | ····· | |
| | pheniramine | + | N/A | N/A (N/A) | 241.1699 | N/A | N/A | ~~~~~~~ | N/A | ······ | ······ | |
| | tetrahydrozoline | + | N/A | N/A (N/A) | 201.1386 | N/A | N/A | ~~~~ | N/A | | ····· | ~~~~ |
| | zaleplon - | † - | N/A | N/A (N/A) | 306.1349 | N/A | N/A | | N/A | | | |
| | zolpidem · | | N/A | N/A (N/A) | 308.1757 | N/A | N/A | | N/A | ····· | *************************************** | |
| | zopiclone - | | N/A | N/A (N/A) | 389.1123 | N/A | N/A | | N/A | | | |
| | duloxetine | | N/A | N/A (N/A) | 298.1260 | N/A | N/A | | N/A | | | |
| ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | | | | | | | 1407 | 23173 | (957.3 | | | |

b6 -1 b7C -1

b7E -2


7-88468


1827-2817

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 4 of 12

b6 -1






TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS


File 20170928\_61 9/29/2017 4:34 Acquired

ကာ ကာ

1027-2017


b6 -1





b6 -1


| Compound: 7-aminoclonazepam | Compound: | 7-aminoflunitrazepam | Compound: | alprazolam | Compaund: | si
bromazepam |
|-----------------------------|-----------|-----------------------------------|-----------|-------------------------------------|---|-------------------------------|
| RT(exp) 2.07 | RT(exp) | 2.27 | RT(exp) | 3.1 | RT(exp) | 2.66 |
| RT(delta) N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| Area: N/A | Area: | N/A | Area: | N/A | Area: | N/A |
| n/z: | m/z: | | m/z: | | m/z: | |
| lefta (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A |
| 22 | 1880
 | 877.1.27
Av. 0.00
23 23 2.4 | 1.8 | 80° 2.50
49: 0.00
30: 30 35 3 | 100 -
50 -
20 -
20 -
22 -
22 -
23 -
24 -
25 -
26 -
27 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 -
28 - | PR 1.86
AS 828
26 27 28 |




File 20170928\_61 9/29/2017 4:34 Acquired

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 7 of 12







File 20170928\_61 Acquired 9/29/2017 4:34

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 8 of 12






File 20170928\_61 Acquired 9/29/2017 4:34

TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 9 of 12

sh

| RT(exp) 1.77 | Compound: | 6-acetylmorphine | Compound: | codeine | Compound: | dihydrocodeine | Compound: | s
 dihydromorphone |
|--|-------------------------|------------------|--|------------|--|----------------|---|-----------------------|
| RT(delta) N/A (N/A) RT(del | (T(exp) | 1.77 | 11 | 1.54 | 1 | 1.5 | | · |
| Area: N/A Area: N/A Area: N/A M/z: Ielta (mmu): N/A Area: N/A M/z: M/z: Area: N/A M/z: | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | 33 | · | 33 | |
| m/z: elfa (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A | rea: | N/A | Area: | N/A | 7 | |] | · |
| delta (mmu): N/A delta | | | | | 1 | | | |
| 2005 14000 15000 | elta
 | /(mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | | (mmu): N/A |
| 1 | 2202-
2522-
2603- | 800.4.27 | 14023-
15000-
170005-
170005-
17003-
17003-
17003- | | 2000 -
1600 -
1600 -
1400 -
1000 -
1000 -
1000 -
1000 - | SC 5.60 | 9008-
5002-
7032-
9023-
9000-
9000-
9000- | |




TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

Page 10 of 12

ch

| Compound: | normorphine | Compound: | noroxycodone | Compound: | oxycodone | Compound: | oxymorphone |
|--|---------------------------------|-----------|--------------|---|------------|--|---|
| RT(exp) | 0.44 | RT(exp) | 1.69 | RT(exp) | 1.72 | RT(exp) | 0.64 |
| RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) | RT(delta) | N/A (N/A) |
| Area: | N/A | Area: | N/A | Area: | N/A | Area: | N/A |
| m/z: | <u></u> | m/z: | | m/z: | | m/z: | *************************************** |
| delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A | delta | (mmu): N/A |
| 1500
1320
1320
1320
1320
1320
1320
1320
13 | AT 0.44
AC 0.00
2.4 32 26 | 2880 | 15 7.5 | 12012
12020
12020
14020
14020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020
10020 | | 3603 - 2460 - 22 | 35 27 22 |





1827-2817

b6 -1

1827-2817

b6 -1






TOX 215 EXCLUSIONARY SCREENING BY UPLC/FTMS

File 20170928\_61 Acquired 9/29/2017 4:34

pheniramine tetrahydrozoline Compound: zaleplon Compound: zolpidem Compound: Compound: RT(exp) 1.93 1.87 RT(exp) 2.86 RT(exp) 2.35 RT(exp) N/A (N/A) RT(delta) N/A (N/A) RT(delta) RT(delta) N/A (N/A) N/A (N/A) RT(delta) N/A Area: Area: N/A N/A Area: N/A Area: m/z: m/z: m/z: m/z: delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A delta (mmu): N/A

| ,, | 1.8 | *,* | 20 | 23 | • |
|---|-----|--------------------|----|----|---|
| 31 | | 877 1.6
844 3.6 | z: | | |
| 20 | | | | | |
| 32 | | | | | |
| 53-
40- | | | | | |
| \$0
50
72
50
50
50
50
50
50
50
50
50
50
50
50
50 | | | | | |
| 72 | | | | | |
| 80-1
20-1 | | | | | |
| 702 | | | | | |



| ٦ | | • |
|----|--|---------------------------------------|
| 1 | yemmenteri, | |
| ŧ | , | 7 |
| ŧ | | : |
| Į, | | ż |
| И | | ÷ |
| ł | | : |
| 1 | (180 <sub>-1</sub> | i |
| н | 200-
80-
80- | į |
| В | | , |
| H | SC. | 1 |
| ŧ | 3 | 1 |
| 31 | and a | ş. |
| 31 | w{ | · · · · · · · · · · · · · · · · · · · |
| Ħ | { · .} | ٤ |
| н | 70.4 | ŝ |
| 33 | / ^ ~ | ï |
| H | : <mark></mark> | ۶ |
| u | 87-4 | ÷ |
| Н | ~~7 | ٤ |
| Н | 4 | ÷ |
| В | 50- √ | : |
| H | · · · · · · · · · · · · · · · · · · · | ٠ |
| к | 1 | ٤ |
| В | ≈ ∞√ | ; |
| Н | 3 | , |
| Н | }} | ٤ |
| Н | x-{ | ż |
| Н | . | į. |
| и | z- | ٤ |
| в | - | ż |
| ĸ | . 🖈 | ! |
| H | W.J | ŧ |
| ti | *** 1.86 | ÷ |
| И | AN:300 | |
| | is the same of the | |
| H | 27 28 29 20 | |
| 1 | - AA 28 20 | į. |
| | | |

| ٦ | | | ••••••••••••••••••••••••••••••••••••••• |
|---|--|------------------|---|
| | 14000 | | - |
| - | 19336-
19336-
11093- | | *************************************** |
| | 10003-
9200- | | |
| | 5000-
7000-
5000- | | |
| | 5000
4500
3000 | ě | |
| | 10003 - 1000 - 1 | 57.1.X
A4.000 | |
| | 3.1 | 33 34 | |

| Compound: | Zobicione | ••••• | Compound: | auloxetine |
|-----------|----------------------|---|---|----------------------|
| RT(exp) | 2.13 | | RT(exp) | 3.02 |
| RT(delta) | N/A (N/A) | | RT(delta) | N/A (N/A) |
| Area: | N/A | | Area: | N/A |
| m/z: | | *************************************** | m/z: | |
| delta | (mmu): N/A | | delta | (mmu): N/A |
| 200 | *07 2:13
AA: 2:00 | | 100 -
50 - | 97: 3.52
A4: 3.22 |
| 28 | 25 25° | 22 | 2 | 38 29 32 |



2017-00469

ACID-NEUTRAL DRUG SCREEN (GC-MS-PIEI Analysis)

Item 2 Urine

hot leter b6 -1 b7C -1

09/25/2017

b6 −1 b7C −1


Analysis – Examiner


Pages, including this cover


20**17-00469 1027-20**17


b6 -1 \_\_\_b7C -1

FBI(2









Dates(s): 09/25 - 09/26/2017

Page 1 of 2

b6 -1 b7C -1

Acid-Neutral Drug Screen (SOP 201-5)

Sample Accession:

Pipets:

| Type | Calibration Due |
|---------------------|---------------------|
| Socorex 100-1000 μI | 02/2018 |
| Socorex 20-200 μl | 02/2018 |
| | Socorex 100-1000 μl |

Controls:

- 1. Four 0.5 ml portions of drug-free human whole blood (Cliniqa lot XR5788, expires 07/2018).
- 2. 0.5 ml drug-free blood spiked with 100 μ l of acid-neutral drug control solution (lot ANPOS170816, expires 08/2019) and 25 μ l of a 1 mg/ml methanolic standard of acetaminophen (Cerilliant lot FN07161504, expires 08/2020).
- 3. 0.5 ml "Surine" synthetic urine (Dynatek lot 72112, expires 01/2018).
- 4. 0.5 ml Surine spiked with 100 μ l of acid-neutral drug control solution (lot ANPOS170816, expires 08/2019) and 25 μ l of a 1 mg/ml methanolic standard of acetaminophen (Cerilliant lot FN07161504, expires 08/2020).

Case Specimens:

| Lab# | Item | Matrix | Amount Used | Notes |
|--------------|--------|--------------|--------------------|--------------------------------|
| PT17-18A | FTC-05 | Blood | 0.5 ml | Plastic bottle |
| PT17-18A | FTC-06 | Blood | 0.5 ml | Plastic bottle |
| PT17-18A | FTC-07 | Blood | 0.5 ml | Plastic bottle |
| PT17-18A | FTC-08 | Urine | 0.5 ml | Plastic bottle |
| 2017-00469 | Item 2 | Urine | 0.5 ml | 1 conical plastic tube |
| 2017-02439#1 | Item 1 | Blood | 0.5 ml | 2 grey-top tubes – tube A used |
| 2017-02440#1 | Item I | Vitreous | 0.25 ml | 2 grey-top tubes – tube A used |
| | | Humour | | – dilute with 0.25 ml DI water |
| 2017-02441#1 | Item 1 | Blood | 0.5 ml | 1 grey-top tube |
| 2017-02632#1 | Item 1 | Blood | 0.5 ml | 1 grey-top tube |
| | | | | 1 grey-top tube |
| 2017-02633#1 | Item 1 | Item 1 Blood | 0.5 ml | NOTE: specimen was very |
| | | | | thick and viscous |

FBI(
2017-00469 1027-2017

| BATCH NO | TES |
|----------|------------|
| | |
| | |

Dates(s): 09/25 - 09/26/2017

Page 2 of 2

b6 -1 b7C -1

> b6 -1 b7C -1

b6 -1 b7C -1 b7E -9

Acid-Neutral Drug Screen (SOP 201-5)

Processing:

Each sample was brought to 1 ml with DI water and spiked with 25 μ l of 30 ppm methylphenylhydantoin. All were processed and extracted per Toxicology SOP 201-5. The dried extracts were each reconstituted in 50 μ l of 4:1 chloroform:methanol and analyzed by GC-MS-PIEI as detailed below.

Analysis:

| Instrument | Method | Data Files | Notes |
|------------|-------------|------------|-----------------|
| CU-MSD-4 | AN_DRUG_SOP | | 2 μl injections |

b7E -9

Each negative control (1 urine, 4 blood) was analyzed twice, a dichloromethane blank was analyzed twice, and methanol blanks were analyzed 12 times.

Additional Standards:

| 20 μl of a 100 ppm methanolic standard of amitriptyline (lot expires 12/2017) was | |
|--|--|
| liluted with 180 µl of 4:1 chloroform:methanol to create a ca. 10 ppm injection standard. This | |
| standard, a dichloromethane blank and a methanol blank were analyzed as described above. | |
| Data Files: | |
| NOTE – This data is included only with cases(s) to which it applies. | |

| NREAL | OF IND |
|--|---|
| agu a tr | OF THE PROPERTY OF |
| Sugar
Sugar | M M |
| The state of the s | FA 60 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 |
| RHORATE | BY DIVISION |

DIRECT SOLVENT EXTRACTION OF ACID/NEUTRAL DRUGS FROM BIOLOGICAL FLUIDS

CHEMISTRY UNIT TOXICOLOGY SOP 201-5

| CHEMIST: | |
|----------|-----------|
| DATE: | 2/25/2017 |

b6 -1 b7C -1

(10/01/14)

| | PROCEDURE: | |
|----|--|------------|
| Ç. | Label 16x125 mm screw-top test tubes accordingly. | |
| | Aliquot negative control(s). Aliquot positive control(s). Lot(s): Lot(s): | |
| 1 | Add 0.5 mL biological fluid (0.5 g food homogenate, 0.5 mL beverage dilution or 1 g tissue homogenate) to test tube. Bring up to 1 mL total volume with deionized water. | ь6
ь7с |
| * | Add 25 uL of MPH Int. Std. sol'n (500 uL for tissue samples) to each test tube. Yields spike conc. of 1.5 ug/mL (10 ug/g). Methylphenylhydantoin Working solution (30 ug/mL) Lot: ANISTO 160505 Actual amount added: 25 | 1 |
| * | Add 1 mL of 5% KH <sub>2</sub> PO <sub>4</sub> buffer to each test tube. Check pH. It should fall between 4 and 6. Lot: Exp: 10/20/17 | ь6 |
| ŧ | Add 5 mL ether:toluene (1:1) to each tube. Extract 20 minutes. Centrifuge 5 minutes. Exp: 10/20/17 | b7C
b7E |
| 1 | Transfer organic (top) layer to 16x100 mm test tube. Evaporate to dryness under nitrogen @ 50°C. If volatile analysis is required (ethchlorvynol or valproic acid) stop evaporating at ~0.5 mL and analyze by GC/MS. | - |
| ř | Transfer dried residue to a 10 cc centrifuge tube with two successive 1 mL washes of CHCl <sub>3</sub> :MeOH (4:1). | - |
| (| Evaporate to dryness under nitrogen at 50°C. | |
| - | Reconstitute dried residue in 2 mL hexane. Lot: EMV 54009 | b6 |
| 2 | Add 200 uL 80% ethanol. Vortex 30 sec and centrifuge 5 min. Lot Exp: 3/20/18 | b7C
b7E |
| E | Discard hexane (top) layer. Transfer ethanol layer to a 12 x 75 mm tube and take to dryness with nitrogen at 50°C. | |
| ? | Reconstitute residue in 25-50 uL CHCl <sub>3</sub> :MeOH (4:1). Actual Recon. Volume: 56 | b6 |
| K | Analyze by GC/MS (EI). To reduce carryover, add a methylene chloride blank at the beginning of the run and after the postiive control. | ь7C |
| 70 | ditional Notes / Deviations | |



Direct Solvent Extraction of Acid/Neutral Drugs from Biological Fluids CHEMISTRY UNIT TOXICOLOGY SOP 201-4

INSTRUMENTAL METHOD PARAMETERS

| CHEMIST: | |
|----------|-------------------|
| DATE: 7 | 1512017-912612017 |
| | 11/6/201/ |

b6 -1

b7C -1

| GC/MS Instrument Name: CV-MSD - 4 | | N | Method File Name: AN_DRUG_SOP | | | | |
|-----------------------------------|----|--------------------------------|-------------------------------|---------------------------|----------|------------------------------|-------|
| GC Oven Program: | × | start at 45°C, hold 1 min | 烙 | ramp 25°C/min to 150°C | 1 | | |
| | × | ramp 15°C/min to 280°C | 7 | hold 14 min | 1 | | |
| GC Inlet: | ¥ | Temp = 220°C. | PÉ | Mode = split | AT | Split Ratio = 10:1 | _ |
| | 区 | Injection Volume = 1-2 μ L | | Actual Injection Volume 2 | 7 | | b6 |
| GC Carrier Gas: | 奥 | Mode = constant flow | Ą | Flow = 1.2 mL/min | T | | ₩ ь7с |
| Thermal Zones: | 区 | Transfer Line = 280°C | 枫 | Source = 230°C | 净 | Quad = 150°C | |
| Mass Spectrometer: | 翼′ | Source = EI, positive ion | A | Mode = full scan | 6/8 | Range = $35-500 \text{ m/z}$ | |
| wrass spectrometer: | 区 | Solvent Delay = 3 min | | | 1 | | |

ALTERNATE CONDITIONS FOR ANALYSIS OF VOLATILE COMPONENTS


| GC/MS Instrumen | nt N | ame: | M | lethod File Name: | | | |
|---------------------------------------|----------|--------------------------------|---|------------------------|---|------------------------------|--------|
| GC Oven Program: | 0 | start at 45°C, hold 1 min | | ramp 25°C/min to 150°C | | hold-2 min | |
| o o o o o o o o o o o o o o o o o o o | | ramp 30°C/min to 280°C | | hold 14 min | | | b6 -1 |
| GC Inlet: | | Temp = 220°C. | 0 | Mode = split | | Split Ratio = 10:1 | b7C -1 |
| | | Injection Volume = 1-2 μ L | | Actual Injection Vol | /, | | |
| GC Carrier Gas: | | Mode = constant flow | | Flow = 1.2 mL/min | | | |
| Thermal Zones: | | Transfer Line = 280°C | | Source = 230°C | | Quad = 150°C | |
| Mass Spectrometer: | <u> </u> | Source = EI, positive ion | | Mode = full scan | | Range = $35-200 \text{ m/z}$ | |
| Trans Special onicies | | Solvent Delay = 3.5 min | | | <u>t.</u> | | |


□ ALTERNATE CONDITIONS FOR CHEMICAL IONIZATION MS (TSQ)

| GC/MS Instrument Name: | | | Method File Name: | | | | |
|------------------------|---|---------------------------|-------------------|------------------------|----------|--------------------------|--|
| GC Oven Program: | 0 | start at 45°C, hold 1 min | | ramp 25°C/min to 150°C | | hold 2 min | |
| GC Oven I Togram. | | ramp 15°C/min to 280°C | | hold 14 min | | | |
| GC Inlet: | | Temp = 220°C. | 旦 | Mode = splitless | | Splitless Time = 1 min | |
| GC inici. | | Injection Volume = 1 μL | | | <u> </u> | | |
| GC Carrier Gas: | | Mode = constant flow | | Flow = 1.2 m | | | |
| Thermal Zones: | | Transfer Line = 280°C | _ | Source = 185°C | | | |
| Mass Spectrometer: | 6 | Source = CI, positive ion | _ | CI Gas = methane | | CI Gas Flow = 2.0 ml/min | |
| | | Mode = full scan | | Range = 100-500 m/z | | Solvent Delay = 4 min | |

NOTES & DEVIATIONS:

b6 −1 b7с −1





| 20) | Sample
Datafile | 3 | methanol blank | |
|-------|--------------------|-----|--|------------|
| | Method | | AN_DRUG_SOP | |
| 21) | Sample | 12 | ANDALUS BLANCE | |
| , | Datafile | 1.2 | negative blood control | |
| | Method | | | |
| 221 | | | AN_DRUG_SOP | |
| 22) | - T | 14 | 2017-02439 Item 1 Blood | |
| | Datafile | | | |
| | Method | | AN_DRUG_SOP | |
| 23) | Sample | 3 | methanol blank | |
| | Datafile | | meetaner brank | |
| | Method | | AN_DRUG_SOP | |
| 241 | Sample | 1 5 | M_DR0G_S0P | |
| 41) | Datafile | 15 | negative blood control | |
| | | | · · · · · · · · · · · · · · · · · · · | |
| 051 | Method | | AN_DRUG_SOP | |
| 25) | - | 16 | 2017-02440 Item 1 Vitreous | |
| | Datafile | | The same of the sa | |
| | Method | | AN_DRUG_SOP | |
| 26) | Sample | 4 | methanol blank | |
| | Datafile | _ | metianor brank | |
| | Method | | AN DRUG GOD | |
| 27) | | 1 = | AN_DRUG_SOP | |
| 2,, | Datafile | 15 | negative blood control | |
| | | | | b6 -1 |
| 001 | Method | | AN_DRUG_SOP | |
| 28) | Sample | 17 | 2017-02441 Item 1 Blood | b7C -: |
| | Datafile | | | b7E - |
| | Method | | AN_DRUG_SOP | |
| 29) | Sample | 4 | methanol blank | |
| | Datafile | | | |
| | Method | | AN_DRUG_SOP | |
| 30) | | 18 | | |
| / | Datafile | 10 | negative blood control | |
| | Method | | | |
| 211 | Sample | 4.0 | AN_DRUG_SOP | |
| 211 | | 19 | <u>2017-02632</u> Item 1 Blood | |
| | Datafile | | | |
| | Method | | AN_DRUG_SOP | |
| 32) | Sample | 4 | methanol blank | |
| | Datafile | | | |
| | Method | | AN_DRUG_SOP | |
| 33) | Sample | 18 | negative blood control | |
| • | Datafile | 0 | negative blood control | |
| | Method | | AN DRIVE CO. | |
| 3/1 | Sample | 2.0 | AN_DRUG_SOP | |
| J.+) | | 20 | 2017-02633 Item 1 Blood | |
| | Datafile | | | |
| a = . | Method | | AN_DRUG_SOP | |
| 35) | Sample | 4 | methanol blank | |
| | Datafile | | | |
| | Method | | AN_DRUG SOP | |
| 36) | Sample | | positive blood control | |
| | Datafile | _ | passage D con control | |
| | Method | | AN_DRUG_SOP | |
| | | | AN_DRUG_SOP | |
| | | | No Marie of | |
| | | | | |
| | | | | |
| | | | en les 12 | |
| | | | | |
| | | | 507 (0 1)-C | _ = |
| | | | al a l | b 6 |
| | | | 1100 | b7C |
| | | | · / / | |
| | | | / / | |
| | | | AN_DRUG_SOP positive blood control AN_DRUG_SOP AN_DRUG_SOP AN_DRUG_SOP AN_AN_AN_AN_AN_AN_AN_AN_AN_AN_AN_AN_AN_A | |
| | | | | |
| | | | | |
| | | | | |

Last Modified:

Page: 2

2017-00469 1027-20FBJI(2


Relative Abundance


50~

100~

2017-00469

1027-2017





JS17092506

15

10-

51.1

50

78.1

100

m/z

190.1

FBI(20-cv-0545)-1351

161.1

132.0 147.1

150

42.1

2017-00469

1027-20

10


11

12

Time (min)


13

14



ဌာ

~



Alkaline Screen 2017-00469

Item 1, blood
Item 2, urine
Item 3, blood
Item 5, urine

ranifidine identified.

The sample was extracted and analyzed on 10/02/2017 (GC), 10/03/2017 (LC), and 10/04/2017 (target LC)

b7C -1

2017-00469 1027-2017

FBI(20-cv-0545)-1354

TEMPLATES FOR LC-ESI TANDEM MASS SPECTRAL COMPARISON

LAB #
DATE OF ANALYSIS
ANALYST

| 2017-00469 |
|--------------------|
| 10/03 - 10/04/2017 |
| |

b6 -1 b7C -

Phenethylamine (ms3)

| | | | Diagnostic Ions (m/z) | | | |
|-----------------|-------------|-------|--|-------|------------|--|
| Specimen | | 79 | ion 2 | ion 3 | time (min) | |
| CK160906I, 1ppm | response | 23784 | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | 3.44 | |
| | ion ratio | 100.0 | 0.0 | 0.0 | 4.44 | |
| item 2, urine | response | 379 | | | 4 42 | |
| | ion ratio | 100.0 | 0.0 | 0.0 | 4.42 | |
| | pass / fail | PASS | PASS | PASS | PASS | |

b6 -1 b7C -1

Phenethylamine (ms3)

| | | | Diagnostic Ions | (m/z) | Retention | |
|-----------------|-------------|-------|--|---|------------|--|
| Specimen | | 79 | ion 2 | ion 3 | time (min) | |
| CK160906I, 1ppm | response | 23784 | ······································ | *************************************** | 4.44 | |
| | ion ratio | 100.0 | 0.0 | 0.0 | 4.44 | |
| item 5, urine | response | 82 | | ***************************** | | |
| | ion ratio | 100.0 | 0.0 | 0.0 | 4.44 | |
| | pass / fail | PASS | PASS | PASS | PASS | |

b6 -1

ENTER CHEMICAL NAME

| | | | Diagnostic lo | ns (m/z) | Retention |
|-----------------|-------------|-----------|---|-----------|-----------|
| Specimen | | base peak | ion 2 | ion 3/ | rel to IS |
| known / control | response | | *************************************** | | |
| | ion ratio | #DIV/0! | #DIV/0! | #D/V/01 | |
| unknown | response | | | | |
| | ion ratio | #DIV/01 | #DIV/0! | #DIV/0! | |
| | pass / fail | #DIV/0! | #DIV/0! | / #DIV/0! | #DIV/01 |

ENTER CHEMICAL NAMÉ

| | | | Diagnostic Ions | (m/z) | Retention |
|-----------------|-------------|-----------|-----------------|--|------------|
| Specimen | | base peak | / ion 2 | ion 3 | time (min) |
| known / control | response | | / | ······································ | |
| | ion ratio | #DIV/01 / | #DIV/0! | #DIV/0! | |
| unknown | response | | | ······································ | |
| | ion ratio | #DIV/Q | #DIV/0! | #DIV/0! | |
| | pass / fail | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/01 |

2017-00469 +Br(20-cV-0545)-1355

TEMPLATES FOR LC-ESI TANDEM MASS SPECTRAL COMPARISON

LAB # 2017-00469

DATE OF ANALYSIS 10/03-10/04/2017

ANALYST Ranitidine

b6 -1 b7C -1

| | | | Diagnostic Ions | (m/z) | Retention | |
|------------------|-------------|---------|-----------------|--------|------------|----|
| Specimen | | 270 | 176 | 124 | time (min) | |
| JCS160831E, 1ppm | response | 2026619 | 1216998 | 947779 | 2 50 | 1 |
| | ion ratio | 100.0 | 60.1 | 46.8 | 3.58 | |
| item 1, blood | response | 97559 | 57273 | 45305 | 2.50 | 1 |
| | ion ratio | 100.0 | 58.7 | 46.4 | 3.58 | |
| | pass / fail | PASS | PASS | PASS | PASS | 11 |
| | • | • | | | • | ` |
| | | | | | | |

Ranitidine

| | | | Diagnostic Ions | (m/z) | Retention |
|------------------|-------------|---------|-----------------|--------|------------|
| Specimen | | 270 | 176 | 124 | time (min) |
| JCS160831E, 1ppm | response | 2026619 | 1216998 | 947779 | 250 |
| | ion ratio | 100.0 | 60.1 | 46.8 | 3.58 |
| item 3, blood | response | 1597580 | 966627 | 769309 | 250 |
| | ion ratio | 100.0 | 60.5 | 48.2 | 3.58 |
| | pass / fail | PASS | PASS | PASS | PASS |

b6 -1 b7C -1

Ranitidine

| | 1 | | Diagnostic Ions | (m/z) | Retention | |
|------------------|-------------|----------|-----------------|----------|------------|--|
| Specimen | | 270 | 176 | 124 | time (min) | |
| JCS160831E, 1ppm | response | 2026619 | 1216998 | 947779 | 2 50 | |
| | ion ratio | 100.0 | 60.1 | 46.8 | 3.58 | |
| item 2, urine | response | 26347408 | 15345290 | 11985789 | 3.51 | |
| | ion ratio | 100.0 | 58.2 | 45.5 | 3.31 | |
| | pass / fail | PASS | PASS | PASS | PASS | |

b6 -1 b7C -1

Ranitidine

| | | Diagnostic lons (m/z) | | | Retention |
|------------------|-------------|-----------------------|-----------|-----------|------------|
| Specimen | | 270 | 176 | 124 | time (min) |
| JCS160831E, 1ppm | response | 2026619 | 1216998 | 947779 | 3.58 |
| | ion ratio | 100.0 | 60.1 | 46.8 | |
| item 5, urine | response | 330191388 | 193054876 | 154074769 | 3.31 |
| | ion ratio | 100.0 | 58.5 | 46.7 | |
| | pass / fail | PASS | PASS | PASS | FAIL |

New



SOLID PHASE EXTRACTION OF ALKALINE DRUGS FROM BIOLOGICAL FLUIDS CHEMISTRY UNIT TOXICOLOGY SOP 203-7

| CHEMIST: | | | | | | ********** | |
|----------|----|-----|----|-------------|----|------------|--|
| DATE: | 10 | 121 | 17 | <u>~ 10</u> | 13 | 17 | |

| 2 | Add 1 ml. biofluid (or 1 g prepared tissue homogenate) to labeled 16x1 | | |
|---|--|--|---|
| 3 | | 198 (BLOOD); 72112 (UNIVE) | |
| _ | | <u>5-170705</u> | ····· |
| E. | Add 50 µL Alkaline Screen Internal Standard Working Solutions to each | ļ |) |
| | | LOT | |
| e. | Add 4 ml. of 100 mM Phosphate buffer. Verify pH = 5.5-6.5. | | |
| | | LOT: EXP: 31/11/r | 7 |
| 2 | For blood / tissue, centrifuge at high speed for 15 minutes. Transfer su | | · |
| Z | Bring volume to 5 mL with DI water. Verify pH = 5.5-6.5 | | ··········· |
| / | Pre-rinse and condition Clean Screen DAU SPE cartridge at 1 mL/min | with: LOT: 612170-QA | *************************************** |
| Į | Do not let sorbent dry. | | |
| 1 | # 3 ml. methanol (HPLC Grade) # 3 ml. deionized water | mL 100 mM Phospate Buffer | |
| 7000000 | LOT: 167576 OPTIMA | Ja . tab too ama 1 stoopaa balaa | |
| 7 | Load sample onto SPE cartridge at 1-2 mL/minute. Do not let sorbent | dry. | |
| Ħ | Wash cartridge at 1-2 mL/min with: 3 mL deionized water | | |
| | ≥ 1 mL of 100 mM acet | tic acid LOT EXP: | |
| | | ¬ | 122/18 |
| | of 3 ml. methanol (MP) | CGrade) | |
| 1 | Dry cartridge under full vacuum for 3 minutes. | | *************************************** |
| 7 | Apply 3 ml. of Elution Solvent at 1-2 ml./min. Collect eluent in 12x75 | mm test tubes. Prepare elution solvent fresh daily | |
| | 20 mL isopropanol (HPLC grade) | LOT: 138898 | |
| | 2 mL conc. ammonium hydroxide (ACS grade) | LOT: 163894 | |
| | 78 mL methylene chloride (HPLC or pesticide grade) | LOT: 163634 | |
| ø | Evaporate to dryness under nitrogen at 40° C. | Temp: 40°C | ********* |
| 2 | Reconstitute in 40-50 μL methanol (GC <sup>2</sup>) for GC/MS(EI) analysis. | LOT: DD267 Recon Volume: 50 | <u> </u> |
| 2 | Add 100 µL DI Water to methanol extract for LC/MS analysis. | LOT: 171725 | |
| ei] | Analyze by any of the following: | | |
| | ∠ LC/MS (ESI) oxes-3 ∠ GC/MS (EI) ANS | \$ 0 ~5 | |
| | los sol | 2 | |
| ئـــ ـــــــــــــــــــــــــــــــــ | Additional Notes / Deviations | | ~~~ |
| | | | |
| | | | |



Alkaline Drugs from Biological Fluids CHEMISTRY UNIT TOXICOLOGY SOP 203-7 INSTRUMENTAL METHOD PARAMETERS

CHEMIST:

DATE: 10/2/17

(04/10/2017)

b6 -1 b7C -1

b6 -1 b7C -1 b7E -9

| GC/MS Instrument Name: CU-MSD-5 | | | Method File Name: ALK_DRUG_SOP | | | | |
|---------------------------------|------------|---------------------------------|---|----------------------|----|----------------------|--|
| GC Oven Program: | £ | start at 60°C, hold 2 min | zi ramp 35°C/min to 280°C zi hold 26.71 min | | | | |
| GC Inlet: | ø | Temp = 220°C. | ø | Mode = split | Ø | Split Ratio = 10:1 | |
| GC inset: | الجفير | Injection Volume = 2 μL | | | | | |
| GC Carrier Gas: | <i>p</i> 5 | Mode = constant flow | Flow = 1.2 mL/min | | | | |
| Thermal Zones: | Par 1 | Transfer Line = 280°C | Z | Source = 230°C (MSD) | Z | Quad = 180°C / 150°C | |
| Mass Spectrometer: | Ø | Source = El, positive ion | Z | Mode = full scan | 20 | Range = 35-500 m/z | |
| | 50 | Solvent Delay = 5 min 4 4.5 min | | | | | |

| LC/MS Instrument Name: CU-ORBITRAP-3 | | | Method File Name: alkaline_screen_new_SOP | | | | | |
|---|--------------|--|---|--------------------------------|------------------------|-----------------------|--|--|
| Mobile Phase #1: | Ø | 0.1% formic acid in water | LO | | EX | | | |
| Mobile Phase #2: | <i>j</i> 22* | 0.1% formic acid in acetonitrile | LO | T: | EX | P: 11/2-/17 | | |
| Mobile Phase | ø | start at 90% #1, hold 5 min | æ | ramp to 10% #1 at 20 min | Ø | | | |
| Gradient: | ø | ramp to 90% #1 at 31 min | <sub>p</sub> ZŠ | hold 5 min | | | | |
| LC Column: | Ø | Xterra C18-MS 3x150 mm, 3.5 um | dp | Column s/n 07.333625 | 39 | 12204 | | |
| N. Commi | ie? | Flow Rate = 0.3 mL/min | j B | Temperature = 30°C | | | | |
| Autosampler: | Z | Injection Volume = 10 μL | سجنز | Temperature = 15°C | | | | |
| Mass Spectrometer: 🗷 Source = ESI, positive ion | | <i>j</i> 27 | # of Segments = 5 | | Events per Segment = 7 | | | |
| Segment Times | ø. | #1; 0-12 min #2; 12-13.5 min | # | 3; 13.5 - 14 min #4; 14-15 min | ŧi | 5; 15-36 min | | |
| Event #1: | P. | Mode = full scan MS | æî | Range = 100-650 m/z | ć | FTMS 15000 resolution | | |
| | je je | Mode = full scan MSMS | Ø | Data Dependent Product Ion | Æ | ITMS unit resolution | | |
| Events # 2-4 | Æ | MSMS of the 1st, 2nd, and 3rd most intense ions in Event #1 from segment-specific precursor target lists | | | | | | |
| | Ø | See SOP for target ion lists; ions may be added or removed - record below if this is done | | | | | | |
| Event # 5 | الإنز | Mode = full scan MS | æ | Range = 100-650 m/z | 2 | FTMS 15000 resolution | | |
| Events # 6-7 | <i>[</i> 2 | Mode = full scan MSMS | Æ. | Data Dependent Product Ion | æ | ITMS unit resolution | | |
| Engara ir Ga | æ! | MSMS of the 1st and 2nd largest ion | as in | Event #5 | | | | |
| Events # 5-7 may be deleted for targeted analysis | | | | | | | | |

TARGET PRECURSOR ION LIST (IF APPLICABLE):

NOTES & DEVIATIONS:

```
LTQ Instrument Method
  Creator: Administrator
  hast modified: 10/4/2017 by Administrator
 MS Run Time (min): 37.00
 Sequence override of method parameters not enabled.
 Divert Valve: not used during run
 Contact Closure: not used during run
 Syringe Pump: not used during run
 MS Detector Settings:
 Real-time wodifications to method disabled
 Stepped collision energy not enabled
 Additional Microscans:
       M82
        M3.3
               - 0
             0
        MSA
             0
        MS5
        MS6
             Ö
        MS7
        MS9
        M29
               0
        MSIO
 Segment 1 Information
 Duration (min):
 Number of Scan Events: 5
 Tune Method:
                       ALKALINE TONE
 Scan Event Details:
 1: PTMS + a norm (corona (pi res=15000 b(100.0-650.0)
       -CV = 0.0V
  2: ITMS + c horm (corona !pi · ( 122.10) -> o (80.0-128.0)
      MS/MS: AT CID OR 40.00 0 0.250 Time 30.000 Isow 2.0
       CV = 0.0V
  3: ITMS + c norm /corona /pi -( 122.10)-> ( 104.85)->c(50.0-135.0)
       MS2: AT CTD CB 40.0% Q 0.250 Time 50.000 Isom D.0
       MS3: AT CIP OF 40.0% Q 0.280 Time 30.000
       CV = 0.10V
 4: TIMS + c norm !corona (pi -( 315.15)->6(85.0-325.0)
       MS/MS: AT CID CE 40.0% Q 0.250 Time 30.000 Isow 2.0
       CV = 0.0V
 5: 1788 + c horm (corona (pi - ( 409,18) - >c(110.0-425.0)
       MS/MS: AT CIU OR 40.0% Q 0.250 Time 30.000 Isow 2.0
Vveunesuay, October 04, 2017 17:36:00
```

Page 1 of 4 FBI(20-cv-0545)-1359

b6 -1

LTQ Instrument Method Look Masses: Pos List Name: N/ASource: API Source Mass List: (none) N/A API Sounce Neg List Name: Source: Mass List: (none) Custom Data Dependent Settings: Not enabled

Wednesday, October 04, 2017 17:36:00

Page 2 of 4 BI(20-cv-0545)-1360

b6 -1

```
Shimadzu LC Method Parameters
Pumps
sac saccated trices.
Pump A Model: LC-20AD
Pump B Model: LC-20AD
Pump C Model: LC-20AD
Pump D Model: LC-20AD
Pumping Mode: Binary Flow
Total Flow: 0.3000 mL/min
Pump B Cano: 10.0 %
B Carve: 0
Pump C Flow: 0.0000 mL/min
Pump D Flow: 0.0000 mL/min
Pressure Range (Fump A/B): 0 - 4000 psi
Pressure Range (Fump C): 0 - 4000 psi
Pressure Range (Fump D): 0 - 4000 psi
Autosampler
***
Model: SIL-20AC/RT
Use Autosampler: Yes
Rinsing Volume: 500 al
Needle Stroke: 52 mm.
Rinsing Speed: 35 uL/sec
Sampling Speed: 15.0 uL/sec
Furge Time: 5.0 min
Rinse Dip Time: 2 sec
Rinse Mode: Before aspiration
Cooler Enabled: Yes
Cooler Temperature: 15 deg. C
Control Vial Needle Stroke: 52 mm
Oven
uturatas
Model: CTO-20AC
Temperature Control: Enabled
Temperature: 30 deg. C
Max. Temperature: 95 deg. C
System Controller
Model: CBM-20A
Power: On
Event 1: Off
Event 2: Off
Event 3: Off
```

Wednesday, October 04, 2017 17:36:00

Page 3 of 4 FBI(20-cv-0545)-1361

b6 -1

| ime Pr | (ogram | | | | |
|--|--|---|--|--|--|
| Time
5.00
0.00
0.00
1.00
7.00 | Module Pumps Fumps Fumps Fumps Pumps Pumps System Controller | Pump B Conc. Pump B Conc. Pump B Conc. Pump B Conc. Pump B Conc. Stop | Parameter
1.0
90
90
1.0
1.0 | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

Wednesday, October 04, 2017 17:36:00


Page 4 of 4 BI(20-cv-0545)-1362

Sequence Name: b6 -1 Comment: ALK screen b7C -1 Operator: b7E -2 Data Path: Instrument Control Pre-Seq Cmd: Data Analysis Pre-Seq Cmd: Instrument Control Post-Seg Cmd: Data Analysis Post-Seg Cmd: Method Sections To Run On A Barcode Mismatch (X) Full Method (X) Inject Anyway () Reprocessing Only () Don't Inject Line Sample Name/Misc Info 1) Sample 1 solvent blank Datafile 01 Method ALK\_DRUG\_SOP 2) Sample 1 solvent blank Datafile 02 Method ALK\_DRUG\_SOP 3) Sample 2 solvent blank Datafile 03 Method ALK\_DRUG\_SOP 4) Sample 3 neg ctrl blood Datafile 04 Method ALK\_DRUG\_SOP b6 -1 5) Sample 4 solvent blank b7C -1 Datafile 05 Method ALK\_DRUG\_SOP 6) Sample 3 neg ctrl blood Datafile 06 Method ALK DRUG SOP 7) Sample 5 2017-00469, 1, blood Datafile Method ALK\_DRUG\_SOP 6 solvent blank 8) Sample Datafile 08 Method ALK DRUG SOP 9) Sample 7 2017-00469, 3, blood Datafile 09 Method ALK\_DRUG\_SOP 10) Sample 8 solvent blank Datafile 10 Method ALK\_DRUG\_SOP 11) Sample 9 2017-02632, 1, blood Datafile 11 Method ALK\_DRUG\_SOP b6 -1 12) Sample 10 solvent blank b7C -1 Datafile 12 Method ALK\_DRUG\_SOP 13) Sample 11 2017-02633, 1, blood Datafile Method ALK\_DRUG\_SOP 14) Sample 12 solvent blank Datafile Method ALK\_DRUG\_SOP Last Modified: Page: 1

15) Sample 13 2017-02692, 1(A), blood Datafile 15 Method ALK\_DRUG\_SOP 16) Sample 14 solvent blank Datafile 16 Method ALK DRUG SOP 17) Sample 15 2017-02693#1, 1(A), blood Datafile 17 Method ALK\_DRUG\_SOP 18) Sample 16 solvent blank Datafile 18 Method ALK DRUG SOP 19) Sample 17 2017-02695, 1(A), blood Datafile 19 Method ALK DRUG SOP 20) Sample 18 solvent blank Datafile 20 Method ALK\_DRUG\_SOP 21) Sample 19 pos ctrl blood Datafile 21 Method ALK DRUG SOP 22) Sample 1 solvent blank Datafile 22 Method ALK DRUG SOP 23) Sample 1 solvent blank Datafile 23 Method ALK DRUG SOP 24) Sample 2 solvent blank Datafile 24 Method ALK DRUG SOP 25) Sample 20 neg ctrl urine Datafile 25 Method ALK\_DRUG\_SOP 26) Sample 21 solvent blank Datafile 26 Method ALK\_DRUG\_SOP 27) Sample 20 neg ctrl urine Datafile 27 Method ALK DRUG SOP 28) Sample 22 2017-00469, 2, urine Datafile Method ALK\_DRUG\_SOP 29) Sample 23 solvent blank Datafile Method ALK\_DRUG\_SOP 30) Sample 24 2017-00469, 5, urine Datafile 30 Method ALK DRUG SOP 31) Sample 25 solvent blank Datafile 31 Method ALK\_DRUG\_SOP 32) Sample 26 pos ctrl urine Datafile 32 Method ALK\_DRUG\_SOP 33) Sample 1 solvent blank Datafile Method ALK DRUG SOP 34) Sample 2 solvent blank Datafile 34







Last Modified:

Page: 2


b6 -1

b7C -1

b6 -1



b6 -1 b7C -1



Qualitative Standards used in Alkaline Screen target 1ppm std mix:

| Compound | | Lot | |
|-------------------------------------|---|-----|--|
| Cyclobenzaprine (100ppm) | | | |
| n-Desmethylcyclobenzaprine (100ppm) | | | |
| Ecgonine Ethyl Ester (100ppm) | П | | |
| 2-Phenethylamine (104.7ppm) | П | | |
| Ranitidine (100.2ppm) | П | | |

b7C -1


~1ppm Mix:

 $10\mu L$ of each 100ppm qualitative standard was added to a test tube with $280\mu L$ of GC<sup>2</sup> Methanol (Lot# DI267). 670 μL of Optima grade water (Lot#171725) was added to the test tube. A portion of the mixture was transferred to an autosampler vial.

| Compound | Lot |
|--------------------|-------------|
| Tamsulosin (94ppm) | CA07012016O |

~1ppm Std:

 $10\mu L$ of the 100ppm qualitative standard was added to a test tube with $320\mu L$ of GC^2 Methanol (Lot# Di267). 670 μL of Optima grade water (Lot#171725) was added to the test tube. A portion of the mixture was transferred to an autosampler vial.



Ini Vol 10 ut b6 -1 b7C -1

b7E -2

b7E -2

File Name Sample Name Position Instrument Method 1 sb 1:01 2 sb 1:01 3 ncb 1:02 4 2017-00469, 1, blood 1:03 5 1:04 6 2017-00469, 3, blood 1:05 7 sb 1:06 8 2017-02632, 1, blood 1:07 9 sb 1:08 10 2017-02633, 1, blood 1:09 11 1:10 12 2017-02692, 1(A), blood 1:11 13 1:12 14 2017-02693#1, 1(A), blood 1:13 15 1:14 16 2017-02695, 1(A), blood 1:15 17 sb 1:16 18 pcb 1:17 19 sb 1:18 20 sb 1:18 21 ncu 1:19 22 2017-00469, 2, urine 1:20 23 sb 1:21 24 2017-00469, 5, urine 1:22 25 sb 1:23 26 pcu 1:24 flush sb-flush 1:06 standby sb-standby 1:08

trgt\_21

trgt\_22

trgt\_flush

trgt\_standby

1ppm std mix

sb

sb-flush

sb-standby


1:25


1:23


1:16


1:21


| Path Inj Vol 10ut | | BUFT | EĐ | | | b6 -
b7С
b7Е |
|---|----------------------------------|--------------|-------------|--|---|--------------------|
| | | | 1014163 | | | |
| File Name | Sample Name | | ment Method | | 1 | |
| trgt_01 | sb | 1:01 | | | | |
| trgt_02
trgt_03 | sb
ncb | 1:01 | | | | |
| trgt_04 | 2017-00469, 1, blood | 1:02 | | | | |
| trgt_05 | sb | 1:03 | | | | |
| trgt_05 | 2017-00469, 3, blood | 1:04 | | | | |
| trgt_07 | 5b | 1:05 | | | | |
| trgt_08 | sb | 1:18 | | | | |
| trgt_09 | ncu | 1:18
1:19 | | | | |
| trgt_10 | 2017-00469, 2, urine | | | | | |
| trgt_11 | sb | 1:20
1:21 | | | | |
| trgt_12 | 2017-00469, 5, urine | 1:22 | | | | |
| trgt_13 | 1ppm std mix | 1:25 | | | | b6 -1 |
| trgt_14 | 1ppm tamsulosin std | 1:26 | | | | b7C -1 |
| trgt_15 | sb | 1:06 | | | | b7E −2 |
| trgt_16 | sb | 1:06 | | | | |
| trgt_17 | ncb | 1:02 | | | | |
| trgt_18 | 2017-02632, 1, blood | 1:07 | | | | |
| trgt_19 | sb | 1:12 | | | | |
| trgt_20 | 2017-02693#1, 1(A), blood | 1:13 | | | | |
| 64 Table 11 | and the second with the property | 30,20 | | | | |















































































































































































































10


12

Time (min)


18 FBI(20-cv-0545)-1444


b6 -1








16


















LC-ESI-FTMS Data


PHENETHYLAMINES




















10

12

14

Time (min)

16

18

12

13

Time (min)

11

10


14


15


16


17


FBI(20-cv-0545)-1460

















Time (min)

(CO)

.s:~~


223

cca


دی

5-12 ----3 ----3

6000 6000



Time (min)



12

14

Time (min)

16

10

(13.8 min)

18

<sub>20</sub>FBI(20-cv-0545)-1472

2

8

Time (min)

10

